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SUMMARY 
 
Introduction. Hereditary Motor Sensory Neuropathy (HMSN), also known as Charcot-
Marie-Tooth disease (MIM118300), is an heterogeneous group of Mendelian diseases which 
affects the peripheral motor and sensory nervous system (PNS). With a prevalence of about 
1/2500 individuals, it is considered the most common inherited neuromuscular disorder. The 
clinical hallmarks include slow and progressive muscular weakness of distal limbs, peroneal 
atrophy and bilateral pes cavus, however they are often associated with other signs such as 
spastic paraplegia, ataxia, mental retardation and incontinence. Distal HMN disorders are a 
subgroup of HMSN characterized by a predominant motor involvement and minor or no 
sensory loss. To date, more than 50 genes have been detected for HMSN and 17 genes for 
dHMN, but many disease-genes have to be identified yet. 
Aim of the study. This study aims to identify and, whenever possible, functionally 
characterise novel genes causing different forms of peripheral neuropathy. In order to achieve 
this objective, four families affected by complex HMSN or distal HMN and showing no 
mutations in known disease-genes were examined.  
Materials and methods. The identification of novel genes was performed by using a strategy 
which integrates the traditional positional cloning approach with the next-generation whole-
exome sequencing. In all the four families candidate linkage regions were identified by 
genome-wide linkage analysis, specifically for the recessive forms they were identified also 
by homozygosity mapping and identity-by-descent analysis using high-density SNPs arrays 
and STR markers. In one family a candidate-genes screening by Sanger sequencing was 
preferred for the small size of the critical region. In the remaining three families the whole-
exome sequencing (WES) approach was adopted in order to inspect all coding variants within 
the previously identified linkage regions. Considering the advantage of having variants within 
the whole exome, known disease-related genes were also analysed and less stringent genome 
wide searches were even conducted. Moreover, coverage analysis was performed and poorly-
covered exons were sequenced. The best candidate variants were selected by filtering and 
prioritization analyses which allowed to evaluate the putative pathogenicity of variants. For 
the variants which represented potential mutations, further confirmations were obtained by in 
silico analyses, control population screening, unrelated patients characterization and 
functional studies. 
Results. In Family 1, affected by a recessive HMSN and spastic paraplegia, only one small 
candidate region encompassing 5 genes was identified by linkage studies on chr13q12.1-
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q12.12. Direct sequencing highlighted in the patients a novel homozygous missense mutation 
in the SACS gene (c.11104A>G). SACS was already associated with a different 
neurodegenerative disorder termed ARSACS. In silico predictions showed that the 
p.Thr3702Ala change falls in a surface-exposed and evolutionarily conserved region of XPCB 
protein domain, suggesting a key role in the interaction with E3 ubiquitin ligase UBE3A. 
Recent studies in mutated fibroblasts indicated an alteration in the dimensions of 
mitochondria and such impairment was assessed for the p.Thr3702Ala mutation identified. A 
higher number of significantly more little and spherical mitochondria was observed in 
proband’s fibroblasts compared with controls. These findings were indicative of a higher 
fragmentation of mitochondria in presence of the p.Thr3702Ala sacsin mutation, in agreement 
with the hypothesis of impairment in fusion/fission mitochondrial dynamics. 
Family 2, affected by a distal form of motor neuropathy (dHMN), is characterized by the 
presence of three consanguineous marriages. Despite this, the homozygosity mapping failed 
to detected a unique candidate autozygous region shared by all affected subjects. In order to 
investigate the hypothesis of two genetic causes, the family was splitted into two nuclei on the 
basis of phenotypic differences between patients. In the first nucleus, linkage analysis 
highlighted a single candidate autozygous region on chr8p23.1-p22 (rs2738148; rs6997599) 
and the analysis of the WES variants identified a novel missense substitution in the SGK223 
gene (c.1529T>C). In silico predictions strongly supported the effect of this variant in a 
splicing alteration. In the second nucleus, 8 candidate regions (>1 Mb) were identified by 
homozygosity mapping but only one of them (chr9p21.1-p13.2) was pinpointed by the IBD 
analysis and was likely to be identical-by-descent (IBD). The analysis of the WES variants 
selected a candidate mutation (c.412G>C) in SIGMAR1. This gene was already associated 
with the motor neuron disorder ALS16. By screening SIGMAR1 in unrelated patients, a 
second variant (c.448G>A) was identified in a different family displaying a recessive form 
dHMN.  
In the consanguineous Family 3, affected by a recessive complex form of neuropathy with 
spastic paraplegia and mental retardation, linkage analysis detected 4 candidate regions on 
chr2p13.3-p12, chr3q27-q28 (2 regions) and chr21q11.2-q21.1. The analysis of WES variants 
enabled to identify in chr2p13.3-p12 an interesting variant (c.950G>A) in the FBXO41 gene. 
This substitution has been never reported in any variant database, was predicted to map in a 
evolutionary conserved region and to play a disruptive functional effect in a α-helix structure. 
In Family 4, affected by an autosomal dominant form of HMSN and spastic paraplegia with a 
marked clinically heterogeneity, different genetic models were investigated including 
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monogenic, digenic and the co-occurrence of two distinct diseases. A high number of 
candidate regions was thus identified by the linkage analysis, with the best candidate region 
on chr9q22.33-9q33.2. Due to a low quality of WES data, the analysis of sequence variants 
highlighted many false positive calls and no variants displayed perfect co-segregation with the 
disease. Also the CNV analysis and the direct sequencing of the poorly-covered exons in the 
chr9q22.33-9q33.2 region did not identified any other significant mutation.  
Discussion. The high clinical and genetic heterogeneity which characterizes distal 
neuropathies represents a clue that the presence of a single genetic cause and a 
straightforward genotype-phenotype correlation cannot explain all Mendelian diseases. Since 
to date many of these cases still remain “orphan” of a molecular explanation, the research of 
novel disease-genes attempts to shed light on the genetics and pathogenic mechanisms which 
are not-well known yet. The combinatorial strategy used in the present study was powerful for 
identifying candidate disease-genes in the families with a recessive transmission (Families 2 
and 3). Indeed, the information on the candidate regions enabled to reduce the great deal of 
variants in order to perform a deeper and more effective analysis. On the other hand, this 
approach revealed more challenging in the picture of dominant transmission and clinical 
heterogeneity of Family 4, proving the already-reported difficulty to unravel dominant traits. 
However this part of the study put in evidence technical and analytical weaknesses which this 
analysis attempted to limit and that the currently-performed WES will enable to overcome. 
This work represents the first evidence for a SACS mutation associated with a non-ataxic 
clinical picture, and for two SIGMAR1 mutations associated with a juvenile distal neuropathy. 
Considering also that the SIGMAR1 gene maps to the “orphan” dHMN Jerash type locus 
(dHMN-J), this finding supports the causality of this gene in dHMN disorder.  The 
demonstration of a growing phenotypic heterogeneity up to an overlap with other neurological 
disorders can be indicative of a more extended phenotypical spectrum associated with these 
genes. This work represents the first step to demonstrate the pathogenicity of a candidate 
variant and dissect the mechanisms underlying distal neuropathies. Indeed, further genetic 
screenings in a large cohort of patients and functional studies will elucidate the actual 
involvement of the novel candidate genes in these disorders. 
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RIASSUNTO 
Introduzione. La neuropatia ereditaria sensitivo-motoria (HMSN), anche denominata 
malattia di Charcot-Marie-Tooth (MIM118300), costituisce un gruppo eterogeneo di disordini 
mendeliani che colpiscono il sistema nervoso periferico motorio e sensitivo. Tale malattia è 
considerata il disordine neuromuscolare ereditario più comune, con una prevalenza stimata di 
1 caso su 2500 nella popolazione. I segni clinici distintivi includono una progressiva ipostenia 
e ipotrofia dei muscoli distali degli arti, un’atrofia peroneale e piede cavo bilaterale. Questo 
fenotipo clinico è di frequente associato ad altri sintomi, quali la paraparesi spastica, il ritardo 
mentale, atassia e disturbi urinari. Le neuropatie ereditarie motorie distali (dHMN) 
costituiscono un sottogruppo delle neuropatie ereditarie sensitive-motorie, caratterizzato da un 
prevalente coinvolgimento motorio e un minore o assente interessamento sensitivo. Ad oggi, 
più di 50 geni sono stati associati alle neuropatie ereditarie sensitivo-motorie e 17 alle forme 
motorie distali, tuttavia molti geni rimangono ancora sconosciuti. 
Obiettivo dello studio. Il presente studio si prefigge di identificare e possibilmente 
caratterizzare dal punto di vista funzionale, nuovi geni causativi di varianti ereditarie di 
neuropatia periferica. A tale scopo sono state studiate quattro famiglie in cui erano presenti 
soggetti affetti da HMSN complesse o dHMN e nelle quali erano state escluse le mutazioni 
nei geni malattia già noti. 
Materiali e Metodi. Al fine di identificare nuovi geni causativi, in questo lavoro è stata 
adottata una strategia che va ad integrare l’approccio tradizionale di clonaggio posizionale 
con il sequenziamento next-generation dell’esoma. Nelle quattro famiglie oggetto di studio, 
mediante SNPs ad alta densità e marcatori microsatelliti, è stata svolta una analisi di linkage 
genome-wide e  si sono identificate regioni candidate; inoltre per le forme recessive si è 
proceduto con il mappaggio per omozigosità e l’analisi di identità per discendenza (IBD). In 
una di queste famiglie, data la ridotta estensione della regione candidata, lo screening 
mutazionale dei geni candidati è avvenuto per mezzo del sequenziamento diretto. Nelle 
rimanenti tre famiglie, invece, è stato adottato l’approccio di sequenziamento next-generation 
dell’esoma, al fine di analizzare tutte le varianti presenti negli esoni codificanti delle regioni 
in linkage. Il vantaggio di avere un’informazione estesa all’intero esoma ha permesso 
un’analisi genome-wide meno stringente e  la ricerca delle varianti nei geni malattia già noti. 
L’analisi dell’efficienza di copertura delle regioni candidate ha permesso invece di 
sequenziare gli esoni poco coperti di queste regioni. Un’approfondita e dettagliata analisi di 
filtraggio e prioritizzazione ha reso possibile  valutare la possibile patogenicità delle varianti e 
di identificare le migliori candidate. A partire da queste, ulteriori validazioni sono state poi 
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ottenute mediante studi in silico, screening di popolazione di controllo, caratterizzazione di 
pazienti non imparentati e studi funzionali. 
Risultati. Nella prima famiglia, in cui segrega una forma recessiva di HMSN e paraparesi 
spastica, si è identificata una sola regione di linkage sul cromosoma 13q12.1-q12.12 e 
contenente 5 geni. Per mezzo del sequenziamento diretto è stata individuata una nuova 
mutazione missenso in omozigosi nel gene SACS (c.11104A>G). Tale gene era già stato 
associato in precedenza a una diversa malattia neurodegenerativa denominata ARSACS. 
Predizioni in silico hanno evidenziato che il cambiamento aminoacidico (p.Thr3702Ala) si 
localizza esposto sul dominio proteico XPCB e in una regione evolutivamente conservata 
nella sequenza aminoacidica. Alla luce di questi dati, si ipotizza per l’aminoacido mutato un 
ruolo chiave  nell’interazione con l’ubiquitin-ligasi E3 UBE3A. Visti i recenti studi condotti 
su fibroblasti mutati che hanno riportato un’alterazione delle dimensioni dei mitocondri, si è 
ritenuto interessante verificare se tale alterazione avvenisse anche nei fibroblasti con la 
mutazione identificata. In tali fibroblasti di paziente, confrontati con fibroblasti di controllo, si 
è osservato un maggior numero di mitocondri caratterizzati da dimensioni statisticamente 
inferiori e da una maggiore sfericità. Tali dati potrebbero essere indicativi di una loro 
maggiore frammentazione in presenza della mutazione missenso, in accordo con il dato di 
alterazione riportato in precedenza. 
La seconda famiglia investigata, affetta da una forma distale di neuropatia motoria, è 
caratterizzata dalla presenza di tre matrimoni fra consanguinei. Tuttavia il mappaggio per 
omozigosità ha escluso un’unica regione di autozigosi condivisa da tutti i soggetti affetti. Al 
fine di investigare l’ipotesi della presenza di due cause genetiche diverse, la famiglia è stata 
divisa in due nuclei sulla base delle differenze fenotipiche dei pazienti. Per il primo nucleo 
l’analisi di linkage ha identificato una singola regione di autozigosi sul cromosoma 8p23.1-
p22 (rs2738148; rs6997599) e la successiva analisi di varianti ha individuato una nuova 
sostituzione missenso nel gene SGK223 (c.1529T>C) come la migliore candidata. Il suo 
effetto nell’alterazione dello splicing è stato fortemente supportato da studi di predizione in 
silico. Nel secondo nucleo invece, l’approccio di mappaggio per omozigosità ha identificato 8 
regioni candidate (>1 Mb) ma solo una di queste (chr9p21.1-p13.2) è stata trovata in 
autozigosi dall’analisi IBD. L’indagine delle varianti ottenute dal sequenziamento dell’esoma 
e presenti in questa regione ha selezionato una mutazione fortemente candidata (c.412G>C) in 
SIGMAR1. Tale gene è già stato associato in precedenza ad una diversa patologia neurologica 
quale la sclerosi laterale amiotrofica giovanile denominata ALS16. Mediante lo screening 
mutazionale di SIGMAR1 in altri pazienti con dHMN e non imparentati tra loro, è stata 
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identificata una seconda variante (c.448G>A) in un’altra famiglia che presentava una analoga 
trasmissione autosomica recessiva.  
La terza famiglia oggetto di studio, anch’essa con consanguineità, presenta invece una forma 
complessa di neuropatia con paraparesi spastica e ritardo mentale. Mediante analisi di linkare 
sono state identificate quattro regioni candidate e nello specifico sul cromosoma 2p13.3-p12, 
3q27-q28 (2 regioni) e 21q11.2-q21.1. L’analisi delle varianti ha evidenziato nella regione 
candidata sul cromosoma 2p13.3-p12 un’interessante sostituzione (c.950G>A) nel gene 
FBXO41, che ad oggi non risulta essere riportata in alcun database di varianti. Studi in silico 
hanno indicato un effetto funzionale del cambiamento aminoacidico nella struttura ad α-elica 
dove si localizza e una regione altamente conservata a livello evolutivo. 
La quarta famiglia, affetta da una forma autosomica dominante di neuropatia ereditaria 
sensitivo-motoria, è caratterizzata da una marcata eterogeneità clinica in quanto in più 
soggetti è presente anche paraparesi spastica ereditaria. Per spiegare tale eterogeneità, sono 
stati adottati diversi modelli genetici che prevedono l’esistenza una singola causa genetica, 
due cause che concorrono allo stesso fenotipo (modello digenico), e la co-presenza di due 
malattie distinte. Dall’analisi di linkage è emerso un alto numero di regioni, tra cui la miglior 
candidata mappante sul cromosoma 9q22.33-9q33.2. Tuttavia la bassa qualità dei dati di 
sequenziamento ha portato ad un’alta percentuale di falsi positivi, e nessuna variante nelle 
regioni candidate ha dimostrato una perfetta co-segregazione con la malattia. Risultati 
negativi sono stati ottenuti anche dall’analisi di Copy Number Variations (CNVs) e dal 
sequenziamento diretto degli esoni a basso coverage della regione 9q22.33-9q33.2. 
Discussione. L’alta eterogeneità clinica e genetica che caratterizza le neuropatie distali è 
indicativa del fatto che un’unica causa genetica e un’univoca correlazione tra fenotipo e 
genotipo non possono essere associate a tutti i disordini mendeliani. Alla luce dei molti casi 
che ad oggi rimangono irrisolti dal punto di vista genetico, la ricerca di nuovi geni malattia ha 
il fine di far luce sulle basi genetiche e i meccanismi patogenetici che per molti aspetti sono 
ancora sconosciuti. La strategia usata nel presente studio è risultata efficace ai fini 
dell’identificazione di geni malattia candidati nelle famiglie con forme a trasmissione 
recessiva (seconda e terza famiglia). La conoscenza delle regioni candidate ha infatti 
permesso di ridurre le varianti ottenute col sequenziamento dell’esoma ad un gruppo limitato 
e analizzabile mediante un’approccio più dettagliato e critico e che ha reso possibile 
l’efficacia dell’analisi. Lo stesso approccio si è rivelato meno efficace in un quadro di 
trasmissione dominante ed eterogeneità clinica (quarta famiglia), mettendo in luce le difficoltà 
di risolvere i tratti dominanti. Tuttavia questa parte dello studio ha permesso di comprendere 
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le criticità tecniche ed analitiche presenti al fine di limitarle, ma che sicuramente verranno 
superate dai sequenziamenti più recenti. 
Tale lavoro rappresenta la prima evidenza di una mutazione nel gene SACS associata a un 
quadro clinico non atassico, e di due mutazioni nel gene SIGMAR1 associate a una forma 
giovanile di neuropatia distale. Inoltre SIGMAR1 mappa in un locus già descritto per una 
forma di neuropatia distale (tipo Jerash) e tale dato supporterebbe la causatività di SIGMAR1 
per tale malattia. La dimostrazione di una crescente eterogeneità fenotipica che si estende fino 
alla sovrapposizione con altre malattie neurologiche può essere indicativa di uno spettro 
fenotipico ben più ampio di quello associato fino ad oggi a questi geni. Tale studio costituisce 
il primo step fondamentale per trovare nuovi geni causativi e studiare nel dettaglio i 
meccanismi alla base delle neuropatie distali. A tale scopo screening genetici su coorti di 
pazienti e studi funzionali potranno far luce sull’effettivo coinvolgimento di questi nuovi geni 
candidati nelle malattie. 
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1. INTRODUCTION 
 
1.1 
1.1.1 Approaches for causal genes identification in Mendelian disorders: state of the 
 art 
 Identifying genes responsible for inherited diseases is fundamental to elucidate their 
pathogenetic mechanisms and better understand the biological pathways and cellular 
processes involved. Uncovering the molecular basis of a genetic disorder opens the possibility 
to molecular diagnosis for patients and carriers, and to prenatal testing; moreover it represents 
the starting point for developing a future therapy. Although many advances in human and 
medical genetics have occurred, the identification of disease genes within the whole genome 
still represents a big challenge, and more than half of about 7500 Mendelian disorders 
classified based on clinical features have not been genetically characterized yet. Indeed, up to 
25 November 2013, a total of 22,111 entries were reported in OMIM (Online Mendelian 
Inheritance in Man) describing 14,432 genes, 3,977 phenotypes with identified molecular 
basis and 3,593 with still unknown genetic cause (http://omim.org/statistics/entry). 
 Amongst the traditional approaches of gene discovery used for Mendelian disorders, 
Sanger sequencing and linkage analysis with positional cloning found the broadest 
applicability in the previous three decades. Thus far, Sanger sequencing method has been 
effective for screening a limited number of genes which have already been associated with a 
specific disease. This approach revealed suitable for disorders that are characterized by a clear 
and straightforward genotype-phenotype correlation and for which a deep medical and 
biological prior knowledge is available.  
 On the other hand, when the prior genetic knowledge is limited or the phenotype is not 
closely related to a underlying unique genotype, genetic mapping has turned out the approach 
of choice. This represents an unbiased approach and allows to analyse the whole genome. 
This method has been particularly powerful in identifying genetic mutations with a large 
effect size and rare prevalence in the population. 
 Over the last years, with the introduction of massively parallel or Next Generation 
Sequencing (NGS) technologies, several limits of the traditional approaches have been 
overcome and novel causal genes have been discovered. The whole genome sequencing 
(WGS) and the target sequencing, such as the whole exome sequencing (WES), have been 
increasingly used to shed light on Mendelian disorders. 
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1.1.2 Linkage analysis 
 Before the advent of the NGS, the genome-wide linkage analysis followed by 
positional cloning was considered the main tool to unravel the genetics of Mendelian diseases 
in families. Noteworthy examples are cystic fibrosis and Huntington disease, for which CFTR 
and HTT genes were identified (Group 1993;Tsui et al., 1985). 
The statistical method of linkage analysis is based on the theory that the absence of 
recombination events between genetic markers and the disease gene during meiosis makes to 
infer they are physically close together on a chromosome. This analysis starts from 
genotyping data of polymorphic genetic markers such as short tandem repeats (STRs) and 
single nucleotide polymorphisms (SNPs), and aims to highlight genomic loci co-segregating 
with the disease allele, which represent the candidate regions where the putative disease-
associated gene map. In order to pinpoint the causal mutations in the causal gene, genes 
within candidate regions are subsequently prioritised based on expression, function and 
homology data available in bioinformatic databases (candidate positional cloning method). 
The best candidate genes are thus screened with Sanger sequencing to look for variants which 
are potential mutations in the disease. 
Even if many cases have been solved by this traditional approach, some disorders present a 
challenge for them. For instance, the linkage approach may display some weaknesses in cases 
of incomplete penetrance, misdiagnosis and occurrence of de novo variants. Moreover low-
prevalence disorders with a small number of available unrelated cases, or a pedigree with few 
individuals, constrain the effectiveness of this analysis (Ku et al., 2011). The following step 
of candidate positional cloning could be arduous as well, even if the human genome reference 
sequence is available today (Consortium 2004). The causal gene can indeed be missed due to 
incomplete information about genes or difficulties in sequencing large linkage regions. 
 
 
1.1.3 Next Generation Sequencing (NGS) approach and “second generation” 
sequencers 
 In 2003 the draft sequence of the human genome was completed by the Human 
Genomic Project by using almost exclusively the “first generation” sequencing or Sanger’s 
method (Consortium 2004;Lander et al., 2001). This goal fuelled the advances in sequencing 
technology, and in few years the first individual genome (James Watson) was successfully 
sequenced by the Illumina NGS platform, termed “second generation” sequencer  (Wheeler et 
al., 2008). 
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Although the capillary-based Sanger sequencing remains the “gold standard” due to its 
99.999% per-base accuracy, the revolutionary NGS technique reveals extremely advantageous 
in terms of costs, time and number of samples that can be analysed (Shendure and Ji 2008). 
High-throughput NGS method is characterised by highly parallelized reactions which use 
smaller reagent volumes in little areas, thus enabling the sequencing of thousands to millions 
molecules at once. NGS generates shorter sequences termed “reads”, with a lower per-base 
accuracy compared with the Sanger sequencing. However this limitation is compensated by 
the high number of overlapping reads, quantified as “depth of coverage”. Furthermore, the 
most time-consuming step of cloning genomic libraries in bacteria, is here overcome by an in 
vitro reaction. 
Despite of traditional linkage approach, NGS directly detects both common and rare variants, 
and enables to identify causal mutations even starting from a small number of patients. In 
addition the discrete information of genotyping moves to a continuous one with a single-
nucleotide resolution in NGS. The gene identification in Mendelian disease is thus 
transforming and shifting from the identification to the interpretation of data. 
In general, NGS relies on DNA synthesis or ligation chemistry strategies to read through 
clones of DNA templates simultaneously and in a parallel fashion. By exploiting DNA 
synthesis cycles alternating with imaging-based acquisitions, sequencers collect data as short 
reads, each of them corresponds to a clone that is spatially clustered on substrate. For signal 
detection, “second generation” sequencers take advantage of Sanger’s synthesis chemistry, 
based on fluorescently labelled nucleotides and optical recording. NGS technology varies 
amongst the main platforms provided by different sequencing companies. Roche 454 
pyrosequencing employs emulsion PCR for clonal amplification and cyclic synthesis; 
Illumina (Solexa) uses bridge PCR and reversible terminator sequencing, Applied 
Biosystem/Life Technologies SoLiD requires emulsion PCR on beads and ligation chemistry 
for sequencing (Hui 2012). 
 
 
1.1.4 Whole-genome and exome sequencing 
 Exome comprises near to 180,000 protein-coding exons in 23,500 total genes and 
constitutes approximately 1-2% of the whole genome. Coding sequence has proven to be the 
prevalent source for the study of disease genes, as exome harbors 85% of the causal mutations 
of Mendelian diseases that have been solved up to now (Choi et al., 2009). 
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As the research of causing mutations requires sifting through a great deal of sequence data, 
the whole-exome sequencing (WES) allows to reduce them to a relatively limited subset 
compared with genome sequencing. Indeed, each genome contains 3.2 billion nucleotide and 
3-4 million sequence variants, whereas each exome about 30 million nucleotides and 25,000 
high-quality single nucleotide variants (Marian 2012). In addition, coding regions are less 
polymorphic because subjected to a major selective pressure, and less repetitive, thus 
reducing misalignment of reads and errors of interpretation. Furthermore the current ability to 
interpret the functional effects of non-coding sequence variations is highly limited. For all 
these reasons, to date an increasing number of genetic studies for Mendelian disorders uses 
the WES approach. Indeed, in the last four years the WES has been confirmed the successful 
approach for identifying genes where traditional methods failed. 
 
 
1.1.5 Exome-sequencing technology 
 The WES experimental pipeline is characterized by three main steps, with 2 and 3 
steps that vary depending on capture kit and platform employed: 
1. genomic library preparation  
2. target enrichment 
3. NGS of the eluted target fragments. 
 1. The genomic DNA is randomly sheared by sonication, nebulization or enzymatic 
digestion to get desired fragments of about 200-250 bp. Fragments ends are repaired by T4 
DNA ligase and ligated to universal adaptors. Taking advantage of standard primers that 
anneal with the adaptors, fragments are amplified by low-cycle PCR (Shendure and Ji 2008). 
 2. The coding-sequences of the genomic library are captured by hybridization of 
biotinylated RNA or DNA probes (Bainbridge et al., 2010;Gnirke et al., 2009). This 
represents the main method, but other methods such as selective amplification by PCR or 
enzymatic methods can be used. The hybridization can be performed in a solid or liquid 
phase, depending on whether the probes are fixed on a solid support or in solution (with 
biotinylated probes and streptavidin-coated magnetic beads) respectively. Different capture 
kits can be preferred because they vary in efficiency and specificity (Parla et al., 2011). 
Through the target enrichment, random fragments corresponding to coding exons/adjacent 
intronic regions are thus selected, whereas the unbound DNA fraction is removed.  
 3. The third step is the sequencing of the exome library by the NGS technology. 
Amongst the most commonly used (in this project as well) platforms there is the Illumina 
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(Solexa) based on bridge PCR. The technique uses universal primers attached to a solid 
substrate through a flexible linker, and these primers are recognized by universal adaptors of 
the exome library. Once single DNA fragments are immobilised on the substrate, they also 
anneal to another adjacent primer, thus creating a bridge structure (Figure 1.1). A single 
fragment is amplified in about 1000 clonal amplicons, which are linearized and sequenced to 
obtain one sequence read. Each added nucleotide is fluorescently labeled and has a 3’-OH 
reversible terminator that blocks the DNA synthesis, to enable fluorescence detection. The 
terminator is then removed and the next nucleotide can be incorporated into a new cycle. 
Reads generated by the sequencer have approximately the same length (50-100 bp) and start 
from one extremity of the library fragment (single-end read) or from both extremities (pair-
end reads).    
 
Figure 1.1: Illumina NGS technology based on solid-phase bridge PCR. (A) Library fragments bind 
complementary primers on the array surface and are amplified in clusters. (B) Clusters are sequenced by PCR 
with four-colour cyclic reversible termination method (Metzker 2010, with permission). 
 
The following phase is characterised by a computational pipeline, in order to analyse 
sequencing data and manage all detected variants. First the reads are aligned and mapped 
against the human genomic reference sequence, a consensus sequence created by the Human 
Genome Project. All sequence differences between reads and reference are annotated as 
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variants, by means of “variants calling” process. Variants are filtered for quality criteria and 
annotated by using several information from databases. The last and the most challenging step 
is the biological interpretation and management of the variation data, with the aim of 
identifying the disease-causing mutations. 
 
 
1.1.6 Successful applications of the Whole-Exome Sequencing 
 The first publication of the WES as a means for identifying disease genes dates at 
2009 (Ng et al., 2009). Up to now, WES has led to the identification of over 100 new genes in 
Mendelian diseases, and there is a increasing number of studies which employes it. Although 
publication bias makes it arduous to estimate the actual success rate of the WES, the major 
disease gene seems identified in at least 60% of projects for Mendelian diseases, mostly for 
recessive traits (Gilissen et al., 2012). 
The study of familial cases has proven that the WES is successful for extremely rare 
Mendelian disorders. For a monogenic inherited disorder, multiple family members can be 
sequenced to search variants shared by affected and absent in healthy individuals. Affected 
members that are preferred for a resolving WES study are the most distantly related, in order 
to reduce the amount of shared “benign” variations. Even non-affected individuals can be 
useful to exclude private benign variations. To cite an example, through the WES of four 
family members affected by dominant spinocerebellar ataxia, a mutation in the TGM6 gene 
was identified (Wang et al., 2010). 
Even the exome sequencing of unrelated individuals proved to be successful for rare 
Mendelian disorders with a little number of available cases. In 2009, WES study of four 
unrelated individuals affected by Freeman-Sheldon syndrome demonstrated its potential by 
finding MYH3, the unique gene with good candidate variants in all subjects (Ng et al., 2009). 
In 2010, a study identified for the first time the genetic cause of a rare recessive disorder, 
Miller’s syndrome; the sequencing of four affected individuals belonging to three independent 
families led to discover the DHODH causative gene (Ng et al., 2010). Other studies identified 
the most likely candidate disease gene by the sequencing of a single individual, but in other 
unrelated patients the same gene was excluded. Two examples are WDR35 for Sensenbrenner 
syndrome (Gilissen et al., 2010) and HSD17B4 for Perrault syndrome (Pierce et al., 2010). 
Exome sequencing of a considerable number of index cases can be even effective for 
phenotypically heterogeneous disorders. A considerable number of samples can improve the 
analysis since the pathogenic mutation could be missed or not shared by all patients. WES of 
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ten sporadic cases allowed to identify MLL2 as the gene underlying the Kabuki syndrome, an 
extremely rare and heterogeneous dominant Mendelian disease. At the beginning, this study 
failed to identify a common genetic cause; only by considering the sample heterogeneity and 
performing a less stringent filtering, MLL2 was successfully identified in seven individuals. 
Sanger sequencing of MLL2 in the remaining subjects did identify mutations in two out of 
three unsolved cases (Ng et al., 2010).  
WES approach even enables to overcome difficulties in studying sporadic disorders with low 
reproductive fitness, which are potentially caused by de novo mutations. For instance, de novo 
variants in SETBP1, the causal gene of Schinzel-Gedion syndrome, would not otherwise be 
identified without the WES, in this case by analysing four unrelated individuals (Hoischen et 
al., 2010). Another good strategy for identifying de novo mutations is the WES of the case-
parents trios, and the following exclusion of all inherited variants. A recent study involving 
175 autism trios put in evidence risk alleles in KATNAL2 and CHD8 genes (Neale et al., 
2012). 
Furthermore, the WES sequencing allows to successfully solve other issues. Noteworthy 
sequencing studies have unmasked misdiagnosis cases or enlarged phenotypic spectrum, by 
revealing mutations in known disease genes which have not been associated with the 
phenotype diagnosed before. For instance, Choi and colleagues identified mutations in 
SLC26A3, a gene coding for an epithelial exchanger, in a case with misdiagnosis of Bartter 
renal syndrome (Choi et al., 2009). 
More complex clinical pictures, characterized by the combination of more than one 
Mendelian phenotype and explained by the co-occurrence of mutations in multiple genes, can 
be unravelled by WES approach. For example in a study of two siblings, mutations in 
DHODH and DNAH5 were identified as the explanation of combined phenotype with Miller 
syndrome and primary ciliary dyskinesia (Ng et al., 2010). 
Other applications of WES approach are the study of common diseases and somatic mutations 
in tumours, and the support to diagnosis of disorders with high genetic heterogeneity.  
 
 
1.1.7 High variability of the human genome 
 With the advent of the NGS, studies of large cohorts became more feasible and the 
human genetic variability more characterised. Several projects collecting variants have 
highlighted higher genome variability than previously reported, with nearly half of the genes 
that are polymorphic in a genome (Levy et al., 2007). This plethora of variants discloses the 
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complexity of the genetic diversity of humans that has been furthered by the recent rapid 
expansion of populations. Considering such a background of thousands of variants (as 
mentioned in 1.3, 3-4 millions in a genome and approximately 25,000 in an exome), 
pinpointing a single mutation becomes extremely difficult. For instance, in every exome 
approximately 13,000 nonsynonymous variants (nsSNVs) could exert biological effects, there 
are more than 100 disease-causing or predisposing variants and 1000 novel variants, of which 
understanding the meaning still remains a challenging topic (Table 1.2). Multiple 
bioinformatics tools for predicting the functional effect tried to improve the analysis, but often 
they do not offer concordant results and still thousands of nsSNVs remain potentially 
“damaging” with this approach (Tennessen et al., 2012). 
However, the deep variant characterization which has been performing by recent projects will 
be useful for filtering analyses, interpreting WES data and better identifying the pathogenic 
effect of low-frequency variants. Indeed, current projects are demonstrating that rare variants 
tend to be recent events that display population-specificity (Abecasis et al., 2012). This 
finding implies that for investigating variant frequency, a control cohort belonging to the 
same geographically context is preferred in order to have the same genetic background. 
Highly polymorphic genes (i.e. olfactory and taste receptor gene families) and a pathway 
specificity for low-frequency variants load have been even detected by these studies. This 
information will be definitely useful for improving the variant filtering in a specific disease 
and to decipher the biological and clinical significance of a variant (Moore et al., 2011). 
 
 
 
 
 
 
 
 
Table 1.1: DNA sequence variants in the human genome. SNVs: Single Nucleotide Variants. CNVs: Copy 
Number Variants. nsSNV: non synonymous single nucleotide variants (modified by Marian 2012, with 
permission). 
 
1.1.8 Combinatorial approach of linkage analysis and WES 
Total variants 4 × 106 
SNVs 3.5 × 106 
CNVs 104-105 
nsSNVs  10,000-13,000 
nsSNV potentially damaging 100s-1,000s 
Loss of Function variants 120 
Associated with inherited diseases 50-100 
Stop codon 25-35 
De novo 30 
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 One of the main problems of WES is the manipulation of a large amount of data. This 
can be partially overcome in family studies, and specifically in the last years the integrated 
approach of WES with linkage analysis or homozygosity mapping has facilitated the 
identification of many disease genes. The traditional mapping approaches have the potential 
to narrow down first the number of variants identified by WES, second the number of 
individuals to be sequenced. In addition, the knowledge of candidate regions can be 
advantageous to apply a target sequencing approach specific for these loci. For instance, the 
combinatorial strategy was useful for identifying the disease gene IFRD1 in autosomal-
dominant sensory/motor neuropathy with ataxia, PIGV as underlying recessive 
Hyperphosphatasia-Mental retardation Syndrome and the causal VCP gene for dominant 
amyotrophic lateral sclerosis (Brkanac et al., 2009;Johnson et al., 2010;Krawitz et al., 2010). 
In cases of consanguineous families with a recessive mode of inheritance, a homozygosity 
mapping approach identifies loci where searching causal variants amongst WES data. For 
example, in a study where the FADD gene was associated with autoimmune 
lymphoproliferative syndrome, this strategy allowed to shortlist 23,146 variations to only 81 
ones (Bolze et al., 2010). 
Considering these advantages, over the last years the interest in linkage analyses is 
undergoing a renaissance due to NGS, which effectively scan nucleotide-by-nucleotide the 
even extended linkage regions. 
 
 
 
1.2 
 
1.2.1 Vulnerability of the neuron 
 Ubiquitously expressed proteins often play crucial roles in specific cell types or 
tissues. This is particularly frequent for proteins that are necessary to maintain the proper 
functionality of one of the most sensitive tissues, the nervous system. Peculiar features of 
neurons predispose to this characteristic sensitivity. First, cell size and axonal length (1 meter 
axon is over 10,000 times its cell body dimension and over 100 times its volume) require an 
efficient intracellular transport system to connect synapse and dendrites to cell body 
(Coleman 2013). For this reason cytoskeleton and motor proteins are critical for a proper 
retrograde and anterograde trafficking of molecules, membrane and organelles. Molecules 
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involved in this process use just one dimension, while most cells can use all three dimensions. 
Second, branching morphology of the neuron makes cell membrane particularly exposed and 
susceptible to mechanical damage and other exogenous stresses. Thus, an efficient stress-
response repertoire with chaperone and other proteins is vital for the neuron. Third, neuron is 
reliant on high energy demands and high metabolic rate, which are supplied by a suitable 
mitochondrial activity. For this reason, mitochondria need to maintain functional dynamics 
and protein quality controls. Fourth, the neuronal peculiarity of having synapse requires 
specialised processes in that districts, like calcium buffering and signalling pathways 
triggered by specific ion channels and receptors. 
An impairment of one of these physiological cellular processes and the presence of stress 
factors including oxidative stress and misfolded proteins can lead to neuronal damages. In 
addition, recent evidences demonstrate that also neighbourhood cells like microglia and 
astrocytes may contribute to this condition (Brambilla et al., 2013;Di Malta et al., 2012). As 
neurons are not promptly regenerated, over time they can undergo a slow process of 
neurodegeneration, which starts long before visible outcomes. An example is the “dying 
back” process, a progressive distal to proximal length-dependent axonal degeneration that 
precedes cell death. Only when many cells die or undergo a functional decline and a part of 
the nervous system becomes damaged, clinical manifestations come out. Specifically, Shaw 
and colleagues tried to explained different neurodegenerative disorders with a selective 
neuronal vulnerability and the consequent neurodegeneration of definite regions, however to 
date the bases of this neuronal specificity remain elusive (Shaw 2005). In addition, a 
stressors-threshold model have recently attempted to explain this selective neuronal 
vulnerability in different genetic disorders. Specific genetic causes appear to enhance the 
sensitivity to stressors of specific subpopulations of neurons, characterized by specific cellular 
proteins, energy and organelle homeostasis processes. Moreover, the accumulation of specific 
combinations of intrinsic and environment-induced stressors can play an important role in 
disease aetiology and progression of neurodegeneration (Saxena and Caroni 2011). 
 
 
1.2.2 Complexities of the inherited neurodegenerative disorders 
 Human neurodegenerative disorders are among the most heterogeneous diseases 
currently known in terms of clinical and genetic features, and for this reason among the most 
difficult disorders to dissect. Variable clinical manifestations, uncertainty of the diagnosis, 
ambiguity in the phenotype and incomplete penetrance represent examples of clinical 
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heterogeneity that can hamper the study of these disorders. In some of these cases the initial 
diagnosis need to be re-evaluated after the identification of the genetic cause or the clinical 
spectrum become wider than previously appreciated. Even in cases with unambiguous 
diagnosis and clear mode of inheritance, there could be a complicated connection between 
phenotypes and their corresponding genetic changes. 
Genetic heterogeneity characterizes several Mendelian disorders. Hereditary Motor Sensory 
Neuropathies (HMSNs) and Hereditary Spastic Paraplegias (HSPs) are exemplifying 
disorders with high genetic heterogeneity: more than 50 genes for HMSNs and 30 for HSPs 
are reported as causal to date. Moreover, specific mutations in the same gene can underlie 
diverse phenotypes. A noteworthy example is the L1CAM gene responsible for agenesis of the 
corpus callosum, CRASH syndrome, hydrocephalus and MASA syndrome or SPG1 (Jouet et 
al., 1994;Menkes et al., 1964). Different mutations can even underlie different modes of 
segregation, such as in MPZ and PMP22 genes which is causal in both autosomal dominant 
and recessive diseases (Baets et al., 2011). 
A detailed description of clinical and genetic features of the diseases studied in this project is 
reported in the following chapters. 
 
 
1.2.3 Hereditary Motor Sensory Neuropathies and their heterogeneity 
Hereditary Motor Sensory Neuropathy (HMSN), also known as Charcot-Marie- 
Tooth disease (MIM118300), is a remarkable phenotypically and genetically heterogeneous 
group of diseases which affect the peripheral motor and sensory nervous system (PNS). 
HMSN is considered the most common inherited neuromuscolar disorder, given the 
prevalence of about 1 in 2500 individuals (Szigeti and Lupski 2009). The common clinical 
hallmarks in HMSN variable phenotypic picture include slow and progressive muscular 
weakness of distal limbs and peroneal atrophy, commonly associated with sensory loss, 
reduced tendon reflexes and skeletal deformities (pes cavus, hammer toes and scoliosis). The 
age of onset, disease course and severity are all variable features, but in general symptoms are 
displayed in the first/second decades of life, with a slowly progressive course. Severity is 
mainly displayed in recessive forms. Moreover, variable expression and oligosymptomatic 
patients were described even in the same families. Unfortunately at present, rehabilitation 
therapy and surgical procedures are the only available treatments for HMSN (Pareyson and 
Marchesi 2009). 
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Peripheral neuropathies have been traditionally classified according with neurophysiology and 
clinical data. A median nerve motor conduction velocity (MCV) below 38 m/s is associated 
with demyelinating forms (dominant CMT1 and recessive CMT4) and prominent 
neuropathologic features are myelin abnormalities. A MCV above 38 m/s instead indicates 
axonal forms (CMT2) with evidence of chronic axonal degeneration and regeneration. Several 
exceptions to this division and mixed features have been increasingly reported. A MCV 
between 25 and 45 m/s characterises dominant-intermediate (DI-CMT) and X-linked forms 
(CMTX). Other CMT-related neuropathies with a normal MCV are distal hereditary motor 
neuropathies (dHMN) and hereditary sensory and autonomic neuropathies (HSAN), 
depending on the affected motor or sensory nerves respectively. More recently, a growing 
number of complex CMT forms involving other tissues such as the central nervous system, 
muscle, bone and skin have emerged. For instance, the FBLN5 gene identified for CMT was 
previously implicated in cutis laxa and macular degeneration (Auer-Grumbach et al., 2011) 
and the TRPV4 gene was already associated with ‘neuro-skeletal’ phenotypes (Chen et al., 
2010). Moreover, cases with phenotypes complicated by pyramidal involvement have been 
described in HMSN type V and optic atrophy in HMSN type VI (Barisic et al., 2008;Pareyson 
et al., 2006). 
At the present time, CMT is still classified into subtypes based on the pattern of inheritance 
and the electrophysiological features (Vallat et al., 2013). However over the last years, a 
classification based on genetics was performed and highlighted a growing genetic 
heterogeneity associated with this disease. The number of causal genes has increased rapidly 
since the first discovery of the most frequent cause (accounts for 40-50% of all CMT cases) in 
1991, the duplication of the PMP22 gene associated with CMT1A (Lupski et al., 1991). Up to 
now more than 50 disease related genes have been identified through classical linkage studies 
followed by Sanger sequencing and recently by NGS approach. These genes are inherited 
through all possible Mendelian transmission patterns. The more common is autosomal-
dominant way of inheritance, followed by X-linked transmission; autosomal-recessive is 
generally rare, except in contexts with a high rate of consanguineous marriages. The analysis 
of HMSN genes and their encoded proteins sheds light on the different molecular mechanisms 
underlying the disease and which convey in a common degenerative process of the peripheral 
neuron. Defects in myelin maintainment, axonal transport and cytoskeletal apparatus, 
membrane trafficking, lysosomal degradation, phosphoinositide metabolism, mitochondrial 
fission and fusion, protein folding and gene transcription were reported (Hui 2012). Besides 
this genetic heterogeneity, genetic studies even highlighted an overlap of genetic causes 
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between different mode of transmission (both dominant and recessive mutations in NEFL, 
EGR2, MFN2 and GDAP1), between different CMT forms (i.e. MPZ, NEFL for both CMT1 
and 2; GDAP1 for CMT2 and 4), between CMT2 and dHMN (the HSPB1, HSPB8, BSCL2 
and GARS genes), and between CMT and other motor neuron diseases such as axonal CMT2 
and spastic paraplegia (HMSN type V caused by BSCL2, GJB1 and MFN2 mutations) (Baets 
and Timmerman 2011;Reilly and Shy 2009). 
 
 
1.2.4 Distal Hereditary Motor Neuropathies: a subgroup of HMSN 
Distal Hereditary Motor Neuropathies (dHMN) are characterized by a  
predominant motor involvement and minor or no sensory loss, with a very rare prevalence (no 
data available) (Siskind et al., 2013). Moreover, dHMN accounts for about 10% of all cases of 
spinal muscular atrophy (SMA) and specifically distal forms (DSMA). The main clinical 
features are usually slowly progressive length-dependent weakness and wasting with 
hyporreflexia. The onset generally occurs in the first two decades of life. Neurophysiology 
studies show increased motor amplitude and duration potentials suggesting a chronic distal 
denervation, and this enables to differentiate dHMN from CMT2 and distal myopathy. 
The first classification of dHMN was based upon clinical phenotype and mode of inheritance 
(Harding 1993). Harding proposed a division in seven categories (types I-VII), with types I, 
II, V and VII autosomal dominant forms and types III, IV and VI autosomal recessive forms. 
Type I and II are typical dHMN, III and IV are chronic forms of dHMN differentiated by the 
diaphragmatic palsy in type IV, type V is characterised by upper-limb onset, type VI is 
instead characterised by distal weakness and respiratory failure, and type VII is mainly 
defined by vocal-cord paralysis (Table 1.2). Considering all dHMN and/or DSMA annotated 
in OMIM database, up to now 17 disease related genes and 4 genetic loci with unidentified 
genes have been identified (Table 1.2). The analysis of encoded proteins sheds light on the 
molecular mechanisms underlying the disease. Defects in protein folding, neuroprotective 
signalling, DNA/RNA processing and metabolism, axonal transport and cation-channel 
dysfunction were described as pathogenetic mechanisms. These diverse functions suggest a 
multifactorial process or numerous possible ways causing the primary damage in the cell body 
of the ventral horn cell (differently from the axonal degeneration of HMSN). Since the 
primary pathologic process occurs in the cell body, neuropathies are even referred to as 
“neuronopathies”. 
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Molecular genetic studies have highlighted a high phenotypic heterogeneity of dHMN. 
Phenotypic variability is both intrafamilial as well as interfamilial, even for the same 
mutation. This suggests additional modifying factors, environmental or genetic, influencing 
the phenotype. An overlap of genetic causes between different modes of transmission and 
different dHMN types has been indeed reported. Moreover, some of these mutated genes are 
common between dHMN and CMT2 (HSPB1, HSPB8, BSCL2, GARS, TRPV4), also for the 
same mutations. For instance, p.S135F HSPB1 mutation results in both dHMN2 and CMT2, 
p.K141N HSPB8 mutation causes both dHMN-II and CMT2L in unrelated families and GARS 
mutations cause both dHMN-V and CMT2 (Antonellis et al., 2003;Houlden et al., 2008;Irobi 
et al., 2004). Clinical variability of dHMN also extends up to upper motor neuron 
involvement, specifically in dHMN complicated by pyramidal signs. This form has been 
associated with mutations in BSCL2, SETX, HSPB1 and three as-yet unidentified genes in loci 
9p21.1-p12 (HMN-Jerash), 7q34-q36 and 4q34.3-q35.2 (Rossor et al., 2012). It is interesting 
to note that BSCL2 p.S90L mutation causes the more severe SPG17 phenotype, with upper 
motor neuron signs and lower limbs spasticity in addition to the muscle atrophy of upper 
limbs (Dierick et al., 2008). Moreover, a digenic inheritance of the neighboring BSCL2 
p.N88S mutation with a second chr16p locus was reported in a dHMN5 family with variable 
presentation and additional pyramidal features (Brusse et al., 2009). In addition, dHMN 
genetic causes can be found in other motor syndromes including juvenile amyotrophic lateral 
sclerosis (ALS), Kennedy disease, myopathy and spastic paraplegia (Table 1.2). 
Despite all these advances in genes discovery, the causal gene has not been identified in more 
than 80% of dHMN patients yet (Rossor et al., 2012). 
 29 
 
Locus Disease Inheritance Overlapping Diseases Gene Protein Clinical  phenotype 
7q34-q36 dHMN I AD  -  
Juvenile onset, lower limb 
predominant distal weakness and 
wasting 
12q24.23 dHMN IIA AD CMT2L HSPB8 heat-shock 22-kD protein-8 
7q11.23 dHMN IIB AD/AR CMT2F HSPB1 heat-shock 27-kD protein-1 
5q11.2 dHMN IIC AD  HSPB3 heat-shock 27-kD protein-3 
Adult onset, lower limb 
predominant distal weakness and 
wasting 
11q13 dHMN III DSMA3 AR  -  
Adult onset, distal weakness and 
wasting 
11q13 dHMN IV DSMA3 AR  -  
Juvenile onset, severe muscle 
weakness and wasting and 
paralysis of  diaphragm 
7p14.3 dHMN VA DSMA5A AD CMT2D GARS glycyl tRNA synthetase 
11q12.3 dHMN VA DSMA5 AD 
Silver syndrome, 
SPG17 BSCL2 seipin 
Upper limb predominant distal 
muscle weakness and wasting 
2p11.2 dHMN VB DSMA5B AD SPG31 REEP1 
receptor expression 
enhancing protein 1 
onset in the first or second 
decade, distal muscle weakness 
and atrophy primarily of  hand 
muscles 
11q13.3 
dHMN VI 
DSMA1 
(SMARD1) 
AR  IGHMBP2 immunoglobulin mu binding protein 2 
Infantile onset, severe form with 
respiratory distress 
2q12.3 dHMN VIIA AD Harper-Young Myopathy SLC5A7 
solute carrier family 5 
member 7 
Adult onset, with vocal cord 
paralysis 
2p13.1 dHMN VIIB AD 
ALS1, Perry 
syndrome, 
dSBMA 
DCTN1 dynactin1 
Adult onset, breathing difficulties 
due to vocal cord paralysis, facial 
weakness and hand muscle 
atrophy 
9q34.13 
dHMN with 
pyramidal 
features 
AD ALS4 SETX senataxin 
Juvenile onset, distal weakness 
and wasting with pyramidal tract 
signs 
4q34.3-
q35.2 
dHMN with 
pyramidal 
features 
AD CMT5 -  
Adult onset, lower limb distal 
weakness and wasting with 
pyramidal tract signs 
Xq12 DSMA X1 AR Kennedy disease AR androgen receptor 
Variable onset, spinal and bulbar 
muscular atrophy, facial 
fasciculations 
Xp11.23 DSMA X2 X-linked  UBE1 ubiquitin activating 
enzyme 1 
Infantile onset, severe hypotonia, 
areflexia, and multiple congenital 
contractures 
Xq21.1 DSMA X3 X-linked 
Menkes disease, 
Occipital horn 
syndrome 
ATP7A 
transmembrane copper-
transporting P-type 
ATPase 
Juvenile onset, distal weakness 
and wasting 
2q35 DSMA5 AR  DNAJB2 (HSJ1) 
heat-shock 40-kD 
protein DNAJ-like 1 
Young adult onset, slowly 
progressive distal muscle 
weakness and atrophy 
1p35 DSMA6 AR 
Recessive 
intermediate 
CMTC 
PLEKHG5 
pleckstrin homology 
domain-containing 
protein, family G 
member 5 
Childhood onset muscle 
weakness and severely decreased 
respiratory function 
9p21.1-
p12 
dHMN-J 
DSMA2 AR  -  
Juvenile onset, distal weakness 
and wasting with pyramidal tract 
signs 
12q24.11 Congenital distal SMA AD 
CMT2C, 
Brachyolmia 
type 3, 
Scapuloperoneal 
spinal muscular 
atrophy 
TRPV4 
transient receptor 
potential cation channel 
subfamily V member 4 
Nonprogressive lower limb  
weakness and paralysis with 
contractures 
14q32.31 
SMA lower 
extremity-
predominant 
AD 
CMT2O, 
Kugelberg-
Welander 
syndrome 
DYNC1H1 cytoplasmic dynein 1 heavy chain 1 
Juvenile delayed motor 
development and lower limb 
weakness 
 
Table 1.2: Classification for dHMN, with causal genes and characteristic signs, based on OMIM annotation 
(http://www.omim.org/). AD = autosomal dominant, AR = autosomal recessive. 
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1.2.5 Co-occurring clinical features of axonal HMSN and HSP 
 In axonal HMSN the most frequent eight genes account for only 25% of cases (Reilly 
and Shy 2009). In addition, several complicated forms are observed for axonal CMT. By the 
traditional classification which divides HMSN from HSP, complex HMSN with pyramidal 
signs and HSP complicated by peripheral neuropathy are separately reported even if they have 
overlapping phenotypes. This dichotomous classification is probably due to the observed 
variable phenotypic spectrum which can ranges from HMSN to HSP even in the same family. 
Indeed, patients with both syndromes, others with a prevalence of peripheral neuropathy or 
pyramidal signs have been described. Genetic studies have increasingly confirmed that 
variable phenotypes are due to the same underlying genetic basis. Interesting examples are 
BSCL2 mutations associated with Silver syndrome and HSP phenotype; KIF5A determining 
peripheral neuropathy and pure HSP; MFN2 responsible for CMT2 and spastic paraplegia; the 
atlastin-1 (SPG3A), REEP1 (SPG33), NIPA1 (SPG6) and spastin (SPG4) genes commonly 
associated with HSP and also extended to peripheral neuropathy (Auer-Grumbach et al., 
2005;Goizet et al., 2009;Hewamadduma et al., 2009;Ivanova et al., 2007;Liu et al., 
2008;Schulte et al., 2003;Zuchner and Vance 2006). 
HMSN type V was the first complicated form of HMSN described in 1968 (Dyck and 
Lambert 1968). It is a rare autosomal dominant form of axonal CMT (CMT2), characterised 
by normal or slightly reduced nerve conduction velocity and lower limb atrophy, with 
additional pyramidal signs typical of spastic paraplegia. Pyramidal tract involvement is 
mainly displayed by spastic gait and variable tendon hyperreflexia manifestations. The onset 
usually occurs in the second decade of life or later and the course is slowly progressive. From 
a genetic point of view, no data are available so far about the genetic mapping of this form. 
Previous studies excluded already known genes and loci, but the rarity of the disorder and the 
limited number of studies hind further genetic investigations (Mostacciuolo et al., 2000;Vucic 
et al., 2003). Defining HMSN type V as a complicated form of CMT2 or HSP, or a stand-
alone clinical entity is still matter of debate. 
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1.2.6 Overlapping molecular mechanisms between HMSN and HSP 
 HMSN and HSP primarily affect specific target tissues, that are peripheral nerves 
(PNS) and corticospinal tracts/dorsal column (CNS) respectively. However both HMSN and 
HSP are considered progressive neurodegenerative disorders, with a length-dependent 
affection and a possible late onset. Besides the above-mentioned common genes, many other 
genes implicated solely in HMSN or HSP are instead involved in similar cellular processes. 
Examples of genes belonging to the same gene family, encoding proteins involved in the 
same biochemical pathway or directly interactors have been reported (Figure 1.2). Common 
cellular processes are membrane traffic, mitochondrial function, myelination, axonal transport 
and cytoskeletal organization (Timmerman et al., 2013).  
 
Figure 1.2: Similar and different cellular processes involved in the pathogenesis of HMSN and HSP. Genes 
associated with HMSN are indicated in blue and with HSP in red. Common genes are in black (Timmerman et 
al., 2013, with permission). 
  
Membrane traffic 
 The complexity of intracellular membrane structures is fundamental to define different 
compartments in neuron, its polarity, branching and long axons. Furthermore an efficient 
transport from cell body to synapses and neurites is necessary for their maintainment. 
Vesicles trafficking and membrane shaping processes can be impaired in HMSN and HSP. In 
HMSN mutated RAB7A and DNM2 genes code for RAB GTPases that play a key role in the 
vesicle formation and transport. Mutated SH3TC2 and SIMPLE proteins interact with other 
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proteins to recycle endosomes and for degradation via lysosomal pathway respectively. 
Mutated MTMR2, MTMR13 and FIG4 genes encode Phosphatidyl-Inositol-phosphatases 
located in the endosomes of Schwann cells. Furthermore, mutated frabin (FGD4) and 
ARHGEF10 are GTP/GDP exchange factors of Rho GTPases implicated in the myelination 
and cytoskeleton maintainment.  
In the same way, HSP genes code for transmembrane proteins involved in membrane 
trafficking. Reticulon2, spastin, atlastin1 and REEP1 are all involved in the endoplasmic 
reticulum (ER) shaping; strumpellin acts to shape endosome, spartin for lipid droplets and 
lysosome shaping. 
Mitochondrial dynamics 
 Dynamics of fusion/fission of mitochondria determine their morphology and size, but 
also regulate their distribution and function. Mitochondrial distribution and transport along 
the long axons play a primary role in the energy transport up to distal parts. Neurons are 
particularly vulnerable to mitochondrial dysfunctions because they require a high metabolic 
rate even in distal terminations and ATP is produced mainly by the mitochondrion. In 
addition, mitochondria are fundamental for the neuron survival because they synthesise key 
metabolites, buffer calcium and protect against oxidative stresses. In HMSN, mutated MFN2 
and GDAP1 proteins impair mitochondria fusion/fission leading to defects in the transport 
and energy production. In HSP, paraplegin AAA ATPase participates in protein quality 
control of misfolded proteins, similarly to the mitochondrial chaperone HSP60. 
Myelination  
 Myelin sheaths around the axons allow their insulation and the proper action potential 
conduction. Schwann cells in the PNS and oligodendrocytes in the CNS are responsible for a 
correct myelin production. For instance, causal genes for HMSN code for PMP22 and P0 
myelin proteins of Schwann cells. Moreover, connexin32 of gap junctions and periaxin for the 
Schwann cell-axon contacts can be also mutated. Mutations in EGR2 and SOX10 
transcription factors regulating the expression of these four proteins have been also identified 
in HMSN. Similarly in HSP, mutated PLP1 and FA2H proteins play a role in the CNS 
myelination, and even the intercellular communication can be involved in the pathogenesis of 
HSP disorders with mutations in the connexin 47 gap junction protein. 
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Cytoskeleton stability and motor proteins 
 The neuronal intracellular transport is essential to supply the axon with newly 
synthesized molecules and for anterograde transport of neurotrophic factors and damaged 
organelles. The neuronal transport requires functional motor proteins and cytoskeletal 
network. For instance, NEFL protein that plays a fundamental role in the intermediate 
neurofilaments assembly and transport, and tubulinβIII for microtubules stabilization are 
mutated in HMSN. Other mutations in dynactin-1, interactor of dynein for the retrograde 
axonal transport, have been associated with HMSN. Likewise in HSP, spastin protein 
catalyses the microtubule severing and KIF5A kinesin has essential roles in the anterograde 
axonal transport. 
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2. AIM OF THE RESEARCH 
 
 This study aims to identify and, whenever possible, functionally characterise genes 
causing highly heterogeneous forms of hereditary peripheral neuropathy. With the purpose of 
shedding light on the genetics of these diseases, four families affected by complex forms of 
hereditary peripheral neuropathy and showing no mutations in already known disease-genes 
have been examined. Three of these families display an autosomal recessive mode of 
inheritance and one family presents an autosomal dominant transmission. 
The identification of novel genes is performed by using a comprehensive strategy of 
traditional approaches coupled with the next-generation approach of whole-exome 
sequencing. Linkage analysis, homozygosity mapping and identity-by-descent analysis enable 
to detect candidate regions in which the disease-associated gene potentially segregates. The 
whole-exome sequencing allows to inspect the variants in the coding exons of the candidate 
regions. Considering the advantage of having variants within the whole exome, the known 
disease-related genes are also analysed and less stringent genome-wide searches are even 
conducted. The best candidate variants are selected by filtering and prioritization analyses 
which allow to evaluate the possible pathogenicity of the variants. For the potential mutations, 
further confirmations are obtained by means of in silico analyses, the study of allelic 
frequencies in the specific population, the genetic screening of unrelated patients and 
functional studies. 
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3. RESULTS 
 
3.1 General approach 
 
 With the aim to identify candidate genes associated with the disease, the study of 4 
independent families started from a genome-wide search performed with SNPs and confirmed 
by STR markers. For all families the most frequently mutated genes causing neuropathy and 
spastic paraplegia have been screened by Sanger sequencing in previous studies, without 
finding the genetic cause amongst the genes identified before 2009. 
In the current project, the candidate linkage regions found by traditional genetic mapping 
strategies were better refined and less stringent analyses were performed to overcome 
technical and computational limits of the technique. For the families with an uncertain 
segregation, different models were taken into account. Whether a low number of genes 
mapped to the linkage regions, the candidate positional cloning by Sanger sequencing was the 
approach of choice. The study of Family 1 is an example of application of this traditional 
method. 
In three other families (Family 2, 3 and 4) large linkage regions with many genes were 
identified and the whole-exome sequencing (WES) approach was used. The first sequencing 
dated 2011, a more recent sequencing dates December 2013. The exome analysis was 
performed by the Beijing Genomics Institute (BGI) which used the Agilent SureSelect Human 
All Exon v4 or v4+UTRs kits for the targeted enrichment and the Illumina (Solexa) Hiseq2000 
platform for the sequencing. End-paired reads of about 90 bp were obtained and aligned 
against the human reference sequence (hg18) (NCBI build 36.3 assembly), in order to detect 
the mismatches and call the variants. The analysis of nearly 100,000 high-confidence variants 
identified by WES focused on the known disease-genes and on genes located in the linkage 
regions. In parallel, the depth of coverage was analysed and the poorly-covered exons were 
sequenced to identify undetected variants. Variants were critically evaluated, filtered and 
prioritized using information annotated in databases and in other in-house exomes. A 
manageable pool of good candidate variants with a putative pathogenicity was obtained and 
validated by Sanger sequencing. The approach to identify a recessive trait was exemplified by 
the studies of Families 2 and 3, whereas the study of a dominant trait was exemplified by 
Family 4. 
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3.2 Identification and characterisation of a novel mutation in the SACS gene 
 
3.2.1 Clinical picture of Family 1 
 This consanguineous three-generation family comes from a little village of Northern 
Italy and presents three brothers (II-2, II-3 and II-4) affected by a severe form of peripheral 
neuropathy and spastic paraplegia. All family members were seen as adults by Dr. Pegoraro 
of the Department of Neurosciences, University of Padova, except the affected brother (II-2) 
who died before the study for lung cancer, but was reported to have the same gait disturbance. 
The age of onset was about 20 years. The patients presented mild hand muscle atrophy and 
distal hypotrophy of the lower limbs, with bilateral Babinski sign and foot deformities 
including bilateral pes cavus and hammer toes. Progressive lower limb spasticity with foot 
drop, incontinence and hyperreflexia were also displayed. Electrophysiological studies and 
nerve biopsy revealed the presence of a severe peripheral sensorimotor neuropathy with 
mixed axonal and demyelinating findings. The muscle biopsy showed a normal mitochondrial 
histochemistry and fibre type grouping, suggesting a re-innervation process. Brain magnetic 
resonance imaging (MRI) showed non-significant evidence of cerebellar and spinal cord 
atrophy. Moreover, ocular fundus appearance was normal without retinal nerve 
hypermyelination. 
The analysis of the pedigree suggested an autosomal recessive way of inheritance of the 
disease. Affected sib’s healthy parents were second cousins and the recurrence of the clinical 
phenotype was observed only in the second generation, without finding any manifestation in 
other generations. 
 
 
 
Figure 3.1: Pedigree of family 1. 
3.2.2 Preliminary results 
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 The first studies on this family excluded mutations on the disease-genes most 
frequently associated with similar clinical pictures including PMP22, SPAST, ATL1, SPG7 
and KIAA1840. Considering the presence of a severe peripheral neuropathy, the MFN2 gene, 
responsible for the most common form (20-30%) of axonal CMT type 2 (CMT2A), was also 
analysed (Ortega-Roldan et al., 2013). Interestingly, a heterozygous missense substitution 
(c.749G>A, p.Arg250Gln) was identified in the proband (II-4) and in two asymptomatic 
subjects (I-2 and III-2) but not in the affected brother (II-3). Despite the specific mutation was 
already identified in literature (McCorquodale et al., 2011;Zuchner et al., 2004), c.749G>A 
substitution did not co-segregate with the disease and it was unlikely to be the primary cause 
of the clinical phenotype in this family. In addition, this variant has been recently reported in 
EVS database at the heterozygous state in 4 out of 6503 human genotypes and in dbSNP 
database as polymorphism (rs140234726). Accordingly, its pathogenic role in CMT2A needs 
further confirmation. 
The presence of a novel disease gene was investigated by a whole-genome scan. The analysis 
was first performed by using 368 STR markers and subsequently by genotyping over 200,000 
SNPs (Illumina Human CNV370-Quad platform). Copy number variant analysis did not 
identify any candidate chromosomal deletion/duplication (>10 kb) and all genes and loci 
already associated with this phenotype were excluded by linkage analysis. However a 
maximum linkage signal on chromosome 13q12.1-q12.12 was highlighted. The LOD score 
value (2.58) was not significant but the only one confirmed in the analyses with different SNP 
sets. It was close to the theoretical maximum value that this relatively small family could 
generate in the case of linkage. 
 
3.2.3 Candidate gene screening  
 The haplotype reconstruction on chr13q12.1-q12.12 confirmed and better refined a 
large homozygous region of 1.6 Mb (312 consecutive homozygous SNPs) which co-
segregated with the disease. The critical interval (rs12868337; rs7997447) contained only 5 
genes: SGCG already associated with muscular dystrophy, SACS associated with the spastic 
ataxia of Charlevoix-Saguenay, non-coding RNA LINC00327, TNFRSF19 involved in the 
embryonic development and MIPEP implicated in the protein maturation. The SACS gene was 
considered the best candidate as it is already associated with a neurodegenerative disease. 
Direct sequencing of the entire gene identified a missense substitution (c.11,104A>G ), which 
leads to the p.Thr3702Ala amino acid change. This substitution co-segregated with the 
disease in the family: both available affected patients (II-3, II-4) were homozygous, whereas 
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their parents (I-1, I-2), the unaffected brother (II-5) and the two unaffected nephews (III-1, 
III-2) were heterozygous. Furthermore, haplotype reconstruction allowed to infer the status of 
the third unavailable affected brother (deceased subject II-2) who could be homozygous for 
the mutation (Figure 3.2). The c.11,104A>G variant was not present in the NHLBI Exome 
Variant Database amongst 6503 exomes, nor in the 1000 Genomes data set, nor in dbSNP 
(build 137) neither in LOVD, HGMD, Uniprot and ClinVar databases which annotate disease 
mutations. In addition, by tri-primer ARMS-PCR (Allele Refractory Mutation System PCR) it 
was excluded from 700 control chromosomes from Northern Italy. 
 41 
 
Figure 3.2: Haplotype on chr 13q12.1-q12.12. Chromosomes in red bear the 1.6 Mb region (limits pointed by 
black arrows) co-segregating with the disease, where the SACS gene carries the c.11,104A>G mutation. 
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3.2.4 In silico analyses  
 SACS (NM_014363.5) was considered the best candidate gene of the chr13q12.1-
q12.12 linkage region as it has been already associated with a neurodegenerative disease 
(Engert et al., 2000). To date the enormous size of sacsin encoded protein (NP_055178) 
(4,579 amino acids and with the largest exon amongst vertebrates of 12.8 Kb) has 
considerably hindered biochemical studies. For this reason, also if more than 100 SACS 
mutations have been identified in patients, very few studies have been published on sacsin 
function (Duquette et al., 2013). 
Considering the limits in the functional studies, the first investigation was performed in silico, 
in order to evaluate whether the c.11,104A>G variant could have a pathogenic significance. 
Sequence conservation was assessed by significant scores obtained by phyloP, GERP and 
phastCons tools, and its pathogenicity was predicted by PolyPhen-2, SIFT and 
MutationTaster prediction softwares. 
Secondly, an assessment of whether the amino acid substitution could affect the stability of 
the protein structure was performed. The secondary structure of the oligopeptide where 
p.Thr3702Ala falls was predicted by Jpred3, Psipred and SOPMA softwares and highlighted a 
longer α-helix for the mutated sequence compared with the reference sequence. This result 
suggested that the change from a polar amino acid (threonine) to an apolar one (alanine) 
potentially destabilizes the sheet structure in favor of an α-helix structure (Figure 3.3). 
 
 
Figure 3.3: The domain of sacsin protein where p.Thr3702Ala falls. It displays a longer α-helix at 42 and 43 
amino acid positions, in correspondence with the mutation (Prediction by SOPMA software). 
 
The domain where p.Thr3702Ala falls is a 75 amino acid sequence (3660–3735) presenting 
35% sequence identity with the NMR structure of Xeroderma pigmentosum C binding 
(XPCB) domain of the hHR23A protein (amino acids 231–285; PDB code 1TP4) (Kamionka 
and Feigon 2004). Binding experiments in mouse demonstrated that hHR23A requires the 
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XPCB domain to interact with UBE3A protein and to deliver ubiquitinated proteins to the 
proteasome (Greer et al., 2010). The interaction with the E3 ubiquitin-ligase UBE3A was 
speculated also for the XPCB domain of sacsin, probably to be itself ubiquitinated and 
degraded via proteasome, or to degrade other misfolded proteins which sacsin chaperonin 
attempts to correctly fold. An inspection of the key amino acids that are potentially involved 
in the interaction with UBE3A was carried out by three-dimensional modeling. The homology 
modeling of the sacsin XPCB domain was performed by HOMER server and took advantage 
from the sequence similarity with hHR23A (Figure 3.4). The model showed the threonine 
residue at 3702 amino acid position exposed on the protein surface, thus revealing a possible 
protein-protein interaction site. Moreover, threonine and its surrounding residues are 
conserved amongst vertebrates (pink colour), suggesting a key role for the interaction with 
UBE3A. A confirmation was obtained by the prediction of ConSeq server which starts from 
the linear amino acid sequence and automatically collects the homologous sequences of the 
database. It predicted threonine position to be “functional” because highly conserved and 
exposed in the protein. In conclusion, in silico prediction of p.Thr3702Ala is in agreement 
with a potential functional effect of the mutation. 
               
.Figure 3.4: (A) Structural model and surface representation of the tertiary structure of sacsin XPCB domain, 
visualized by PyMol (cartoon and surface representations). The threonine at position 3702 (indicated by the 
arrow) shows localization within an exposed region which is conserved during evolution across sacsin 
orthologues (pink colour) as shown by the ConSurf program. Prediction obtained in collaboration with Dr. 
Tosatto’s laboratory. (B) Specific amino acid sequence where the change falls, with threonine position (indicated 
by the arrow) predicted to be functional by the algorithm of ConSeq server, because highly conserved and 
exposed. 
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3.2.5 Studies on fibroblasts of the proband 
 Early studies in literature revealed SACS transcript in fibroblasts, skeletal muscle and 
brain motor system at high levels, whereas the sacsin protein presented a cytoplasmic 
distribution with a partial mitochondrial localization (near to 30%) in different cell lines 
(Parfitt et al., 2009). In 2012 Girard and colleagues demonstrated that sacsin is required for 
the mitochondrial functionality, morphology and localization in neurons. They explained 
these findings through an imbalance between mitochondrial fusion and fission, probably due 
to the disruption of Drp1 function. In addition to sacsin knockdown studies, an alteration of 
mitochondrial dimensions was even indicated in the fibroblasts of patients homozygous for a 
frame-shift SACS mutation (c.8844delT) (Girard et al., 2012). Starting from this background 
of knowledge, the current study aimed to assess such mitochondrial impairment in the 
fibroblasts of the proband. The experiments were performed in the laboratory of Dr. Chapple 
(Barts and The London, School of Medicine and Dentistry, London), a collaborator in 
Girard’s project. Before studying mitochondria, SACS mRNA and sacsin protein were 
quantified by quantitative PCR and Western blot assays respectively, in order to check 
whether the mutation could affect the expression. The comparison were performed between 
fibroblasts derived from the proband and healthy controls. No evident differences were found, 
suggesting a normal mRNA and protein expression in the patients homozygous for the 
c.11,104A>G variant (Figure 3.5). Moreover, full-lenght protein of 520 kDaltons was 
detected by Western blot, thus excluding a mutational effect in splicing processes and a 
truncated protein. 
 
Figure 3.5: SACS expression assays. (A) real-time PCR analysis of SACS mRNA expression in fibroblasts;  
values were normalized to GAPDH gene expression.  The data represent mean ± SEM (n = 3). (B) Sacsin protein 
expression detected by Western blot method. 
 
After the confirmation of unaltered sacsin expression levels in patients, the mutational effect 
on mitochondria was investigated by evaluating mitochondria volumes and surface areas. 
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Immunostaining experiments with the antibody against TOM20 which labels mitochondria 
were carried out for 100 mutated and 100 control fibroblasts. Fluorescent z-stacks acquired by 
confocal microscope were volume rendered by Imaris software, in order to obtain 3D 
mitochondria as objects (Figure 3.6). First, the analysis highlighted an increased number of 
mitochondria in mutated fibroblasts. Indeed, 3849 mitochondria in proband’s fibroblasts and 
3482 in control fibroblasts were counted. On the other hand, the analysis of mitochondria 
volumes showed a mean value of 20.8 µm3 for controls and 17.4 µm3 for mutated fibroblasts, 
displaying a statistically significant decrease in presence of the p.Thr3702Ala mutation (p-
value= 0.031). Similarly, the surface area was  significant decreased in mutated fibroblasts (p-
value= 0.036; mean value of 53 µm2 for controls and 46.7 µm2 for mutated fibroblasts). The 
opposite trend was showed by sphericity data, which reflect how well an object fits a sphere 
(maximum score of 1 indicates a sphere). The mean value of 0.813 for mutated fibroblasts is 
significantly higher than 0.8 of controls (p-value= 0.003), indicating an increased sphericity 
for the more fragmented mitochondria of patients, as expected. Obviously these three-
dimensional morphometry measures require further supporting evidences, however these first 
findings are indicative of a higher fragmentation of mitochondria in presence of p.Thr3702Ala 
sacsin mutation, whereas in control fibroblasts the mitochondrial network is characterized by 
a typical interconnected tubular structure. These data are in agreement with the hypothesis of 
impairment in fusion/fission mitochondrial dynamics. 
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Figure 3.6: (A) An example of the three dimensional rendering of mitochondria in fibroblasts, labelled by 
TOM20 antibody (red). Nuclei are labelled by DAPI (blue). Scale bar, 20 µm. Box indicates the region enlarged 
at right (B).  
(C) Histograms of volumes, surface area and sphericity of mitochondria. Non parametric Mann-Whitney test of 
medians was used for the analyses, since a non-gaussian distribution of data was confirmed by D’Agostino test 
(p-value<0.05). Error bars represent standard error; one asterisk indicates a p-value<0.05, two asterisks indicate 
a p-value<0.01. 
 
Concluding, the findings obtained by the study of Family 1 seem consistent with the 
pathogenicity of the novel variant c.11,104A>G identified in the SACS gene. They 
suggest a role of the mutated sacsin protein in the pathogenic mechanisms underlying 
the clinical picture of peripheral neuropathy and spastic paraplegia. 
 
 
 
 
 
 
 
 
 
 47 
3.3 Identification of SIGMAR1 and SGK223 as candidate genes associated with distal 
Hereditary Motor Neuropathy 
 
3.3.1 Clinical picture of Family 2 
 This consanguineous family comes from a small and isolated village of Southern Italy, 
with a reported high rate of inbreeding. A detailed anamnesis of the whole family enabled to 
reconstruct a complex, seven-generation pedigree. This family presents four affected subjects, 
and amongst them the patient VII-1 refused the genetic investigation. Clinical data were 
collected by Dr. Cavallaro at the Hospital of Verona, and Dr. Tessarolo at S. Camillo-
Forlanini Hospital of Rome, who diagnosed a distal Hereditary Motor Neuropathy (dHMN). 
Even if the clinical hallmarks of lower limb weakness and bilateral pes cavus seemed shared 
by all patients and suggested a dHMN clinical picture, a more detailed diagnosis highlighted 
differences between the affected subjects V-3, VI-6 (gray symbols in the pedigree of Figure 
3.7) and patients VII-1, VII-2 (black symbols in the pedigree). Subjects V-3 and VI-6 
displayed a late-onset peripheral neuropathy (in third and second decade respectively), with a 
clinical picture characterized by lower limb weakness and atrophy, denervation of muscles, 
reduced osteotendinous reflexes and mild disfagia. Electrophysiological studies and nerve 
biopsy confirmed the diagnosis of dHMN. On the other hand, two other patients (VII-1 and 
VII-2) showed an earlier onset (in the first decade of life) and more severe clinical features, 
with even proximal signs, atrophy of the upper limbs, absent osteotendinous reflexes and a 
reduced motor conduction velocity with proximal conduction blocks (not altered in patients 
V-3 and VI-6). 
The analysis of the pedigree suggested an autosomal recessive mode of inheritance for the 
disease. Three consanguineous marriages (between IV-1 and V-3; IV-2 and IV-3; VI-1 and 
VI-2) with a clear kinship between spouses were showed, except for the union between 
individuals VI-3 and VI-4. Even if cases of incomplete penetrance have been already reported 
in literature for dHMN, an autosomal dominant transmission seemed less likely in this 
consanguineous family. 
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Figure 3.7: Pedigree of Family 2. Differently coloured symbols indicate distinguishable clinical pictures. 
 
 
 
3.3.2 Preliminary results 
 Over the previous years, the most frequently mutated genes for dHMN forms and for 
phenotypically overlapping forms of SMA and HMSN (i.e. HSPB1, HSPB8, GARS, BSCL2, 
IGHMBP2, SETX, DCTN1; SMN1 for SMA, PMP22 and MPZ for HMSN) were excluded by 
direct sequencing of genomic DNA. First linkage studies by using STR markers excluded also 
the already known loci for recessive forms of dHMN (11q13 for dHMN III, 11q13.3 for 
dHMN VI and 9p21.1-p12 for HMN-J). The presence of a novel disease locus was 
hypothesized and it was investigated by a whole-genome scan. Homozygosity mapping 
identified a candidate 1.1 Mb region on chromosome 11p12 (N11S409754; N11S23943), the 
only candidate region shared by all three patients available (V-3, VI-6 and VII-2). In this 
region, only the 5'-UTR of the LRRC4C gene, encoding NGL-1 protein, maps. Direct 
sequencing did not identify any variant co-segregating with the disease and unmasked a false-
positive autozygous region (identical-by-status) in VII-2. A high-density genome-wide 
linkage analysis was thus performed with over 160,000 SNP markers (Affymetrix Mendel 
Nsp 250K chip) distributed evenly across the genome. The multipoint linkage analysis was 
carried out by assuming an autosomal recessive model with 95% penetrance and disease allele 
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frequency of 0.0001. Since the analysis excluded a common genetic cause amongst all three 
patients, the model with two distinct genetic causes was considered. 
 
3.3.3 Analysis of two nuclei 
 The lack of shared candidate regions and the presence of two distinguishable clinical 
pictures led to the exclusion of a common genetic cause among all patients. Moreover, the 
family originates from a little village and the high inbreeding increases the probability that 
more disease alleles can segregate in the same family. For these reasons the whole family was 
splitted into two nuclei (Figure 3.8) by taking into account the patients with a more similar 
phenotype. The nucleus with V-3 and VI-6 patients was analysed separately from the nucleus 
with the two more severely affected subjects VII-1 and VII-2.  
 
 
Figure 3.8: Pedigree of Family 2 was splitted into 2 nuclei on the basis of the phenotypes. 
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3.3.4 Study of nucleus 1 
 
3.3.4.1 Homozygosity mapping  
 For identifying the disease-gene in this little consanguineous nucleus, the traditional 
homozygosity mapping approach was used to identify candidate regions co-segregating with 
the disease. Indeed, affected individuals are expected to share the mutation and the 
surrounding regions in an autozygous state because transmitted as identical by descent (IBD) 
by both consanguineous parents. The analysis of 160,000 SNP genotypes with 
HomozygosityMapper software highlighted 14 homozygous regions shared by the two 
affected subjects (V-3 and VI-6) with a homozygosity score higher than 0.8 (probability of 
homozygosity compared with control haplotypes of the CEPH collection of the HapMap 
project) (Figure 3.9). For each of these peaks, the haplotypes were evaluated in order to 
exclude regions shared by healthy subjects (V-4, V-5, V-6, VI-4 and VI-5). Through this 
analysis, two candidate regions were obtained: the interval on chromosome 11p12 previously 
identified and already excluded by direct sequencing and a novel candidate region on 
chromosome 8p23.1-p22 (Figure 3.9 and Table 3.1). 
 
 
Figure 3.9: Graphical representation of the homozygosity regions obtained for the two patients of nucleus 1. Red 
bars indicate the most promising genomic regions above the threshold value (0.8). Candidate regions selected 
after the haplotype evaluations and segregation are indicated by the two arrows. 
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Chr from (bp) to (bp)  from SNP to SNP Mb Total RefSeqs 
8 6754919 12718090 rs2738148 rs6997599 5.96 120 
11 39300178 40369557 rs10837138 rs11035793 1.06 1 
    total 7.02 121 
 
Table 3.1: Candidate regions selected after haplotype evaluations. For each region the chromosomal positions 
(hg19 release), flanking SNP markers, total validated Refseqs and OMIM genes mapping to the region were 
annotated. 
 
Haplotype reconstruction of chr8p23.1-p22 region pointed out a telomeric recombination 
event occurred at SNP_A-2207444 in previous generations and transmitted to both patients 
(II-2 and III-4 in Figure 3.10) by their healthy fathers (I-1 and II-1 respectively in the 
haplotype). This crossing-over defines the telomeric limit at 17.16 cM corresponding to 
6,734,409 genomic position. On the other hand, the recombination event occurred in patient 
II-2 at SNP_A-1911827 defines the centromeric limit at 26.05 cM (chr9: 12,964,191 genomic 
position). It is interesting to note that the patient III-4 displayed downstream a more extended 
homozygosity than his affected mother (II-2). 
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Figure 3.10: Haplotype reconstruction of chr8p23.1-p22 region in a subpedigree with the genotyped family 
members. Haplotypes associated with the disease are indicated in black. The autozygous region shared by the 2 
patients of nucleus 1 (here II-2 and III-4 indicated by gray symbols) is indicated by the box.  
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A less stringent homozygosity mapping was performed for the 2 patients separately in order 
to overcome any limit due to genotyping errors and for identifying also very narrow regions. 
It must be considered that a far common ancestor can imply many possible recombination 
events in previous meioses and the presence of small shared regions. Moreover, given the 
complexity of this family, the alternative hypothesis of transmission with one patient in 
homozygous state and the other one compound heterozygous in the same gene was 
investigated by this analysis. It is interesting to note that two narrow regions were identified 
on chr7q33-q36.2 and chr12q12 and were shared by both patients (Table 10 in Appendix E). 
For a complete inspection, all shared/not shared candidate regions were considered during the 
subsequent analyses of the variants identified by the exome sequencing. 
 
3.3.4.2 Whole-exome sequencing 
 Considering the large number of genes mapping to the candidate homozygosity 
regions (more than 120 genes for shared regions and more than 1000 genes for not shared 
regions), the identification of disease-causing mutations in the nucleus 1 was carried out by 
the whole-exome sequencing approach (WES). Exome capture and sequencing were 
performed by the BGI for the two affected individuals V-3 and VI-6 (more technical details in 
Materials and Methods). 
 
3.3.4.3 Statistical evaluation of the performance for patients V-3 and VI-6 
 First the performance of the WES technology applied to these samples was evaluated. 
To address this, the critical steps of exome capture (here with Agilent SureSelect Human All 
Exon v4 kit), sequencing (of Illumina-Solexa NGS platform) and read alignment (by 
SOAPaligner/SOAP2 program) were considered. The specificity of the technique is mainly 
due to the target (50 Mb) enrichment and the read alignment steps. The percentage of 90-bp 
reads that mapped to target regions was about 72% for both subjects, whereas the uniquely 
mapped reads were 81.5% for V-3 and 84.7% for VI-6 (more data in Appendix F). These 
relatively low percentages of good-quality data were expected for an exome sequencing 
performed in 2011 since the technique still required improvements.  
The read depth was one of the most relevant parameters that were taken into consideration 
(number of reads mapping to a single genomic position). Since a high inter-exon and intra-
exon variability was observed, the mean values of 77X and 91X read depth for V-3 and VI-6 
individuals respectively should be regarded as indicative only. A more interesting parameter 
was the coverage of the target regions, that is the percentage of target regions covered by a 
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certain read depth. 97% target regions was covered with at least 1X read depth in both 
samples, conversely a more desirable read depths above the threshold of 10X and 20X, which 
contributed to a higher confidence of the variant calls, displayed lower coverage values. With 
a threshold of 10X read depth, only 87% (V-3) and 88.5% (VI-6) of target regions were 
covered, whereas 79% and 81% respectively with a minimum of 20X read depth. The subject 
VI-6 obtained higher values of sequencing depth and cumulative read depth as showed in the 
graphs of Figures 3.11 and 3.12.  
 
 
Figure 3.11: Histograms of distributions for sequencing depth in target regions. 
 
 
Figure 3.12: Cumulative distributions for sequencing depth in target regions. 
 
 
3.3.4.4 Single Nucleotide Variants (SNVs) and indels annotation 
 The final set of high-confidence variants obtained by the exome sequencing and called 
by SOAPsnp program was annotated in the following tables (Table 3.2 and 3.3). A high 
confidence was established on the basis of the minimal distance from another variant to avoid 
error-prone nucleotide stretches (5 bp), a minimum 4X of read depth and a Phred-like quality 
score higher than 20. 
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Categories of SNVs Patient V-3 Patient VI-6 
Number of genomic positions for calling SNVs(1) 134752579 135216361 
Total number of high-confidence SNVs 84213 90776 
Homozygous 30959 32804 
Heterozygous 53254 57972 
Intron 50682 55690 
Intergenic 1347 1584 
5’-UTR 3169 3374 
3’-UTR 4043 4493 
Synonymous 10148 10359 
Splice site(2) 2472 2539 
Missense 12122 12510 
Stop codon abolishing 54 59 
Nonsense 176 168 
 
Table 3.2: High-quality SNVs annotated in the snp.filter.gff file. (1) Capture target regions and its 200bp 
flanking regions; (2) Intronic SNPs within 10bp of exon/intron boundary. 
 
Categories of indels Patient V-3 Patient VI-6 
Total number 6780 7168 
Total insertions 3215 3434 
Total deletions 3565 3734 
Homozygous 2761 2845 
Heterozygous 4019 4323 
Intron 5102 5416 
Intergenic 61 66 
Promoter (1000bp upstream) 22 32 
5’-UTR 278 305 
3’-UTR 415 445 
Non-frameshift 175 181 
Splice site 404 395 
Insertions in coding sequence 242 250 
Deletions in coding sequence 256 259 
Frameshift 323 328 
  
Table 3.3: Indels annotated in the indel.gff file. 
 
The higher number of variants in the subject VI-6 compared with V-3 reflects the higher 
coverage seen beforehand. It is interesting to note that the number of total high-confidence 
SNVs is higher compared with other data in literature (Abecasis et al., 2012). More than 
80,000 SNVs are reported here, whereas an exome of about 30 million nucleotides commonly 
contains 25,000 high-quality SNVs. The reason is the inclusion of all the SNVs in the 200bp-
flanking regions in this analysis. Without intron and intergenic variants, the total number of 
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coding/splice site variants detected here becomes similar to other studies. For the current 
study, the analysis started from the entire pool of nearly 100,000 total SNVs and indels 
annotated in *.snp.filter and *.indel.gff files, focusing on the most probably pathogenic indels 
and non-synonymous SNVs. 
 
3.3.4.5 Variants in disease genes and loci and CNV analysis 
 All known disease-genes and loci implicated in dHMN, as well as all genes annotated 
in OMIM database and associated with similar phenotypes were analysed for WES variants. 
Variants in coding exons and close to splice sites were firstly considered. Their potential 
pathogenicity was evaluated by taking advantage of the available information on variants 
already annotated in databases and on known or predicted functional domains. No 
homozygous variant calls shared by both patients were identified. A further investigation for 
compound heterozygous or hemizygous traits was performed and highlighted 4 variants in the 
PLEKHG4 and ABCD1 genes (Table 3.4). 
 
Chr Candidate Variant 
Variant call 
V-3 
Variant call 
VI-6 
Predicted 
Effect 
Allele 
frequency Haplotype Functional Role 
Confirmation 
by Sanger 
sequencing 
16 PLEKHG4 
c.1658C>G 
C(ref)13/G7 
(Q=32) 
C(ref)10/G3 
(Q=0) 
Missense 
tolerated 
Novel 
variant 
False Positive 
call 
16 PLEKHG4 
c.1986G>T 
G(ref)5/T0 
(Q=35) 
G(ref)6/T3 
(Q=32) 
missense 
damaging 
Novel 
variant 
False Positive 
call 
16 PLEKHG4 
c.3190C>T 
C(ref)32/T12 
(Q=99) 
C(ref)22/T24 
(Q=99) 
Missense 
damaging 
Combination of 
variants 
excluded from 
unaffected 
subjects 
PLEKHG4 causes SCA31 
(AD)  
Rho GTPases pathway for 
cytoskeleton dynamics 
- 
X ABCD1 
c.1823G>A 
G(ref)8/A4 
(Q=63) 
G(ref)3/A5 
(Q=32) 
missense 
damaging 
Rs, no in 
EVS 
not 
validated, 
unknown 
frequency 
Not informative 
(few SNPs) 
Cause of 
Adrenomyeloneuropathy, 
adult (X-linked,Recessive) 
False Positive 
call 
 
Table 3.4: Filtered SNVs found in genes annotated in OMIM and related to neurodegenerative disorders. Variant 
calls are expressed with number of reads for each allele (ref=reference allele) and Q=Phred-like quality score of 
variant call. Homozygous and compound heterozygous calls were considered. AD= autosomal dominant, AR= 
autosomal recessive, SCA= spinocerebellar ataxia, DSMA= distal spinal muscular atrophy. 
 
3 out of 4 variants were not confirmed by Sanger sequencing, highlighting the presence of 
false-positive calls even after the filtering for quality. Heterozygous genotypes seemed to be 
more error-prone than homozygous ones as the background noise can be misinterpreted as an 
effective heterozygous allele, mainly for calls with a low read depth. The remaining fourth 
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variant c.3190C>T in PLEKHG4, heterozygous in both patients, also segregated in 2 healthy 
subjects. Therefore, all variants mapped to disease and OMIM genes, and loci implicated in 
dHMN were excluded or could not explain alone the disease. 
The whole SNV dataset from the exome sequencing was also analyzed by the BGI using 
Copy Number Inference From Exome Reads (CoNIFER) program. A total of 11 copy-number 
variants (CNVs) were identified (>1.5 kb), but none of them was shared by the 2 affected 
subjects (Table 17 in Appendix G). 
 
3.3.4.6 Variants in the candidate region chr8p23.1-p22 
 The exclusion of the known disease-related loci suggested the presence of a novel 
disease gene. For this reason the analysis of WES variants was performed for the candidate 
homozygous regions detected before. The candidate region on chromosome 8p23.1-p22, 
which was shared by the two patients and contained 120 genes, was characterized by a high 
number of pseudogenes, paralogs and genes belonging to gene families. For instance, the 
DEF genes encode defensin proteins belonging to the family of microbicidal and cytotoxic 
peptides for host defense. However, they seemed unlikely to be the primary cause of the 
neurological clinical phenotype in this family. Unfortunately other genes with a more 
interesting function such as USP17L (ubiquitin specific peptidase) and ZNF205 (zinc finger 
protein) showed many paralogs and pseudogenes. As a consequence, several reads mapping to 
multiple regions led to a high number of false positive calls in these genes. Parameters of read 
aligners, even if restricted and with maximum 3 tolerated mismatches, cannot prevent this 
problem. In order to address this issue, a multiple sequence alignment of the USP17L and 
ZNF205 genes, with their corresponding pseudogenes and paralogs were performed, enabling 
to identify and exclude all variants mapping to them. 
The analysis of the remaining variants in the chr8p23.1-p22 region started from a manageable 
pool of 221 SNVs and 4 indels for patient V-3, and from 232 SNVs and 5 indels for 
individual VI-6. Amongst these variants, a total of 78 and 81 for V-3 and VI-6 respectively 
were prioritized because in coding exons and close to splice sites. After the filtering process 
only one variant in the SGK223 gene (NM_001080826, chr8: 8234390 in hg19 release) was 
identified as putative disease-causing. Since it was present only in one of the two patients, a 
further inspection of *.snp file containing all raw calls was carried out. Surprisingly, the 
analysis highlighted the same variant also in the second patient (Table 3.5). 
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Chr Candidate Variant 
Variant call 
V-3 
Variant call 
VI-6 
Predicted 
Effect 
Allele 
frequency Haplotype 
Functional 
Role 
Confirmation 
by Sanger 
sequencing 
8 SGK223 
c.1529T>C 
A(ref)0/G5 
(Q=6) 
A(ref)0/G10 
(Q=26) 
Missense 
tolerated 
Novel 
variant 
Excluded from 
unaffected 
subjects 
Rho GTPases 
pathway yes 
 
Table 3.5: Filtered SNV found in genes of the 8p23.1-p22 homozygous candidate region. Variant calls are 
expressed with the number of reads for each allele (ref=reference allele) and Q=Phred-like quality score of the 
variant call. 
 
It is interesting to note that this was due to the low quality score (Q = 6) of the call in the 
patient V-3, which led to its exclusion from *.snp.filter file. The c.1529T>C substitution has 
never been identified before in variant databases and Sanger sequencing confirmed the 
homozygous status in both patients. 
Homozygosity regions separately detected for the two patients were even investigated by the 
same analysis, and the two found candidate variants were excluded (Table 11 in Appendix E). 
Specifically, these genes displayed interesting functional roles and the variants were 
annotated in the variant databases with low allele frequencies. It seemed reasonable to take 
into account also rare polymorphisms given that the variant databases could collect healthy 
subjects that should display a late-onset phenotype in the future. However, these two variants 
could explain the trait of only one patients and were not homozygous or compound 
heterozygous in the second one. 
Therefore, this analysis highlighted the SGK223 c.1529T>C homozygous substitution shared 
by both patients as the only good candidate that alone can explain the disease in nucleus 1. 
This finding was further enforced by the exclusion of all high-quality variants within the 
whole exome. Indeed, for this purpose all variants of the final *.xls file were even analysed. 
 
3.3.4.7 Coverage analysis for the chr8p23.1-p22 candidate region 
 In order to enforce the hypothesis of causality of the SGK223 c.1529T>C substitution, 
the exclusion of all other possible variants in chr8p23.1-p22 candidate region was carried out. 
Indeed, false negative calls are heavily influenced by a poor sequence coverage. The read 
depth within the region was analyzed through the visualization of the read alignment by NCBI 
Genome Browser and MapView tool. On the basis of many observations, a read depth under 
10X was arbitrarily evaluated insufficient to accurately call homozygous or two compound 
heterozygous mutations, or to pinpoint a false positive call (Figure 3.13 and Table 3.6). 
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Figure 3.13: Depth of coverage per exon, on chr8p23.1-p22 region. Y-axis indicates the number of coding exons; 
the correspondent percentage is indicated above each histogram bar. Poorly-covered coding exons were 
annotated for each patient. Table 3.6: Exons for each category of coverage depth on chr8p23.1-p22 region. 
 
This analysis allowed to highlight problematic regions that were not captured by probes or not 
well-sequenced. The first finding was a comparable read depth for both subjects with slightly 
higher values in VI-6, turning out in agreement with the above-mentioned statistical WES 
data. However, the coverage over 10X read depth was improved for this specific region (91% 
and 92% for V-3 and VI-6 respectively) compared with WES data (mean value 88%). The 
capture kit appeared adequately designed for all coding exons, with a capture efficiency that 
showed little variability between samples. Interestingly, only a small portion of the coding 
exons characterized by a GC content >60% or <40% was more difficult to capture. 
On the basis of the gene function, the poorly covered exons were prioritized and selected for 
direct sequencing in order to identify potentially not-detected variations. Table 3.7 reports the 
analyzed exons together with the new variants identified. 
 
 
 
 
 
 
 
 
 
 V-3 VI-6 
Total coding exons 298 298 
High coverage depth 
(≥10 reads) 272 275 
Low coverage depth 
(<10 reads) 20 18 
No reads 6 6 
No probes 0 0 
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Gene and Exon Gene function Expression (Gene Cards) Variants Comments 
SGK223_exon2 Tyrosine-protein kinase, 
cytoskeleton regulation 
High levels in 
nervous system 
rs150979349 
c.1050_1051insAGCGGC 
unknown frequency 
even in related and 
independent healthy 
individuals 
SGK223_exon5 Tyrosine-protein kinase, 
cytoskeleton regulation 
High levels in 
nervous system - - 
RP1L1_exon4 microtubule polymerization Also in brain - - 
ERI1_exon1 
mRNA Exonuclease1,  
histone mRNA decay 
after replication 
Also in nervous 
system 
rs2288672 (MAF>1%) 
rs28510464 (MAF>1%) Only polymorphisms 
TNKS_exon1 
ADP-Ribose 
Polymerase,  
vesicle trafficking 
Also in brain - - 
NDRG1_exon16 
cell trafficking, notably 
of the Schwann cell; 
causes CMT4D 
Also in nervous 
system - - 
 
Table 3.7: Poorly-covered exons selected for Sanger sequencing with the relative information and variants 
eventually detected. 
 
Besides the two high-frequency polymorphisms in ERI1 gene, the homozygous rs150979349 
6-nucleotides insertion was identified in the same SGK223 gene where the candidate variant 
was detected by the WES. The hypothesis of a pathogenic effect exerted by the co-occurrence 
of these two homozygous variants exclusive of the 2 patients was also supported by the 
presence of the same insertion with a second synonymous substitution in another dHMN 
patient (data of Genomes Management Application database, with data from patients with 
neuromuscular disorders and unidentified genetic cause). This insertion was annotated 
without allele frequency data and by several submissions, suggesting a certain frequency in 
the population. On the contrary, its mapping to different positions in a tandem 6-nucleotide 
repetition corroborated the hypothesis of a very rare frequency. The involvement of this 
second variant in the disease was subsequently excluded by a genotyping study of healthy 
controls, where a high frequency was found. Concluding, also this analysis excluded other 
candidate variants, thus enforcing the hypothesis of causality of the SGK223 c.1529T>C 
missense substitution in the disease. 
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3.3.5 Study of the nucleus 2 
 In this second nucleus the DNA samples of the left branch of the pedigree were not 
available for the current study. However, the information about the consanguineous marriage 
between VI-1 and VI-2 subjects corroborates the hypothesis of a recessive mode of 
inheritance of the disease. Considering also that VI-2 and VI-3 are brothers and that they 
should carry the same disease allele, this data gave the idea to verify the consanguinity 
between VI-3 and VI-4 spouses that was only reported but not confirmed. 
 
 
Figure 3.14: Pedigree of the nucleus 2 of Family 2. 
 
3.3.5.1 Homozygosity mapping  
 As for the nucleus 1, the recessive trait was studied by using the genome-wide 
homozygosity mapping approach. The analysis of 160,000 SNP genotypes identified a high 
number of homozygous regions in patient VII-2 and not shared by the healthy brothers VII-3 
and VII-4 (Figure 3.15). For each of these regions, haplotypes were compared with the 
healthy sibs and evaluated for possible genotype-calling errors. The 11 candidate regions 
identified are listed in Table 3.8. 
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Figure 3.15: Graphical representation of homozygosity regions obtained for patient VII-2 of Nucleus 2. Red 
peaks indicate the most promising genomic regions. 
 
 
 
Chr from (bp) to (bp) from SNP to SNP Mb Total RefSeqs 
OMIM 
genes 
OMIM genes and loci for recessive 
neurological disorders 
1 75263485 76401812 rs1969111 rs1770887 1.14 6 1 - 
2 82286435 83378207 rs17642475 rs1430271 1.09 1 1 - 
3 8046509 8601764 rs3902639 rs7639343 0.55 2 - - 
6 53292013 53876547 rs4715392 rs1409101 0.58 3 1 - 
6 90651785 92241291 rs210052 rs10498974 1.59 2 - - 
6 97234028 99159601 rs1854269 rs7776218 1.93 4 1 NDUFAF4 for Mitochondrial complex I deficiency 
8 63999561 65448437 rs6994076 rs12056691 1.45 4 - - 
8 76140789 77390676 rs1351225 rs6985886 1.25 2 - - 
9 30504349 38362713 rs17775810 rs1022770 7.86 95 19 
- APTX for Ataxia; 
- B4GALT1 for disorders of 
glycosylation; 
- SIGMAR1 for Juvenile amyotrophic 
lateral sclerosis 16; 
- SPG46 for Hereditary Spastic 
Paraplegia; 
- GNE for Inclusion Body Myopathy-2 
and Nonaka Myopathy; 
- EXOSC3 for Pontocerebellar hypoplasia 
1B 
- DHMN-J locus for Jerash type dHMN 
11 13886922 15220073 rs1827516 rs1540151 1.33 9 2 - 
11 123880722 124345791 rs4936879 rs10431091 0.46 2 - - 
    total 19.03 130 
 
Table 3.8: Candidate regions identified after haplotype evaluations. For each region the chromosomal positions 
(hg19 release), flanking SNP markers, total validated Refseqs and OMIM genes mapping to the region were 
annotated. 
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3.3.5.2 Identical-By-Descent (IBD) analysis 
 The kinship between VI-3 and VI-4 spouses was assessed by Identity-By-Descent 
(IBD) analysis. This approach estimates the probability of sharing alleles identical by descent 
(IBD) between pairs of subjects. Starting from about 64,000 genotypes of SNPs that were in 
approximate linkage equilibrium with each other, only one region displayed an IBD1 
probability close to the  maximum of 1 within the whole genome (Figure 3.16). This 
chromosomal segment maps on  chr9p21.1-p13.2 and it is likely to be inherited by VI-3 and 
VI-4 from a distant common ancestor. 
 
 
 
Figure 3.16: The IBD1 analysis between patient’s parents (VI-3 and VI-4) identified an unique peak on 
chr9p21.1-p13.2. This peak reaches the maximum probability (value of 1) of this analysis. 
 
 
Interestingly, the shared IBD1 region was transmitted by the two analysed individuals 
exclusively to their affected daughter (IV-1 in the haplotype of Figure 3.17) and corresponded 
to one of the homozygous regions identified in the previous analysis. The haplotype 
reconstruction shows the recombination event in unaffected patient’s sister, which defines the 
telomeric limit of the homozygous candidate region (in the haplotype SNP_A-1933680 at 
61.33 cM). Centromeric limit is instead defined by a recombination event occurring in 
patient’s father (in the haplotype SNP_A-1812761 at 70.13 cM). 
It is noteworthy that this autozygous region overlaps with a locus previously associated to a 
rare form of dHMN termed Jerash type (Table 3.8) (Christodoulou et al., 2000). 
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Figure 3.17: Haplotype segregation on chromosome 9p21.1-p13.2. The disease haplotype is in black, the 
candidate homozygous region shared exclusively by the patient is indicated by the box. 
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3.3.5.3 Whole-exome sequencing 
 The identification of potential disease-causing mutations in the 95 genes mapping to 
the chr9p21.1-p13.2 candidate region was carried out by the exome-sequencing approach. 
When this analysis was performed, WES data were available for the affected individuals V-3 
and VI-6 of nucleus 1. Considering the haplotype segregation reported in Figure 3.17, these 
individuals carried in heterozygosis the IBD segment. Accordingly, heterozygous variants 
shared by both patients were searched on WES data. On December 2013, the high-coverage 
WES (at least 100X read depth) of patient VI-2 was performed in order to get further 
confirmations and exclusions. UTR regions were also included in the analysis by using the 
Agilent Select Human All Exon v4+UTRs kit for the target enrichment. 
 
3.3.5.4 Variants in the candidate IBD region on chr9p21.1-p13.2 
 WES variants of the subjects V-3 and VI-6 were inspected in the IBD region paying 
particular attention to the genes underlying neurodegenerative and movement disorders with 
recessive transmission. Amongst them, the APTX gene is associated with a form of ataxia; 
B4GALT1 with disorders of glycosylation; SIGMAR1 underlies Juvenile amyotrophic lateral 
sclerosis 16; SPG46 is associated with Hereditary Spastic Paraplegia, GNE with Inclusion 
Body Myopathy-2 and Nonaka Myopathy, and EXOSC3 resulting in Pontocerebellar 
hypoplasia type 1B (Al-Saif et al., 2011;Date et al., 2001;Eisenberg et al., 2001;Hansske et 
al., 2002;Martin et al., 2013;Wan et al., 2012). Filtering and prioritization steps allowed to 
identify one highly candidate variant in the SIGMAR1 gene (34,637,027 genomic position in 
hg19 release) (Table 3.9). 
 
Chr Candidate Variant 
Variant call 
V-3 
Variant call 
VI-6 
Predicted 
Effect 
Allele 
frequency Haplotype Functional Role 
Confirmation 
by Sanger 
sequencing 
9 SIGMAR1 
c.412G>C 
C(ref)11/G9 
(Q=99) 
C(ref)12/G18 
(Q=99) 
Missense 
damaging Novel variant 
Homozygosity 
exclusive of 
patient VII-2  
ER intracellular 
receptor, 
nervous system 
development 
yes 
 
Table 3.9: The best candidate SNV found in the two exome-sequenced patients, heterozygous for the IBD 
candidate region of patient VII-2. Variant calls are expressed with the number of reads for each allele 
(ref=reference allele in the genome) and Q=Phred-like quality score of the variant call. ER=endoplasmic 
reticulum. SIGMAR1 showed the complementary alleles in the genome since the transcript is oriented on minus 
strand. 
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All undetectable variations (SNVs, indels and CNVs) of the poorly-covered exons and UTR 
regions were excluded by means of the high-coverage exome sequencing (mean read-depth of 
100X) that have been recently carried out for patient VII-2 (data not shown). This analysis 
excluded a common genetic cause between the 2 nuclei because no homozygous mutations 
shared by all affected subjects were identified. WES analysis pointed to the SIGMAR1 
c.412G>C substitution that was confirmed by Sanger sequencing in homozygous state 
exclusively in patient VII-2. 
 
3.3.6 Confirmations for SIGMAR1 and SGK223 variants 
 The analyses of Family 2 pinpointed two novel variants, the c.1529T>C in SGK223 
and the c.412G>C in the SIGMAR1 gene, as the best candidate mutations for nucleus 1 and 2 
respectively.  
The segregation of both variants (obtained by genotyping all the available family members) 
confirmed previous haplotype analyses as reported in Figure 3.18. 
  
Figure 3.18: Genotypes of the two candidate variants identified for the SGK223 and SIGMAR1genes in Family 2. 
Genotypes in parentheses of individual IV-3 are inferred. 
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3.3.7 Characterization of the c.1529T>C variant in the SGK223 gene 
 In order to characterize the functional effect of the c.1529T>C variant, further 
information from literature, databases and prediction tools were collected. The SGK223 gene 
(NM_001080826) codes for PRAGMIN (NP_001074295, homolog of rat pragma of Rnd2), a 
still not well characterized Tyrosine-protein kinase, probably involved in the regulation of 
Rho GTPase pathway for the cytoskeleton dynamics (Tanaka et al., 2006). Unfortunately, the 
paralogous gene PEAK1 is not deeply characterized as well. Full-length protein were first 
investigated to study potential functional domains of the N-terminus half where the 
substitution falls. InterproScan server showed that several tools predict at C-terminus a 
catalytic kinase domain confirming data of literature, but did not provide insights into the 
function of the N-terminus half (Figure 3.19). 
 
 
Figure 3.19: Result of PRAGMIN protein for domain prediction/identification by InterProScan. 
 
The missense substitution determines the p.Val510Ala amino acid change from valine to 
alanine. Even if this variant has never been reported in variant databases, it was not predicted 
to be deleterious by SIFT, Polyphen2, MutationTaster and LRT tools, suggesting a neutral 
effect at protein level. This result was probably influenced by the biochemical similarity 
between valine and alanine, and by the presence of alanine in the wild-type protein of other 
organisms (Figure 3.20). 
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Figure 3.20: Multiple amino acid sequence alignment of PRAGMIN where the substitution falls. Higher amino 
acid identity corresponds to more intense colour. Amino acid at position 510 is marked by a box. Alignment was 
provided by UCSC MultiZ46Way GRCh37/hg19. 
 
On the other hand, valine 510 is conserved in primates, indicating a possible primate-specific 
evolution of this allele. Phosida, NetPhos and NetAcet prediction tools did not showed 
evident alterations in the most common post-translational modifications such as 
phosphorylation and acetylation (data not shown). Conversely, the c.1529T>C nucleotide 
substitution could affect the mRNA splicing. Indeed, data obtained by different prediction 
tools were in agreement with an alteration of the correct splice site selection and usage. (Table 
3.10). To increase the reliability of this in silico analysis, multiple tools were used. They rely 
on the sequence information, the intrinsic strength by which the splice sites are recognized by 
the spliceosome, as well as the antagonistic dynamics of proteins that bind Exonic Splicing 
Enhancers (ESEs) and Exonic Splicing Silencers (ESSs). ESE-finder and FAS-ESS have 
already successfully predicted the disruption of ESEs/ESSs in a variety of genes, including 
SMN1, SMN2 and POMGNT1 involved in neuromuscular diseases (Cartegni and Krainer 
2002;Oliveira et al., 2008). 
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Prediction tool Result Reference 
motif 
Mutated  
motif 
Wild 
Type Mutant Variation 
Acceptor 
Splice site ctccgaggtaggt ctccgaggcagGT 75.65 83.33 
10,2% (significant 
difference >10%) 
Human Splicing 
Finder 
Donor 
Splice site gaggtaggt GAGgcaggt 89.9 63.06 
-30% Site broken 
(significant difference 
>10%) 
gaggt GAggc 4.9 (∆R) 6.5 (∆R) 
Increased  
(Fold change -131, 
%binding 0.7) 
ASSEDA server Splice site 
gaggtAggt gaggcaggt 8.2 (∆R) 1.2 (∆R) 
Decreased 
 (Fold change +3, 
%binding 303.3) 
Splice site taggtgaag CAGgtgaag 3.29 6.66 +102% (significant difference >20%) 
MaxEntScan 
Splice site gaggtaggt GAGgcaggt 9.65 1.9 -81% (significant difference >20%) 
ESE Finder 
Exonic 
Splicing 
Enhancer 
ggtaggt ggcaggt - 82.59 
New Site, specific for ASF 
splicing factor (significant 
difference >10%) 
- Computational 
approach for 
Silencer motifs 
(Sironi et al., 
2004) 
- FAS-ESS server 
Exonic 
Splicing 
Silencer 
ggtaggtg ggcaggtg 69.88 - Site broken 
 
Table 3.10: Predictions of splice site and ESE/ESS elements for the c.1529T>C in SGK223 and relative scores. 
Mutated position is underlined in the nucleotide sequence. 
 
Interestingly, these analyses predicted in the reference sequence the presence of a natural 
splice site that has never been annotated among the human SGK223 transcripts of NCBI 
Genome Browser database. Conversely, the splicing event seemed to occur in non-human 
transcripts displaying the same allelic variant in the reference sequence. A further analysis of 
human expressed sequenced tags (ESTs) identified 4 human ESTs encompassing this region: 
two not-spliced and expressed at embryonal stages (CN341734 and CN341745) and two 
spliced and expressed in adult brain (HY116488 and HY306767). These findings might 
indicate the presence of a cryptic splice site with a tissue-specific and developmental 
activation. According to the late onset of the disease, the c.1529T>C substitution could 
modify the strength of this cryptic splice site or its regulation in the adult. 
  
3.3.8 Characterization of the c.412G>C variant in the SIGMAR1 gene 
 Ascertained from literature that SIGMAR1 underlies a motor neuron disorder (ALS16) 
and is a good candidate gene, the pathogenic effect of the specific missense variant was 
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investigated. The c.412G>C substitution has never been reported in variant databases neither 
in LOVD, HGMD and ClinVar mutation databases. It was predicted to be deleterious by 
Polyphen2, MutationTaster and LRT tools. Moreover, in the current study it was excluded 
from 200 control chromosomes belonging to same geographic area of this family. The 
c.412G>C substitution falls within exon 3 which is not present in all alternative SIGMAR1 
transcripts (isoforms 2 and 10 lack exon 3 as reported in Figure 3.21). However, the 
pathogenic effect of the c.412G>C substitution implies the expression of full-length isoforms 
in the nervous system. The majority of isoforms that are currently annotated in UCSC 
Genome Browser presents the exon 3 (Figure 3.22). Moreover, the analysis of spliced ESTs 
confirmed the presence of isoforms with exon 3 in the nervous system (for instance ESTs 
DA075272, CD519094, BI596428 and AL537799). 
 
 
Figure 3.21: All transcript variants for SIGMAR1 currently annotated in RefSeq Genes track of UCSC Genome 
Browser. From top to bottom, transcript variant 1, 2, 6, 7, 11 (non-coding), 8, 10 and 9, all under review and not 
still validated. From the genomic positions, transcripts are oriented on minus strand and are here reversed. 
 
The exon 3 of SIGMAR1 encodes the ligand-binding domain of the protein where specific 
anionic residues were showed to be critical for its function (Seth et al., 2001). The residue at 
position 138 (glutamic acid) is negatively-charged and is here substituted by an uncharged 
one (glutamine). It is interesting to note that the whole gene is highly conserved and only 6 
polymorphisms are reported in the coding region (dbSNP137 and dbSNP138 annotations, 
MAF>1%). Also p.Glu138Gln change falls in a highly conserved sequence (Figure 3.23), as 
confirmed by phyloP, GERP and phastCons tools. 
In order to confirm the SIGMAR1 involvement in dHMN, a genetic screening was performed 
in other 12 unrelated index cases displaying a clinical picture similar to patient VII-2 and 
without an identified genetic cause yet. Surprisingly, a second variant (c.448G>A) was 
identified in one patients belonging to a small family with two affected brothers. The family 
came from South of Italy and was clinically ascertained by Dr. Bengala and Petrucci at S. 
Camillo-Forlanini Hospital of Rome. Both patients presented a phenotypic onset and 
progression similar to that of the subject VII-2 of nucleus 2, and the absence of the disease in 
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the parents suggested a recessive inheritance. Sanger sequencing enabled to confirm the 
homozygous segregation of the c.448G>A variant in the two affected subjects II-1 and II-2 
(Figure 3.22). 
 
 
Figure 3.22: Electropherogram with the homozygous SIGMAR1 c.448G>A variant indicated by the arrow, and 
the genotyping in the available family members. 
 
Also the c.448G>A variant has never been reported in variant databases, neither in LOVD, 
HGMD and ClinVar mutation databases. It was predicted to be deleterious by different tools 
and was excluded from 200 control chromosomes from South of Italy. It maps to exon 4 near 
the splice-site junction with exon 3 and leads to the substitution of a glutamic acid residue 
with a hydrophobic phenylalanine at position 150 (p.Glu150Phe). The change occurred in the 
same conserved amino acid motif of the first mutation, for which the anionic residues have 
been previously described as playing a critical role (Figure 3.23). The two mutations fell in 
the same C-terminus chaperone domain that was demonstrated exposed in the inner ER 
membrane, and a similar pathogenic role was thus attributed to two variants (Ortega-Roldan 
et al., 2013). 
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Figure 3.23: Multiple amino acid sequence alignment of SIGMAR1where p.Glu138Gln and p.Glu150Phe 
substitutions fall. Higher amino acid identity corresponds to more intense colour. Amino acid at position 138 and 
150 are marked by a box. Alignment was provided by UCSC MultiZ46Way GRCh37/hg19. 
 
In conclusion, these findings strongly support the causality of the SIGMAR1 c.412G>C 
and c.448G>A mutations in the dHMN disease and prompt to consider SIGMAR1 the 
gene of the dHMN Jerash type locus. 
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3.4 Identification of the candidate gene FBXO41 associated with a complicated form 
of peripheral neuropathy and spastic paraplegia 
 
3.4.1 Clinical picture of Family 3 
 This consanguineous family comes from a little village in Veneto region and presents 
three brothers (IV-2, IV-6, IV-7) affected by a complex form of motor neuropathy with 
spastic paraplegia and mental retardation. Neurological exam was performed in all subjects of 
the fourth generation (both healthy and affected individuals) by Dr. Micaglio of Neurology 
Division, Hospital of Montebelluna (Treviso). The three patients displayed a similar clinical 
picture, characterized by weakness of the lower limbs, bilateral pes cavus, spastic gait, 
hyperreflexia and mild hypertonicity. The age of onset was the third decade of life. 
Electrophysiological studies and nerve biopsy revealed a reduced motor conduction velocity 
and the presence of a distal motor neuropathy. Brain magnetic resonance imaging, computed 
axial tomography and electroencephalography showed non-significant CNS involvement. In 
addition, all affected members showed a neuropsychological impairment characterized by 
mild mental retardation, visual agnosia, short- and long-term memory deficiency, signs of 
perseveration and confabulation. 
The analysis of the pedigree suggested an autosomal recessive way of inheritance of the 
disease.  Indeed, as reported in Figure 3.24, the healthy parents (III-1 and III-2) of the affected 
sibs were first cousins and the recurrence of the clinical phenotype was observed only in one 
generation. 
 
 
Figure 3.24: Pedigree of Family 3. 
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3.4.2 Preliminary results 
 First studies of whole-genome scan were performed with 382 STR markers and 
identified a candidate region on chromosome 3q27-q28 (D3S1580 and D3S3669 flanking 
markers), defined SPG14 locus (Vazza et al., 2000). A further investigation with other 50 
STRs allowed to detect a second chromosomal region on chr21q11.1-q21.1. Screening of 
candidate genes in this region, identified the c.*377T>C substitution in the 3’UTR of the 
HSPA13 gene (NM_006948.4). This sequence variant was absent in 300 healthy individuals 
and a luciferase assay showed a decrease of the protein translation in presence of the 
substitution, probably due to a mechanisms of post-transcriptional regulation by microRNAs 
(unpublished data). A further genome-wide search by using over 200,000 SNP markers 
(Illumina Human CNV370-Quad platform) excluded all known HMSN and HSP genes and 
loci associated with this phenotype, confirmed the two candidate regions already detected, 
and highlighted a new linkage signal on chr2p13.3-p12. The homozygous status was assessed 
for three candidate regions. 
 
3.4.3 Better definition of the candidate regions 
 The high number of genotyped individuals (3 affected and 8 unaffected individuals) 
and the clear recessive mode of inheritance enabled to use well-defined parameters for a 
robust linkage analysis (autosomal recessive model, full penetrance and disease allele 
frequency of 0.001). Indeed, maximum linkage peaks displayed significant LOD score values 
of 3.86 (3 is the minimum value to accept the hypothesis of linkage), indicating 3 reliable 
candidate regions. For each linkage peak identified, haplotypes with SNPs were combined 
with STR markers previously genotyped, thus unifying the advantages and compensating the 
limits of both (i.e. STR markers are more informative for their high variability but more 
interspersed than SNPs, that are more dense in the genome). 
For instance, this analysis allowed to divide the centromeric terminus of linkage region on 
chr3q27-q28 into 2 chromosomal segments according with the haplotype (Figure 3.25). 
Flanking makers were identified by taking advantage of recombination events in unaffected 
and affected brothers IV-1 and IV-6 respectively. All candidate linkage regions with refined 
limits are reported in Table 3.11. 
Furthermore, considering the recessive trait and the consanguinity, a more-dense 
homozygosity mapping (with 350,000 SNPs) was performed to overcome computational 
limits of multipoint linkage analysis and to confirm the linkage regions, since it required a 
lower number of SNPs (about 25,000 SNPs). Also in this family a less-stringent analysis was 
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carried out by considering the homozygosity of 2 patients at least, thus limiting genotyping 
errors and incomplete detections (regions reported in Table 12 of Appendix E). 
 
 
Figure 3.25: Key recombination events occurred in unaffected and affected sisters define upper and lower 
linkage regions on the centromeric terminus of chr3q27-q28 region. Markers reported in bold type are novel 
flanking markers, in the table previous flanking markers were annotated. 
 
Linkage 
region from (bp) to (bp)  
from 
SNP to SNP Mb 
Total 
RefSeqs 
OMIM genes for 
neurological disorders 
2p13.3-p12 72251751 75681462 rs1878503 rs10496198 3.4 56 
- ALMS1 for Alstrom 
syndrome (AR) 
- DCTN1 for HMNVIIB 
(AD) 
3q27-q28 
Centromeric 
region 
188161706 188500658 rs2162259 rs3846183 0.34 1 - 
3q27-q28 
Telomeric 
region 
188952524 192088525 rs1562761 rs9859577 3.14 16 - 
21q11.2-
q21.1 14658830 19044397 rs2258300 rs2824435 4.4 21 - 
    total 11.3 94  
 
Table 3.11: Limits of linkage regions obtained by the combinations of haplotypes with SNPs and STRs. AR= 
autosomal recessive, AD= autosomal dominant. 
 
3.4.4 Whole-exome sequencing 
 Considering the 94 genes mapping to the linkage regions, even in Family 3 the 
identification of disease-causing mutations was carried out by the exome-sequencing 
approach. Exome capture, sequencing and computational analysis were performed by the BGI 
Linkage 
region 
Previous 
centromeric 
limit (SNP) 
Previous 
centromeric 
limit (micro 
satellite) 
3q27-q28 rs6444286 D3S1580 
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for the proband IV-2 in 2011 and recently (December 2013) for the patient IV-7 (more 
technical details in Materials and Methods). 
 
3.4.5 Statistical evaluation of the performance 
 The performance of WES for IV-2 appeared similar to that of Family 2. On the other 
hand, recent data obtained on December 2013 from patient IV-7 have shown a higher 
performance due to the optimization of the technique and the higher coverage achieved. The 
specificity, which was calculated through the percentage of reads mapped to the target regions 
(70% in 2011 and 78% in 2013) and uniquely mapped (81% in 2011 and 87% in 2013), has 
been increased over two years as expected. It is interesting to note that the mean read depth of 
149X for IV-7 strongly overcame the value of IV-2 (101X), even if this value is only 
indicative because of the high variability between genes and exons. The coverage for target 
regions (more than 1X read-depth) was high for both samples (97.8% for IV-2 and 99.8% for 
IV-7), but the 10X read-depth required for a high-confident variant calling increased from 
89% in 2011 to 99.5% in 2013  The better quality of the more recent techniques can be also 
appreciated through the following histograms (Figure 3.26). 
 
Figure 3.26: Histograms of distribution and cumulative distribution for sequencing depth in the target regions. 
Subject IV-2 was analysed in 2011, IV-7 has been recently sequenced (December 2013).  
 
3.4.6 Single Nucleotide Variants (SNVs) and indels annotation 
 The final set of high-quality variants obtained by the exome sequencing was annotated 
in the following tables (Table 3.12 and 3.13). 
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Categories of SNVs Patient IV-2 (2011) 
Patient IV-7 
(2013) 
Number of genomic positions for calling SNPs(1) 135216361 134975362 
Total number of high-quality SNVs 91935 108898 
Homozygous 33653 41279 
Heterozygous 58282 67619 
Intron 56440 64477 
Intergenic 1553 3450 
5’-UTR 3519 3922 
3’-UTR 4555 7257 
Synonymous 10440 5973 
Splice site(2) 2549 2729 
Missense 12620 11119 
Stop codon abolishing 69 60 
Nonsense 190 120 
 
Table 3.12: High-quality SNVs annotated in the snp.filter.gff files. (1) Capture target regions and its 200bp 
flanking regions; (2) Intronic SNPs within 10bp of exon/intron boundary. 
 
Categories of indels Patient IV-2 (2011) 
Patient IV-7 
(2013) 
Total number 7067 11855 
Total insertions 3335 5471 
Total deletions 3732 6384 
Homozygous 2926 4831 
Heterozygous 4141 7024 
Intron 5343 8537 
Intergenic 63 325 
Promoter (1000bp upstream the gene) 29 120 
5’-UTR 319 354 
3’-UTR 393 761 
Non-frameshift 193 258 
Splice site 386 499 
Insertions in coding sequence 277 267 
Deletions in coding sequence 257 282 
Frameshift 341 291 
  
Table 3.13: Indels annotated in the indel.gff files. 
 
The analysis of the current study started from 91,935 high-quality SNVs and 7067 total indels 
for the subject IV-2. From a comparison between variants obtained in 2011 (sample IV-2) and 
2013 (sample IV-7), a higher accuracy and the inclusion of UTR regions were evident for the 
most recent data. A decrease of false positive variants in non-synonymous SNVs and a higher 
sensitivity in indels detection were observed. 
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3.4.7 Coverage analysis 
 Before having the confirmation with the recent WES, the coverage was analysed for 
the patient IV-2 who displayed a low accuracy of the technique. The read depth within the 4 
linkage regions on 2p13.3-p12, 3q27-q28 (centromeric and telomeric regions) and 21q11.2-
q21.1 was visualized through the read alignment. After many observations, a read depth under 
10X was arbitrarily evaluated as insufficient to accurately call homozygous mutations or to 
assess false positive calls (Figure 3.27 and Table 3.14). 
 
Figure 3.27: Depth of coverage per exon, on 3 linkage regions. Y-axis indicates the number of coding exons; the 
correspondent percentage of total is indicated above each histogram bar. Poorly-covered coding exons were 
annotated for IV-2 patient. Table 3.14: Exons for each category of coverage depth on 3 linkage region. 
 
This analysis allowed to highlight problematic exons that were not captured by probes (1%) 
or not well-sequenced (12%) within the 4 candidate regions. Moreover, the capture kit was 
not adequately designed for 22 exons. For these reasons the 3.5% coding exons required a 
coverage by direct sequencing. The performance for these regions was lower than for the 
whole exome. Over 10X read depth, the 89% coverage for the whole exome decreased to 
83.5% for the 4 candidate regions. All variants identified by Sanger sequencing in the selected 
poorly-covered exons were detected in the patient IV-7 recently sequenced but none of them 
was considered a good candidate (poorly-covered exons in Table 8, Appendix D; variants in 
Table 13, Appendix E). The missense variant and the deletion mapping in CLDN16 have been 
reported with several ID in the same G homopolymeric stretch, suggesting different 
submissions for a unique variant. The high-frequency of the missense variant (MAF>5%) 
could be thus extended to the deletion. Moreover the CLDN16 gene was reported to be the 
primary cause of Renal hypomagnesemia 3, characterized by the specific involvement of renal 
epithelial cells and not related with nervous system (Simon et al., 1999). Also the ALMS1 
gene, where the second candidate deletion (c.63delGAGGAGGAG) was detected, have been 
associated with Alström syndrome that is mainly characterized by renal involvement (Hearn 
 IV-2 
Total coding exons 625 
High coverage depth 
(≥10 reads) 522 
Low coverage depth 
(<10 reads) 75 
No reads 6 
No probes 22 
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et al., 2002). This in-frame deletion of 9 nucleotides has never been reported before but maps 
in a GGA simple repeat, where many other in-frame insertions and deletions have been 
annotated. A relative frequency and a neutral effect were thus suggested for the indels of this 
region. 
 
3.4.8 Variants in disease genes and loci and CNV analysis 
 Whole SNV dataset deriving from the WES was analyzed by CoNIFER program and a 
total of 21 and 8 CNVs (>1.5 kb) were identified for patients IV-2 and IV-7 respectively. No 
CNVs shared by the 2 affected subjects were observed (Table 14 in Appendix F).  
The analysis of the variants in the known disease-associated genes and loci implicated in 
distal neuropathies and HSP, as well as all genes annotated in OMIM database associated 
with similar phenotypes enabled to exclude them. Indeed, very few variants in these genes 
showed a homozygous call different from the reference allele and with a lower than 2% 
frequency. Two variants in the SHROOM4 (c.3385A>C) and FAM58A (c.49A>G) genes 
explained a dominant X-linked trait and they were not consistent with the autosomal mode of 
inheritance in this family. In addition, their disease haplotype segregated in more than one 
unaffected subject. Therefore, all OMIM genes or implicated in neurodegenerative disorders 
seemed unlikely to be the primary cause of the clinical phenotype in this family. 
 
Chr Candidate Variant 
Variant call 
IV-2 
(2011) 
Variant call 
IV-7 
(2013) 
Predicted 
Effect 
Allele 
frequency Haplotype Functional Role 
Confirmation 
by Sanger 
sequencing 
X SHROOM4 
c.3385A>C 
T(ref)0/G2 
(Q=35) 
T(ref)3/G9 
(Q=73) 
missense 
tolerated 
rs199502054, 
not validated, 
unknown 
frequency 
X-linked 
transmission, in 
more than one 
unaffected 
individual 
Cause of Stocco dos 
Santos mental retardation 
syndrome (X-linked) 
- 
X FAM58A 
c.49A>G 
T(ref)0/G0 
(Q=1) 
T(ref)0/G15 
(Q=37) 
missense 
tolerated Novel variant 
X-linked 
transmission, in 
more than one 
unaffected 
individual 
Cause of STAR 
syndrome 
(Dominant X-linked) 
- 
 
Table 3.15: Filtered SNVs found in genes annotated in OMIM and related to neurodegenerative disorders. 
Variant calls are expressed with the number of reads for each allele (ref=reference allele) and Q=Phred-like 
quality score of variant call. Homozygous status was considered.  
 
3.4.9 Variants in the candidate linkage regions 
 The exclusion of the known disease-related loci suggested the presence of a novel 
disease gene and a similar analysis was performed for the WES variants mapping to the 
candidate linkage regions chr2p13.3-p12, chr3q27-q28 (centromeric and telomeric regions) 
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and chr21q11.2-q21.1. A total of 214 variants mapped to these regions and 45 were 
prioritized because in coding exons and close to splice sites. Finally 7 SNVs with a lower than 
2% frequency were filtered. Amongst them, the analysis highlighted 3 best candidate variants 
(Table 3.16). 
 
Chr Candidate Variant 
Variant call 
IV-2 
(2011) 
Variant call 
IV-7 
(2013) 
Predicted 
Effect 
Allele 
frequency Haplotype Functional Role 
Confirmation 
by Sanger 
sequencing 
2 FBXO41 
c.950G>A 
C(ref)1/T18 
(Q=26) 
C(ref)1/T135 
(Q=64) 
Missense 
damaging Novel variant 
Excluded from 
unaffected 
subjects 
F-box protein 41, 
ubiquitin ligase yes 
2 NAT8B 
c.355G>T 
C(ref)1/A118 
(Q=72) 
C(ref)1/A254 
(Q=85) 
Missense 
? 
rs62619834, 
Rare, MAF= 
0.356% 
Excluded from 
unaffected 
subjects 
N-
acetyltransferase 
(pseudogene) 
- 
3 LPP 
c.1142C>T 
T83/A2(Cref) 
(Q=68) 
C(ref)0/T253 
(Q=99) 
Missense 
tolerated 
rs139075681, 
in EVS: 
MAF=0.02% 
(1 / 4545) 
Excluded from 
unaffected 
subjects 
Cause of Lipoma 
and acute 
myeloid 
Leukemia  
yes 
 
Table 3.16: Filtered SNVs found in genes of the homozygosity candidate regions. Variant calls are expressed 
with number of the reads for each allele (ref=reference allele) and Q=Phred-like quality score of variant call. 
Alleles in the genome and in the transcript are complementary for transcripts oriented on minus strand. 
 
The variant c.355G>T in NAT8B seemed unlikely to be the genetic cause of the disease. Even 
if not-well characterized yet, NAT8B has been reported to be the pseudogene of NAT8. Unlike 
NAT8 that encodes a N-acetyltransferase, NAT8B is described not encoding a functional 
protein in humans due to premature stop codons (Veiga-da-Cunha et al., 2010). The variant 
c.1142C>T in the LPP gene maps to the small centromeric region on chr3q27. This missense 
variant was predicted to be “tolerated” although the gene is causal of disorders, probably 
because this specific variant is annotated in variant databases. Even though any point 
mutations have not been reported in the LPP gene to date, rearrangements have been 
associated with lipoma and acute myeloid leukemia, characterized by pathogenetic 
mechanisms and involvement of tissues apparently not related with neurodegenerative 
disorders and nervous system (COSMIC and OMIM databases). In addition, LPP protein 
seems mainly expressed in internal organs such as kidney, liver and lung, suggesting a non-
neuronal primary function and specificity.  
On the contrary, the “damaging” effect predicted for the novel missense variant c.950G>A in 
the FBXO41 gene was in agreement with a putative pathogenic role. The involvement in the 
ubiquitin-proteasome pathway was reported for FBXO41 protein, which represents a 
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pathogenic mechanism already associated with neurodegenerative disorders. In addition 
FBXO41 is ubiquitously expressed but mainly in the nervous system, suggesting a specific 
key role in it (data of GeneCard database). For these reasons, the c.950G>A substitution in 
FBXO41 gene was considered the best putative mutation in this family. 
 
3.4.10 Confirmation and characterization of the c.950G>A variant in the FBXO41 gene 
 Previous analyses of this study pinpointed one novel variants, c.950G>A in the 
FBXO41 gene, as the candidate disease-causing mutation in Family 3. Segregation analysis 
was performed by genotyping all family members for which the genomic DNA was available 
and as expected the c.950G>A variant was homozygous exclusively in the affected subjects 
IV-2, IV-6 and IV-7 (Figure 3.28). 
 
Figure 3.28: Genotypes of the candidate variant identified for the FBXO41gene in Family 3. 
 
This substitution has been never reported in any variant database and was predicted to be 
“damaging” and “conserved” by the majority of prediction tools (Table 3.17). Moreover, the 
c.950G>A variant was excluded from 400 chromosomes of control subjects from  Northern 
Italy. 
 
 
SIFT 
(deleterious<0.05) 
Polyphen2 
(probably 
damaging: 0.9-1) 
Mutation 
Taster 
(0-1) 
GERP++ 
score 
(>2) 
PhyloP 
score 
SiPhy 
score 
FBXO41 
c.950G>A Tolerated (0.15) 
Probably damaging 
(0.99) 
Damaging 
(0.99) 
Conserved 
(5.17) Conserved (2.4) 
Conserved 
(17.2) 
 
Table 3.17: Prediction tools with relative scores (in parenthesis) 
 
The FBXO41 gene (NM_001080410) encodes for the 875 amino acids protein FBXO41 (F-
box only protein 41, NP_001073879), one of 46 members of the F-box protein family. 
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FBXO41 is not-well functionally characterized, and the only defined role is due to the F-box 
domain. Indeed, all proteins presenting F-box are involved in the E3 ubiquitin ligase complex 
SCF (SKP1-CUL1-F-box protein) for the recognition and ubiquitination of other target 
proteins. 
In order to characterize the functional effect of the c.950G>A mutation, the full-length protein 
was first investigated to study potential functional domains in the N-terminus half where the 
substitution falls. InterproScan server showed that several tools predicted the well-
characterized F-box domain in C-terminus half, confirming data in literature, but it did not 
provide insights into the function of the N-terminus (Figure 3.29). 
 
 
Figure 3.29: Result of FBXO41 protein for domain prediction/identification by InterProScan. 
 
On the contrary, literature data reported at the N-terminus half an apolipophorin III-like 
domain, suggesting a role in cholesterol transport (Jin et al., 2004). Lipophorin ApoL-III was 
already described in insects as a multifunctional lipoprotein involved in lipid binding and 
transport, displaying an amphipathic structure of 5 α-helices (Weers and Ryan 2006). 
Specifically, hydrophylic residues were described to be crucial for the lipid-induced opening 
of the structure and the protein-lipid interactions (Weers et al., 2005). The secondary structure 
of FBXO41 was predicted by Jpred3 and Psipred softwares and revealed the p.Arg317Gln 
amino acid change localizing to a α-helix structure. The α-helix was also confirmed by 
ConSeq server which predicted an alternation between exposed and buried amino acids, 
indicative of a α-helix. Arginine localizes to an exposed position (indicated by “e” letter) like 
all charged amino acids in a α-helix (Figure 3.30). The p.Arg317Gln determines a change 
from the strongest positive-charged amino acid (arginine) to an uncharged residue 
(glutamine), leading to strongly change chemical properties. Glutamine could destabilize the 
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structure of α-helix or disrupt a crucial function already described for hydrophylic residues by 
Weers and colleagues. 
 
 
Figure 3.30: (Top) α-helix structure predicted by Psipred software for the specific amino acid sequence where 
p.Arg317Gln falls (indicated by the arrow). (Bottom) Alternating exposed and buried amino acids predicted by 
the algorithm of ConSeq server, indicative of a α-helix structure with arginine in exposed position. 
 
This position and the surrounding amino acid region appeared extremely conserved, in 
agreement with a functional role at protein level (Figure 3.31). 
 
 
Figure 3.31: Multiple amino acid sequence alignment of FBXO41 where the substitution falls. Higher amino 
acid identity corresponds to more intense colour. Amino acid at position 317 is marked by a box. Alignment was 
provided by UCSC MultiZ46Way GRCh37/hg19. 
 
Unfortunately, the homology modelling based on the sequence similarity was hampered by 
the lack of templates already crystallized and displaying a more than 30% of sequence 
identity for N-terminus half. Global and local alignments of full-length protein performed 
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with BLAST tool found sequence conservation exclusively for the F-box domain, whereas the 
N-term portion displayed no significant similarity with other proteins. 
 
Despite the paucity of information on the function of FBXO41, our findings strongly 
support the role of the c.950G>A mutation in the development of the disease in this 
family. For this reason, a mutation screening of the FBXO41 gene in patients exhibiting 
a similar clinical picture is currently under way. 
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3.5 Insight into the genetic causes of HMSN and HSP with a dominant transmission 
 
3.5.1 Clinical picture of Family 4 
 This four-generation family presents patients affected by a typical form of HMSN type 
V with heterogeneous clinical signs. Clinical features of axonal peripheral neuropathy 
(HMSN type II) such as weakness, atrophy of lower limb muscles and bilateral pes cavus 
were associated with pyramidal signs with spasticity of lower limbs and hyperreflexia. Two 
clinical pictures typical of HMSN and HSP co-occurred in many cases, in patients II-8, III-11, 
III-13, IV-3 and IV-5 the involvement of peripheral nervous system was predominant or 
exclusive, whereas in the patients III-2 and III-3 the central nervous system was mainly 
affected. Family members were seen by Dr. Angelini of the Department of Neurosciences, 
University of Padova. Motor conduction velocity was slowed ranging from 38 to 44 m/s, and 
cerebral and spinal MRI revealed no abnormalities. The age of onset was about the third or 
fourth decade of life, with a variable and  progressive course. 
The analysis of the pedigree suggested an autosomal dominant mode of inheritance of the 
disease, since the recurrence of the clinical phenotype was observed in all generations, in both 
male and female and there was one male-to-male transmission. To explain the phenotypic 
heterogeneity, an unique genetic cause or two distinct genetic causes for HMSN and HSP 
were proposed. 
 
 
Figure 3.33: Pedigree of Family 4. 
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3.5.2 Preliminary results 
 First studies on this family were focused on the disease genes most frequently 
associated with a similar clinical picture (i.e. MPZ, PMP22, MFN2, SETX, GJB1 and SPG4) 
and they were excluded by Sanger sequencing. A linkage analysis performed with 368 STRs 
enabled to highlight two linkage regions on chr1q33.3 and on chr9q33.1-34.11 (LOD score 
value higher than 2). A second high-density genome-wide linkage analysis with over 200,000 
SNP markers (Illumina Human CNV370-Quad platform) allowed to ruled out all genes and 
loci already associated with this phenotype. A linkage signal on chr9q31.33-q31.2 (LOD 
score value of 2.75) was detected; a lower peak was even obtained on chr5q33.1-q35.2 (LOD 
score value of 0.75) which co-segregated in all affected subjects and was shared by also 4 
unaffected individuals (II-7, III-8, IV-1 and IV-2). Haplotype reconstruction confirmed and 
better refined the region on chr9q31.1-q31.2 of 2.98 Mb (rs2049347; rs7875152) co-
segregating with the disease. Moreover, CNV analysis did not identify candidate 
deletions/duplications spanning more than 10 kb. 
 
3.5.3 Re-evaluation of the linkage data  
 In addition to the linkage regions identified by previous studies, a less stringent 
linkage analysis with only affected subjects (“affected only” approach) was performed to 
overcome cases of incomplete penetrance and later onset. It broadened the region on 
chr9q31.1-q31.2 and highlighted a novel candidate region on chr5q33.1-q35.2, explaining 
together a digenic model. In addition, considering the clinical heterogeneity, a model 
accounting for two distinct genetic causes for HMSN and HSP was used. A genome-wide 
linkage analysis was thus carried out by stratifying patients displaying predominant HMSN or 
HSP clinical features. For the HMSN phenotype (individuals III-4, III-11, III-13, IV-3) 
linkage signals on chr1q21.3-q31.1, chr4q28.3-q35.1, chr8p21.2-q13.3 and chr9q21.13-q34.3 
were identified; conversely, for the HSP phenotype (individuals III-2, III-3, III-4 and III-6) 
linkage peaks on chr1p36.32-p36.31, chr1p32.1-p31.3, chr2q36.3-q37.3, chr4q22.1-q26, 
chr5p13.2, chr9q31.1-q33.2 and chr21q22.11-q22.12 were obtained. 
 
3.5.4 Whole Exome Sequencing 
 Patients III-2, III-4 and III-6 were chosen for the whole-exome sequencing in order to 
identify disease-causing mutations among the shared variants in all candidate regions.  
The performance of WES technology appeared similar to that of previous families (Table 12, 
Appendix E). It is interesting to note that the mean read depth of 65X is lower than in other 
 87 
families (77X and 91X in Family 2 and more than 100X in Family 3). Also the coverage of 
target regions was lower and a read depth more than 20X (required for confident calls of 
heterozygous variants) was achieved for only 76% of the target. These low values could 
negatively affect the performance of variant callings in particular for heterozygous variants, 
which are those expected in patients for a dominant trait. 
The final set of high-quality variants obtained by the exome sequencing was similar to other 
families (about 85,000 high-quality SNVs). The higher number of intergenic variants (more 
than 12,000 variants in this family versus the 1500 in other families) and the lower number of 
coding SNVs (about 7200 missense variants vs more than 12000 in other families) confirmed 
the low quality of these WES data. 
 
3.5.5 Variants in disease-genes and loci and CNV analysis 
 As the HMSN type V was not genetically characterized and the clinical classification 
not well-established, all the known disease-genes and loci implicated in HMSN and HSP, as 
well as all the genes annotated in OMIM database were analysed for the WES variants. 
Variants in at least one of the 3 patients, in coding exons and close to splice-sites, with a MAF 
lower than 1% were considered. After the filtering and prioritization, 5 candidate variants 
were detected in the known disease-genes, but none of them was confirmed by Sanger 
sequencing even if with a high quality score (Table 3.18). All these false positive calls 
mapped in homopolymeric stretches and 3 of them were identified in other in-house unrelated 
exomes confirming error-prone positions. Therefore, no candidate mutations were identified 
in the known HMSN and HSP genes and in other disease-related OMIM genes. The analysis 
of the whole dataset of WES variants identified 9 total CNVs (>1.5 kb), but none of them was 
shared by at least 2 affected subjects (Table 15, Appendix F). 
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Chr Candidate Variant 
Variant call 
III-2 
Variant call 
III-4 
Variant call 
III-6 
Predicted 
Effect 
Allele 
frequency 
In-house 
exomes/in 
stretch 
Functional 
Role (of 
mutations) 
Confirmatio
n 
by Sanger 
sequencing 
1 MAPKAPK2 
c.643A>C 
A(ref)43/C17 
(Q=0) 
A(ref)44/C14 
(Q=89) 
A(ref)39/C17 
(Q=78) 
Missense 
damaging Novel variant Yes / yes 
HSPB1 
target, cause 
of HMSN 
False 
Positive call 
6 SYNE1 
c.20242C>T 
C(ref)28/T17 
(Q=44) 
C(ref)26/G6 
(Q=21) 
C(ref)36/T10 
(Q=0) 
Missense 
damaging Novel variant No / yes 
cause SCA, 
HMSN and 
HSP 
False 
Positive call 
7 hnRNPA2B1 
c.1048T>C 
T(ref)46/C35 
(Q=99) 
T(ref)38/C39 
(Q=99) 
T(ref)48/C34 
(Q=92) 
Missense 
damaging 
rs117917826, 
MAF<1% Yes / yes cause ALS 
False 
Positive call 
9 FNBP1 
c.941T>G 
A(ref)201/C45 
(Q=0) 
A(ref)185/G3
5 
(Q=0) 
A(ref)198/G4
1 
(Q=0) 
Missense 
damaging Novel variant Yes / yes 
regulation of 
the actin 
cytoskeleton 
False 
Positive call 
12 KCNMB4 
c.604G>A 
G(ref)22/A13 
(Q=27) 
G(ref)26/A16 
(Q=31) 
G(ref)18/A9 
(Q=10) 
Missense 
damaging Novel variant No / yes 
cause 
Dyskinesia 
False 
Positive call 
 
Table 3.18: Filtered SNVs found in genes annotated in OMIM and related to neurodegenerative disorders. 
Variant calls are expressed with number of reads for each allele (ref=reference allele) and Q=Phred-like quality 
score of variant call. 
 
3.5.6 Coverage analysis for the best linkage region on chr9q22.33-9q31.2 
 The accuracy in heterozygous variants calling is necessary to unravel an autosomal 
dominant trait. The variants at the heterozygous state are more susceptible to technical 
artefacts and more difficult to identify than homozygous sites, particularly in regions of low 
coverage. 
The coverage in the best candidate region on chr9q22.33-9q31.2 was analyzed using the 
visualization of read alignments. After the observation of many regions, a read-depth under 
20X was arbitrarily evaluated as insufficient to accurately call heterozygous mutations or to 
assess a false positive call. The analysis was performed for the three patient separately and 
gave comparable results, reported with mean values in Figure 3.34 and Table 3.19. 
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Figure 3.34: Depth of coverage per exon, on chr9q22.33-9q31 linkage region. Y-axis indicates the number of 
coding exons; the correspondent percentage of total is indicated above each histogram bar. Means values of 
poorly-covered coding exons were calculated considering 3 patients. Table 3.19: Exons for each category of 
coverage depth for linkage region. 
 
The 21% targeted coding exons displayed a low read depth due to problems of probe design, 
capture, preferential amplification, low complexity sequence or poor alignments. On the basis 
of the gene function and pathways in which the encoded protein is involved, the poorly-
covered exons were prioritized and selected for Sanger sequencing, in order to identify 
potential mutations still not detected by the WES (Table 9, Appendix D). From this analysis 
no significant variants were identified. 
 
3.5.7 Variants in the linkage regions 
 The exclusion of the known disease-related loci suggested the presence of a novel 
disease gene. For this reason a similar analysis of the WES variants was performed for the 
linkage regions. Considering the above-mentioned low quality of the WES data, variants 
called in at least 2 out of 3 patients were scored. No WES variants were found in the best 
linkage region on chr9q31.1-q31.2, thus the analysis was extended to the other regions 
identified by the “affected only” linkage analysis. The analysis highlighted 7 candidate 
variants (Table 3.20). 
 
 
 
 
 
 
Mean value 
of 3 patients 
Total coding exons 355 
High coverage depth 
(≥20 reads) 316 
Low coverage depth 
(10<reads<20) 15 
Very low coverage depth (≤10 
reads) 19 
No reads 2 
No probes 3 
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Chr Candidate Variant 
Variant call 
III-2 
Variant call 
III-4 
Variant call 
III-6 
Predicted 
Effect 
Allele 
frequency 
In-house 
exomes/in 
stretch 
Confirmation 
by Sanger 
sequencing 
9 RNF20 
c.2854A>C 
A(ref)41/C18 
(Q=0) 
A(ref)33/C26 
(Q=26) 
A(ref)33/C12 
(Q=59) 
Missense 
damaging Novel variant No / Yes 
False Positive 
call 
9 SMC2  
c.1583C>T 
C(ref)37/T20 
(Q=99) 
C(ref)33/T12 
(Q=37) 
C(ref)26/T15 
(Q=98) 
Missense 
damaging 
rs201083116, 
No data Yes / Yes 
False Positive 
call 
9 SVEP1 
c.4781C>A 
G(ref)158/T35 
(Q=0) 
G(ref)158/T35 
(Q=0) 
G(ref)158/T35 
(Q=0) 
Missense 
tolerated Novel variant Yes / No 
False Positive 
call 
9 HSDL2  
c.130G>C 
G(ref)21/C11 
(Q=77) 
G(ref)38/C10 
(Q=29) 
G(ref)49/C14 
(Q=78) 
Missense 
damaging 
rs184202621, 
MAF(A)<0.2% Yes / Yes 
False Positive 
call 
9 MEGF9 
c.380C>T 
G(ref)1/A2 
(Q=19) 
G(ref)3/A3 
(Q=31) 
G(ref)1/T0 
(Q=2) 
Missense 
tolerated 
rs149898889, 
MAF(A)= 
0.96% 
No / No yes 
5 
CLINT1_intron10 
g.157218708 
T>C 
T(ref)124/C90 
(Q=99) 
T(ref)126/C117 
(Q=99) 
T(ref)124/C90 
(Q=99) 
Splice Site 
activation 
rs14385761, 
MAF=0.09% No / No yes 
5 RANBP17 
c.2548G>A 
G(ref)74/A81 
(Q=99) 
G(ref)55/A56 
(Q=99) 
G(ref)82/A56 
(Q=99) 
Missense 
tolerated 
rs14366219, 
MAF=0.1% No / No yes 
 
Table 3.20: Filtered SNVs found in genes of the 9q22.33-9q31.2 and chr5q33.1-q35.2 candidate regions. Variant 
calls are expressed with number of reads for each allele (ref=reference allele) and Q=Phred-like quality score of 
variant call. 
 
The 3 variants confirmed by Sanger sequencing were not identified in other in-house exomes 
or in homopolymeric stretches. Even if their functional role could be interesting for the 
pathogenesis of the disease, they were already annotated in variant databases with a low 
frequency and did not displayed a correct segregation without assuming non-penetrant 
subjects. Also the MEGF9 c.380C>T variant mapping to the best linkage region on 
chr9q31.1-q31.2 segregated in 3 unaffected subjects (IV-4, IV-6 and IV-8). These data were 
not able to fully explain the disorder except for the digenic model which relies on the co-
occurrence of the two candidate regions chr9q31.1-q31.2 and chr5q33.1-q35.2 exclusively in 
affected subjects. In addition, further analyses were performed with the stratification of 
patients according to their prevalent HMSN or HSP phenotype. Also in this case 3 candidate 
variants were identified and listed in Table 3.21. 
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Segregation of the haplotype Candidate 
Variant 
Predicted 
Effect 
Allele 
frequency 
In-house 
exomes/in 
stretch 
Phenotype 
considered 
for 
analysis 
Linkage region 
Affected Unaffected  
SLC26A7 
c.808T>C 
Synonymous 
tolerated 
rs373170016 
Unknown 
frequency 
No / No HMSN chr8p21.2-q13.3 All the affected by HMSN III-8 
c21orf67 
c.579C>A 
Stop gaining 
tolerated Novel variant No / No HMSN 
chr21q22.11-
q22.12 
All the affected by 
HMSN except for IV-5 III-8 
FARP2 
c.2530A>T 
Missense 
tolerated 
rs150786024, 
MAF= T: 
0.15% 
No / No HSP chr2q36.3-q37.6 All affected by HSP 
and IV-3 (HMSN) III-8, IV-1, IV-2 
 
Table 3.21: Candidate SNVs confirmed by Sanger sequencing and correct segregation in patients with HMSN or 
HSP phenotype. 
 
Despite the FARP2 variant with a partial co-segregation with the disease, the variant 
displaying the best segregation was the synonymous substitution (c.808T>C) in the SLC26A7 
gene. Several tools displayed notable difficulties to reliably predict the effect of a 
synonymous variant, however the SLC26A7 gene characterized by a renal expression seemed 
unlikely to be the primary cause of a neurological clinical phenotype. On the other hand, the 
c.579C>A substitution in C21orf67 was interesting because of the stop codon introduction. 
The interpretation of a possible effect was hindered by the lack of information on this gene 
that is annotated as long non-coding RNA. Therefore, also these variants or a combination of 
them were not able to fully explain the affection status without assuming non-penetrant 
individuals.  
  
 In conclusion, the analysis of Family 3 has identified a pool of variants within 
genes displaying functions of interest. All variants are unable to explain the disease 
without assuming non-penetrant subjects or the involvement of a second genetic cause 
(such as the digenic model). Except for one candidate variant mapping to a long non-
coding RNA, other variants are low-frequency polymorphisms. In order to unravel the 
genetic cause in this family, further evidences are required. For this reason other 2 
patients have been sequenced with high-coverage WES and the analysis of their data is 
currently under way. 
 92 
4. DISCUSSION AND CONCLUSIONS 
 
 The present study was focused on searching novel causal genes in different forms of 
hereditary peripheral neuropathies or HMSN (Hereditary Motor Sensory Neuropathy). The 
growing genetic heterogeneity of these disorders is shown by more than 50 genes identified 
up to now. Although several efforts have been recently made by genetic studies, many cases 
still remain “orphan”. For instance, in more than 80% distal HMN patients which undergo 
molecular diagnosis, the causal mutation is not identified (Rossor et al., 2012). In the four 
families of the present work, a previous exclusion of the known disease-genes associated with 
the peripheral neuropathies failed to detect causative mutations, indicating a further genetic 
heterogeneity.  
This already complex background is further complicated by the phenotypic heterogeneity of 
the disease. Indeed, clinical pictures associated with these neuropathies display variable 
symptoms, age of onset, disease course, severity and expression even in the same family 
(Brusse et al., 2009). The four families object of this study are all affected by peripheral 
neuropathy, but different additional signs and modes of inheritance are described. Considering 
these dissimilarities, the study of each family was conducted separately by taking into account 
the specific peculiarities and developing, whenever required, more sophisticated strategies of 
study. Indeed, in a context of clinical and genetic heterogeneity, unravelling the genetic bases 
can be more challenging respect to the majority of Mendelian disorders with a straightforward 
genotype-phenotype correlation. However the recessive transmission and the consanguinity 
loops which characterize three of these families represented a considerable advantage for the 
study. Indeed, consanguineous pedigrees, even with a low number of individuals, are 
invaluable to mapping recessively acting disease genes since rare alleles are expected to be 
overrepresented and with homozygous state in the patients. For these families the approach of 
homozygosity mapping enabled to successfully identify homozygous segments in patients, 
but at the same time it highlighted striking unexpected findings that further support the 
growing genetic heterogeneity which is increasingly being characterised the distal 
neuropathies and other neurological disorders. 
 
 Family 2 represents a very good example of this fact. It displays three consanguineous 
marriages, suggesting a recessive transmission. The presence of such a high inbreeding rate in 
the same family apparently seemed unlikely, but became reasonable considering the origin 
from a closed community located in a little village. Unexpectedly, homozygosity mapping 
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failed to identify an autozygous region shared by all patients suggesting a more complex 
inheritance model. The presence of two slightly different clinical pictures between patients 
prompted the existence of two different genetic causes that were effectively identified by 
studying separately two nuclei of the family. 
In the first nucleus, the homozygosity mapping strategy efficiently detected a single 
autozygous regions of 6 Mb on chr8p23.1-p22 (rs2738148; rs6997599) shared exclusively by 
the two patients of the I and II generation. On the other hand, the availability of only one 
patients in the second nucleus (III generation) decreased the robustness of this analysis, 
identifying 11 homozygous regions with many identity-by-status  regions due to high-
frequency homozygous SNPs. The combination of this approach with the Identity-By-Descent 
(IBD) analysis enabled to definitely overcome the pitfall of IBS regions. In this study IBD 
analysis has turned out the approach of choice to confirm the distant kinship among the 
patient’s parents, relying on rare IBD chromosomal segments shared in single copy. It 
revealed very powerful as enabled to define an ancestral haplotype (IBD1) which surprisingly 
matched with one of the 11 homozygous regions inherited in double copy exclusively by the 
affected child. Therefore, this more specific approach allowed to pinpoint one candidate 
region on chr9p21.1-p13.2 (rs17775810; rs1022770) amongst the IBS and IBD regions 
detected by the single-patient homozygosity mapping. Given that more than 120 genes and 95 
genes (respectively for nucleus 1 and nucleus 2) mapped in the candidate regions, the Whole 
Exome Sequencing (WES) approach was applied. The information of candidate regions was 
absolutely necessary to reduce the number of the sequenced family members and the relative 
costs, but especially to dramatic reduce the high number of WES variants. Indeed, nearly 
100,000 high-confidence variants were markedly narrowed down to less than 250 between 
SNVs and indels. Starting from this manageable pool of variants, a deeper investigation 
further supported by manual reviews was more feasible for both low and high-confidence 
variants. This strategy have been powerful in identifying the two different genetic causes 
expected by this complex model of segregation. In the first nucleus, the candidate variant was 
identified in the SGK223 gene (c.1529T>C) of the chr8p23.1-p22 candidate region, and it 
was absent in the variant databases. The hypothesis of its causality in the disease is enforced 
by the interesting functional role of the PRAGMIN encoded protein. Even if not-well 
characterized yet, it has been described as regulator of the RhoA protein for the reorganization 
of cytoskeleton filaments (Tanaka et al., 2006). Interestingly, dysfunctions in cytoskeleton 
maintenance have already been considered one pathogenic mechanism of neuropathies. 
Moreover, PRAGMIN seems to plays the same role of FRABIN protein, another Rho 
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GDP/GTP exchange factor that has been associated with CMT4H (Delague et al., 2007). In 
silico predictions of this study strongly support the effect of this variant in a splicing 
alteration. Even if to date the SGK223 transcript is not well-characterized, these findings are 
indicative of the presence of a natural cryptic splice site that is activated by a developmental 
regulation (probably after differentiation) with a tissue-specificity. According to the late onset 
of the phenotype, the effects of this substitution on the strength of the splice site could be 
evident only after the development, when this splice site becomes activated. Further 
characterisations of the SGK223 transcript in normal and mutated conditions will help to 
verify this hypothesis. Therefore, SGK223 is strongly candidate to be a novel causal gene for 
the dHMN and further evidences could confirm this finding. 
 For the patient of nucleus 2, the analysis of the WES variants mapping to the IBD 
region effectively detected the candidate mutation (c.412G>C) in SIGMAR1, a gene that was 
already associated with the Juvenile amyotrophic lateral sclerosis 16 (ALS16) (Al-Saif et al., 
2011). As expected, Sigma receptor-1 protein plays more than one function in pathways 
involved in the pathogenic mechanisms of neuropathies. It has been described as an 
endoplasmic reticulum chaperone and a regulator of Ca2+ signaling, with a main expression in 
motor neurons (Crottes et al., 2013;Pabba 2013;Prause et al., 2013). By the SIGMAR1 
screening, a second variant (c.448G>A) was identified in another unrelated case displaying a 
recessive form of dHMN. Both mutations were novel and excluded from 200 control 
chromosomes. At a protein level, the two amino acid substitutions (p.Glu138Gln and 
p.Glu150Phe) seem to modify the chemical properties of the chaperone domain that is 
exposed to the endoplasmic reticulum (ER) lumen. Even if the involvement in different 
pathways makes it difficult to link the mutations to a specific role, a mutational effect on the 
folding/degradation of proteins in the ER is speculated. In line with this hypothesis, ongoing 
experiments in NSC34 cells will attempt to verify an effect in the unfolded protein response. 
All these notable findings confirm the causality of the SIGMAR1 gene in dHMN disorder. 
This is also supported by the mapping to the “orphan” dHMN Jerash type locus (dHMN-J) 
(Christodoulou et al., 2000). Indeed, a similar form of autosomal recessive dHMN was 
described by Christodoulou and colleagues in their families.  
In literature only one homozygous mutation (p.Glu102Gln) has been reported in SIGMAR1 
(Al-Saif et al., 2011). This is interesting because in spite of the paucity of mutations 
worldwide, two mutations (p.Glu138Gln and p.Glu150Phe) have been identified in the same 
Italian region and do not share a common ancestral allele. A possible explanation could be a 
mutational frequency in SIGMAR1 higher than expected. The known association with ALS16 
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could have prevented the screening of SIGMAR1 in many dHMN cases which still remain 
unsolved. For this reason we believe that our finding will have strong consequences for the 
diagnosis of dHMN. 
Interestingly, the problem we face is the traditional categorization of diseases. Whether 
dHMN and ALS16 are considered two distinct disorders, we can state that this study allows to 
extend the phenotypic spectrum associated with SIGMAR1 mutations. In regard to this, 
similar genetic overlaps between dHMN and ALS diseases have been observed for DCTN1 
and SETX genes (Pierce et al., 2010). On the other hand, the dichotomous classification has 
been questioned by other evidences. First, a difficulty in differentiating the diagnosis of ALS 
from hereditary  peripheral neuropathies emerged in several cohort studies (Davenport et al., 
1996;Riva et al., 2011). Second, SigmaR1 knock-out mouse model showed more slight motor 
abnormalities than observed for classical ALS phenotype, more similar to neuropathy 
(Mavlyutov et al., 2013). Third, also the neuropathy could hamper a differential diagnosis, as 
it is a common sign in many disorders and not a specific hallmark. Considering these 
limitations, a classification based on molecular basis could be preferable but even necessary 
to unravel and clarify a definitive genotype/phenotype correlation. However our data enable 
to link the SIGMAR1 gene to the dHMN Jerash type locus, thus explaining it for the first time.  
 
  Also the study of Family 1 put in evidence the heterogeneity of the neurodegenerative 
disorders and the consequent problem of the traditional categorization of these diseases. The 
analysis of this family, affected by a recessive form of distal neuropathy and spastic 
paraplegia, is an example of application of the traditional approach. Only one candidate 
region was highlighted by the genome-wide linkage analysis on chr13q12.1-q12.12, and only 
5 genes map to this interval. These findings allowed to use the traditional Sanger sequencing 
of the coding exons to identify the variants in this region. A homozygous missense mutation 
(c.11104A>G, p.Thr3702Ala), co-segregating with the disease in the patients was identified 
in the SACS gene. The mutation was absent in all variant databases and was not detected in 
350 healthy controls. Interestingly, SACS is responsible for the autosomal recessive spastic 
ataxia of Charlevoix-Saguenay (ARSACS) and more than 100 different missense, nonsense 
and frameshift mutations have been reported since 2000 up to now. (Engert et al., 
2000;Thiffault et al., 2013). The identified substitution p.Thr3702Ala is the first amino acid 
change affecting the XPCB domain of sacsin protein, which was reported to interact with the 
E3 ubiquitin ligase UBE3A (Greer et al., 2010). In the current study, in silico predictions 
showed that p.Thr3702Ala change falls in a surface-exposed and evolutionarily conserved 
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region, suggesting a key role in UBE3A binding and the consequent ubiquitination of 
proteins. Indeed, even if sacsin has not been well characterized because of its large size, a role 
in the protein quality control has already been reported for sacsin (Kozlov et al., 2011;Parfitt 
et al., 2009). It is interesting to note that the same function was reported for LRSAM1 and 
TRIM2 E3 ubiquitin ligases responsible for HMSN (HMSN2P and HMSN2R respectively) 
and for the E3 interactor spartin which causes HSP (Bucci et al., 2012;Finsterer et al., 2012). 
Recently, Girard and colleagues described an imbalance between mitochondrial fusion and 
fission in fibroblasts of patients homozygous for the c.8844delT SACS mutation (Girard et al., 
2012). In the present research such impairment was assessed for the mutation identified, and a 
higher number of significantly more little and spherical mitochondria was observed in the 
proband’s fibroblasts. These findings were indicative of a higher fragmentation of the 
mitochondria in presence of the p.Thr3702Ala sacsin mutation, in agreement with the 
hypothesis of impairment in the fusion/fission mitochondrial dynamics. Previous studies for 
mutations in MFN2 complained several limitations in studying mutational effects in patient’s 
fibroblasts (Amiott et al., 2008). This aspect could explain the reason why the differences 
here observed between mutated and control fibroblasts are significant but not so striking. 
Nevertheless a deeper investigation is required in order to confirm and lend further weight to 
the hypothesis supported by these data. A better model for studying neuron mechanisms could 
be obtained by reprogramming these fibroblasts into neurons (Vierbuchen et al., 2010). 
Considering that the current knowledge on sacsin is related to the protein quality control, the 
p.Thr3702Ala mutation could impair the mitochondrial proteostasis specifically through 
UBE3A binding, thus affecting the mitochondrial functionality and consequently causing the 
morphological changes here observed. In line with this speculation, a study revealed smaller 
mitochondria and “dense spheroids” associated with UBE3A deficiency (Su et al., 2011). 
Mitochondrial impairment has been also reported in HMSN patients with MFN2 and GDAP1 
mutations, whereas the paraplegin and HSP60 which are mutated in HSP, participate to the 
mitochondrial protein-quality control as hypothesized for sacsin (Timmerman et al., 2013). 
Therefore, further studies on the mitochondrial functionality (by checking the membrane 
potential or oxidative damages) might explain whether this finding is solely a secondary effect 
of the mutation. 
 The results obtained in this family represent the first evidence for a SACS mutation associated 
with a non-ataxic clinical picture (Gregianin et al., 2013). Indeed, ARSACS is mainly 
characterized by early-onset spastic ataxia (i.e. uncoordination of voluntary movements) and 
pyramidal tract signs. Even if a clinical variability have been increasingly described, the 
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cerebellar ataxia and typical features in the magnetic resonance imaging (MRI) are 
fundamental hallmarks for the diagnosis of ARSACS (Masciullo et al., 2012;Pyle et al., 
2012;Shimazaki et al., 2007;Synofzik et al., 2013;Takiyama 2006). Interestingly, the patients 
in this family did not show overt evidence of cerebellar abnormalities in MRI. This novel and 
atypical non-ataxic phenotype may be effectively explained by the first substitution affecting 
the XPCB domain. Indeed, ARSACS phenotype has been mainly defined on the basis of cases 
in Quebec region (Canada), where a founder effect for truncating mutations has increased the 
prevalence of a severe and relatively homogenous disease phenotype. On the other hand, a 
growing phenotypic variability has been recently demonstrated in other populations, mainly 
associated with missense mutations which cause only a partial loss of function (Thiffault et 
al., 2013). This could explain the later onset in this family compared with the early childhood 
onset of ARSACS. In agreement with this suggestion, other cases displaying a later onset 
have been reported for SACS missense mutations (Baets et al., 2010). 
In conclusion, our findings expand the genetic spectrum of SACS mutations and further 
broaden the 
ARSACS phenotype described up to now. In line with a growing number of reports, the 
increasing clinical variability supports the hypothesis that SACS mutations are more common 
than previously known and that they might be underdetected (Synofzik et al., 2013). 
Accordingly, the SACS screening has to be considered in still-unsolved cases with unusual 
clinical presentations such as late onset, prominent peripheral neuropathy and spastic 
paraplegia. A not-biased approach of whole-exome sequencing could be useful to find these 
cases. Considering the limitations of the traditional classification, ARSACS disease could be 
better indicated by the term “sacsinopathy” to specify all diseases caused by SACS mutations 
(Takiyama 2006). A disease classification based on molecular evidences is becoming 
increasingly necessary to unravel and clarify a definitive genotype/phenotype correlation. 
Moreover, as for other not-well characterized proteins, mutation discoveries like this one 
represents a stimulus for shedding light on the sacsin role which is still poorly characterized. 
 
The approach of homozygosity mapping/linkage analysis combined with WES enabled to 
powerfully shed light on the genetic bases of the third consanguineous family. The Family 3, 
affected by a recessive complex form of neuropathy with spastic paraplegia and mental 
retardation, was investigated by robust homozygosity mapping/linkage analysis because of 
the clear recessive monogenic model and the high number of genotyped individuals (3 
affected and 8 unaffected family members). Despite the high informativeness of the family, 4 
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candidate regions on chr2p13.3-p12, chr3q27-q28 (centromeric and telomeric regions) and 
chr21q11.2-q21.1 were surprisingly identified. Amongst the 94 genes mapping to these 
regions, the analysis of WES variants enabled to identify in chr2p13.3-p12 region the best 
candidate variant in the FBXO41 gene. The missense variant c.950G>A has never been 
reported in variant databases and was excluded from 400 control chromosomes. FBXO41 
protein has been described with a role in the E3 ubiquitin ligase complex SCF and probably in 
cholesterol transport, with a main expression in the nervous system (Jin et al., 2004). Several 
data in literature are in agreement with a putative pathogenic role of this variant. First, the 
ubiquitin proteasome pathway is a mechanism already associated with the pathogenesis of 
HMSN, with mutations in the TRIM2 and LRSAM1 genes encoding E3 ubiquitin ligases 
(Guernsey et al., 2010;Ylikallio et al., 2013). Second, the paralogs FBXO48, FBXO7 and 
FBXO38 have been already associated with clinical features found in Family 3, such as 
neuropsychological signs (Parkinson Disease), spastic paraplegia and neuropathy (Shojaee et 
al., 2008;Sumner et al., 2013). Third, spartin protein (SPG20) that has already been 
associated with a very similar complex picture, presents the two same functional roles of 
FBXO41 (Eastman et al., 2009). Concluding, even if the underlying mechanism remains 
unclear and functional studies on FBXO41 will be required to gain further information, at 
present the FBXO41 gene appears the best candidate disease-causing gene in Family 3. In 
order to shed light on many of these aspects, a mutation screening of FBXO41 gene is 
currently under way in unrelated patients. At this time, FBXO41 is strongly candidate to be a 
novel causal gene for this disease and further evidences could confirm the findings of the 
current study. 
 
As reported in literature, the majority of the novel genes identified by the WES approach 
underlies recessive diseases, whereas dominant disorders are more difficulty to unravel to date 
(Gilissen et al., 2012). Indeed, data obtained in the current study for Family 4, which is 
affected by an autosomal dominant form of HMSN and/or spastic paraplegia, have been 
insufficient to pinpoint a candidate genetic cause. Alternative genetic hypotheses such as the 
digenic model and the co-occurrence of two independent causes were also proposed in order 
to explain the intrafamilial clinical heterogenity, with patients exhibiting either a prevalence 
of peripheral neuropathy or pyramidal signs or both of them. Linkage analysis enabled to 
detect a high number of candidate regions, with the best candidate one on chr9q22.33-9q33.2 
(rs2297602; rs1041356) that was defined by the analysis with only surely affected individuals 
and the integration with microsatellite genotypes. WES variants were inspected in all these 
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regions but no variants displaying a correct segregation without assuming at least one non-
penetrant subject were selected. Also the CNV analysis and the direct sequencing of the 
poorly-covered exons in the chr9q22.33-9q33.2 region did not identify any other significant 
variant. However, through this study the weaknesses of the WES technique came to light. 
Firstly, technical artefacts created by the sequencing and read alignment steps were 
highlighted. The presence of allelic variants in homopolymer nucleotide stretches and in other 
in-house unrelated exomes proved to be good selection criteria to filter them out. Also the 
presence of multiple-mapping reads due to repetitive regions in paralogs and pseudogenes 
were indicative of spurious variant calls. For instance, in all exomes a huge number of 
variants in olfactory and taste receptor gene families was found. Second, the automatic 
thresholds that are commonly used by the algorithms of aligners and variant callers to select 
high-quality variants, may instead produce unfavourable results. Only a manual review of the 
allele-specific read depths allowed to unmask missed variants and miscalled heterozygous 
calls. As expected, the heterozygous calls were more error-prone than homozygous ones due 
to misinterpreted background noise, and strong evidences were observed in this family. 
Indeed, a high number of variants called in poorly-covered regions failed to be confirmed by 
Sanger sequencing. Third, the coverage had a systematic impact on the sensitivity and 
specificity of the technique. The visualisation of the depth of coverage in the critical intervals 
revealed a similar trend among different samples, but an inter-exonic and intra-exonic uneven 
distribution. The sequences characterized by extremely low (<40%) or high (>60%) GC 
contents appeared the most affected in capture and sequencing yields. Therefore, Sanger 
sequencing of a high number of poorly-covered exons was necessary to detect missed variants 
and exclude homozygous deletions. Only recent improvements in the accuracy have been able 
to bridge this gap. Indeed, thanks to technology advances, a higher quality of WES data was 
observed in the high-coverage exomes (100X of depth) sequenced at December 2013. 
Samples sequenced in 2011 (with a mean 75X read-depth) displayed 80% target sequences 
with more than 20X depth of coverage, whereas in recent WES the value increased to 98%. 
Unfortunately optimal values of sensitivity and specificity and their relationship with the 
mean on-target read depth are not well-defined to date. Guidelines and standardization criteria 
have only recently been taken into account for diagnostic purposes. Unfortunately a better 
understanding is also hampered by the multiplicity of capture technologies, sequencing 
platforms and aligners. Moreover longer reads, local realignments and more efficient 
algorithms should improve the currently limited efficiency of investigating structural 
variations, chromosome rearrangements and short indels.  
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In conclusion, this project supplies an original contribution for the study of peripheral 
neuropathies, for which many cases are still “orphan” today. In detail, the results provide the 
first evidence that SACS mutation can be associated with non-ataxic phenotypes, and that 
SIGMAR1 mutations cause a form of distal motor neuropathy. Considering also that the 
SIGMAR1 gene maps to the “orphan” dHMN Jerash type locus (dHMN-J), this finding 
supports the causality of this gene in dHMN disorder. Moreover, the SGK223 and FBXO41 
genes, identified by the combinatorial strategy of linkage and WES approach in families with 
recessive transmission, are strongly candidate to be novel causal genes for the inherited 
peripheral neuropathies. This study represents the first step to demonstrate the pathogenicity 
of a candidate variant and dissect the mechanisms underlying the pathology. Indeed, further 
genetic screenings in a large cohort of patients and functional studies are currently undergone 
and will elucidate the actual involvement of the novel candidate genes in these disorders. The 
demonstration of a growing phenotypic heterogeneity up to an overlap with other neurological 
disorders can be indicative of a more extended phenotypic spectrum associated with these 
genes, which could be masked by a neat categorization based on traditional diagnostic criteria 
and clinical features. Even if a complicated task, the classification of these diseases based on 
genetics criteria is becoming increasingly useful to unravel and clarify the heterogeneity of 
these disorders. 
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5. MATERIALS AND METHODS 
 
5.1 Traditional approach of genome-wide scan 
 
Linkage analysis and haplotype reconstruction 
This analysis starts from high-density SNP genotyping obtained by different platforms. For 
the families 1, 2 and 4 genotyping was carried out with Illumina Infinium HD 
HumanCNV370-QuadV3 BeadChip (average density of 1 SNP per 8 Kb), for the family 3 
with the Affymetrix Mendel Nsp 250K chip (average density of 1 SNP per 12 Kb). 
Linkage analysis was performed for each family by GENEHUNTER-PLUS program 
(Kruglyak et al., 1996) through the graphical user interface easyLINKAGE PLUS (Lindner 
and Hoffmann 2005). 
The program calculates a parametric multipoint LOD score, which indicates the eventual 
presence of linkage and considers the probability of co-segregation between disease and allele 
markers. This analysis takes into account parameters that define the disease model, such as 
the mode of inheritance, disease allele frequency, penetrance and possibility of phenocopy. 
For each region of interest, since the genome-wide analysis uses a limited number of 
SNPs, haplotype reconstruction allows to consider a higher SNP number and to obtain a more 
detailed segregation. Moreover EasyLINKAGE provides input files for the HaploPainter 
program (Thiele and Nurnberg 2005). HaploPainter is used to draw pedigrees and visualise 
coloured haplotypes of SNP markers with their genetic positions and eventual recombination 
events. In order to confirm haplotypes of SNP markers, they are manually integrated by 
microsatellite genotypes collected in previous analyses. 
 
Homozygosity mapping analysis 
For consanguineous families with a recessive mode of inheritance and few affected 
individuals, autozygosity regions was confirmed by the analysis carried out by 
HomozygosityMapper software (Seelow et al., 2009). Moreover, for a dominant trait the 
homozygosity mapping can highlight possible hemizygous deleted regions. Starting from 
SNP genotyping data of more than one individual, HomozygosityMapper screens patients 
(cases) for blocks of homozygous genotypes in contiguous markers. Homozygosity scores are 
reported and candidate genomic regions are visualized and compared with genotypes of 
unaffected individuals, in order to exclude shared homozygous regions. Frequencies of 
homozygous genotypes for SNP markers are obtained from the CEPH (Centre d'Etude du 
Polymorphisme Humain) collection of HapMap project. To circumvent the problem of 
genotyping errors, single heterozygous genotypes with seven or more homozygous genotypes 
on each side are ignored. A homozygosity score higher than 80% of the maximum value is 
considered suggestive of the most interesting genomic regions. A manual inspection of 
genotypes allowed to evaluate genotype-calling errors and better define recombination events 
of candidate regions. 
 
IBD sharing analysis 
The program performs a non-parametric statistical analysis and estimates the probabilities of 
sharing alleles identical by descent (IBD) between pairs of relatives. Multipoint estimates of 
IBD sharing at any genomic location are based on the implementation of Lander-Green 
algorithm (Kruglyak et al.,1996). The obtained scores represent the probabilities that two 
relatives share 0, 1 or 2 IBD alleles (maximum value =1) and a sharing of the same ancestral 
alleles can be suggestive of a kinship. To prevent bias in the analysis due to linkage 
disequilibrium (LD), SNPs in strong LD with other SNPs were previously removed and a 
pruned subset of about 64,000 SNPs in approximate linkage equilibrium was used. 
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 5.2 Whole-exome sequencing approach 
 
Exome sequencing 
Exome capture and following sequencing were performed by Beijing Genomics Institute 
(BGI) in affected individuals. The first sequencing of subjects V-3 and VI-6 of Family 2, IV-2 
of Family 3 and III-2, III-4 and III-6 of Family 4 dated 2011; the second sequencing of VII-2 
of Family 2, IV-7 of Family 3 dated December 2013. 
In this project, Agilent SureSelect Human All Exon v4 kit and Agilent Select Human All Exon 
v4+UTRs kit were used for the targeted enrichment of coding regions and all exons 
respectively. 
The first kit contains probes designed with the aim of capturing 51 Mb of the genome by 
hybridization and to obtain 4 Gb of sequences, the second kit covers 71 Mb of genome with 6 
Gb of sequences. Probes are designed for capturing exon sequences, their flanking regions 
and a pool of non-coding RNAs based on ENCODE, Ensemble (GRCh36 assembly) and 
Consensus Coding Sequence (CCDS) gene annotation. Two kits are composed by 120-mer 
biotinylated single strand RNA probes, synthesized by a transcription from a DNA library and 
with biotin-conjugated uridine-5’-triphosphate incorporation. 
Genomic DNA of patients (5 µg) was randomly fragmented by sonication and ligated to 
standard adaptors. Fragments of 250 bp were selected and amplified by polymerase chain 
reaction (PCR) with standard primers. This genomic library was hybridized in liquid-phase 
with the biotinylated RNA probes, which in turn were captured by streptavidin-coated 
magnetic beads to purify targets from nonspecific fragments. Captured fragments were 
quantified and sequenced by Illumina Hiseq2000 platform. Illumina (Solexa) NGS platform 
relies on bridge PCR amplification, where single strand templates bind a solid support and 
form a “bridge” structure by means of their standard adaptors which recognize 
complementary primers. Each single template is amplified to obtain a cluster that will be 
sequenced with reversible terminators and cycles of single-base extension. After each 
incorporation of a single nucleotide, fluorescence imaging allows the base calling. In this 
project sequences were generated as 90 bp reads and from both extremities of each library 
fragment (end-paired reads). 
 
Output files from the exome sequencing 
The creation and managing of output files was entirely performed by the BGI. The Genomic 
Institute developed a pipeline of analysis and provided files for each sequenced individual. In 
the last steps data from different family members were pooled together. 
The raw data obtained by the sequencer were processed by Illumina base-calling Software 
1.7, which converts fluorescence signals into base calls. All reads were annotated in FASTQ 
format file (*. fq) with their identifier, sequence and single-nucleotide quality scores.  
 
 
Table 5.1: Example of *.fq file. Row 1: read identifier; row 2: read sequence; row 3: eventual annotations; row 
4: string of single-nucleotide quality scores, expressed in ASCII character and corresponding to a probability of 
error for single base calls. 
 
1 @FC81EBGABXX:7:1101:1359:2102#GCCAATAT/1 (or 2) 
2 ATCCTGAAGACTTCTAGAGAGCTATCCACTTCCCCATGTAATCCCATAGTTCGCCAGAAAGAATCTGACTTACAAATGACATCTGCAGCC 
3 + 
4 gggggggggegggggdgfgeeggggggeggggggggee[gcggggegegcge^egggbgbdccUedccSbddfa`efaeegggfc^^dec 
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Reads were aligned against the existing UCSC reference human genome by 
SOAPaligner/SOAP2 (Short Oligonucleotide Analysis Package) program created by the BGI 
(http://soap.genomics.org.cn/). This software calculated the best alignment with maximum 3 
mismatches per read and the parameters -a -b -D -o -u -p -2 -m -x -s 40 -l 35 -v 3. The used 
reference genome was based on March 2006 human reference sequence (hg18) (NCBI build 
36.3 assembly) from University of California, Santa Cruz (UCSC).  The *.soap output file 
contains for each read information about the mapping position and nucleotide mismatches. 
 
Table 5.2: Example of *.soap file: Column 1: read identifier; 2: read sequence; 3: string of single-nucleotide 
quality scores; 4: number of read mapping in the genome; 5: forward “a” or reverse “b” sequence of pair-end 
reads; 6: nucleotide lenght; 7-9: strand and chromosomal position; 10: number of mismatches; 11: nucleotide and 
position of mismatch (reference allele >alternative sequenced allele, quality score); 12: matches number; 13: 
consecutive matches number. 
 
The consensus sequence was obtained by SOAPsnp (BGI), a program that calls consensus 
genotypes and measures their call accuracy. The following parameters were set: -i -d -o -r 
0.0005 -e 0.001 -u -L 150 -T -s -2. SOAPsnp takes into account different scores indicating 
data quality, alignment and recurring experimental errors, and it converts them into a single 
Phred-like quality score. The *.cns file indicates for each position the consensus diploid 
genotype and the more likely nucleotides, based on Bayes’ theorem. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
chr1 19850 T T 99 T 36 67 67 C 0 0 0 67 1 255 0 
chr1 19851 G G 99 G 39 29 35 A 0 0 0 35 1 255 0 
 
Table 5.3: Example of *.cns file. Column 1 and 2: chromosomal position; 3: reference allele; 4: consensus 
genotype of the sample; 5: Phred-like quality score of the genotype; 6-9: more representative allele, quality 
score, uniquely mapping reads number and total reads; 10-13: second more representative allele, quality score, 
uniquely mapping reads number and total reads; 14: total reads or read-depth; 15: p-value; 16: copy number of 
adjacent regions; 17: annotation in dbSNP database, “1” if annotated, “0” if absent. 
 
 
All genomic positions where the consensus genotype differed from the reference sequence 
were annotated in the *.snp file as candidate variants.  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
chr1 25621 C T 1 C 0 0 129 T 0 0 14 151 1 2,81457 1 33138 
chr1 58759 G A 3 A 38 2 6 G 0 0 0 6 1 2,16667 1 167 
chr1 58926 T Y 0 C 39 1 46 T 0 0 217 263 0 2,61217 0 167 
 
Table 5.4: Example of *.snp file. Column 1 and 2: chromosomal position; 3: reference allele; 4: consensus 
genotype of the sample; 5: Phred-like quality score of the genotype; 6-9: more representative allele, quality 
score, uniquely mapping reads number and total reads; 10-13: second more representative allele, quality score, 
uniquely mapping reads number and total reads; 14: total reads or read-depth; 15: p-value; 16: copy number of 
adjacent regions; 17: annotation in dbSNP database, “1” if annotated, “0” if absent; 18: distance from the nearest 
variant (bp). The distance from the nearest variant allows to detect regions prone to high error rates. 
1 2 3 4 5 6 7 8 9 10 11 12 13 
73 
ATAAATCTGAATGGCATATTGTACA
TGTAGAAATTTGTGGTGTTCACTTT
TTATCAGAACTAAATCCGGATTCTG
GGGCTGGAGGACAGA 
gggggggggggggggggggggeegfff
effeegggggeggegggggggggggeg
gefgfdfebeeggfdcgggfggfgegdc
W_d[dcd\ 
1 a 90 + chr12 108946177 0  90M 90 
96 
GGGACAATGAACTATTCATTAAAA
AAAATACGCTTAGATACCTACCTCA
CACCATATACAAAAATCATTTCCAG
ATGGATTAAAGAGCTC 
SUQSSWWWSVYYYY]_ccZY
YXXXYc_[cc_____ccccc^^^^^
__________cXXcccccccccccccc
ccccccc_[[[]]YWXUB 
1 b 90 - chr15 86229884 1 A-
>89C21 90M 
89
A 
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In order to discard false positive calls, filtering criteria were applied. For each variant call, 5 
bp minimal distance from another variant, ≤2 estimated copy number of a nearby region, ≥20 
Phred-like quality score and 4X read-depth were considered. Resulting high-confidence 
variants were reported in *.snp.filter file, which shows the same structure of *.snp file. 
Further information was added in *.snp.filter.gff file, such as rs identifier for already reported 
variants or snp number for new variants, gene name and other annotations. 
 
 
Table 5.5: Example of *.snp.filter.gff. file. Column 1, 4, 5 and 7: chromosomal position and strand; 2: variant-
caller program; 3, 6: variant type and Phred-like quality score; 8: codon position; 9: SNP identifier, status, 
reference allele, genotype, mapped reads, homozygosity or heterozygosity, transcript, exon and mRNA position, 
codon and residue change and function. 
 
 
Short insertions and deletions (indels) were identified by Genome Analysis ToolKit software 
(GATK, Broad Institute) and collected in *.indel.gff file. 
 
 
Table 5.6: Example of *.indel.gff file. Column 1, 4, 5 and 7: chromosomal position and strand; 2: variant-caller 
program; 3, 6: variant type and read-depth; 8: codon position; 9: more details such as variant identifier, status, 
type, genotype, homozygosity or heterozygosity, transcript, exon and mRNA position, codon and residue change 
and function. 
 
 
The high-confidence indels and single nucleotide variants were filtered out whether annotated 
with a MAF (minor allele frequency) ≥0.5% in the following variant databases: dbSNP130 
and 132 (different versions depending on more or less recent sequencing), 1000 genome 
project (pilot 1, 2, 3), eight HapMap exomes, YanHuang project and BGI database. Rare and 
novel variants were annotated in a *.xls file. 
Upon request, a re-alignment was performed by BGI in 2013 and new *.xls file was created. 
Variants were updated to the assembly GRCh37 (hg19) and information from KEGG database 
(Kyoto Encyclopedia of Genes and Genomes) and Gene Ontology were added. 
Furthermore a *.xls file containing CNV (copy number variants) called by Copy Number 
Inference From Exome Reads (CoNIFER) program were analyzed (Krumm et al., 2012). 
1 2 3 4 5 6 7 8 9 
chr1 SOAPsnp SNP 743132 743132 46 + 1 
ID=rs3115861; status=dbSNP; ref=C; alleles=G/G; support=17/17; 
name=FAM87B; geneID=ENSG00000177757; mutType=Hom; 
transcriptID=ENST00000326734; mRNAtoChr='+'; exonNum=1; 
mRNA_pos=380; codonNum=127; codonChange='ACT=>AGT'; 
residueChange='T=>S'; function=missense; 
chr1 SOAPsnp SNP 798791 798791 42 + . 
ID=rs11240780; status=dbSNP; ref=C; alleles=T/T; support=247/247; 
name=AL669831.13-2; geneID=ENSG00000209354; mutType=Hom; 
transcriptID=ENST00000386619; mRNAtoChr='-'; exonNum=1; function=5-
UTR; 
1 2 3 4 5 6 7 8 9 
chr1 GATK Indel 1148397 1148397 5 + . 
ID=rs59317408; status=-8; indelType=+2; Base=AC; mutType=Het; 
name=SDF4; geneID=51150; transcriptID=CCDS12.1; mRNAtoChr='-'; 
exonNum=3,4; function=intron; 
chr1 GATK Indel 1637753 1637753 87 + 1 
ID=rs35961525; status=-8; indelType=+6; Base=TTTCTT; mutType=Het; 
name=CDK11B; geneID=*; transcriptID=NM_033489; mRNAtoChr='-'; 
exonNum=6; mRNA_pos=278; codonNum=93; function=cds-Indel; 
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Coverage analysis 
Output files obtained by exome sequencing, for which a visualization standard tool is not 
provided, were displayed in UCSC Genome Browser after modification (http: //genome. ucsc. 
edu/). *.soap, *.snp, *.snp.filter, *.indels files were converted to *.bed files and displayed as 
custom tracks of a work session. Moreover, a file with sequences of Agilent probes was 
added. By a manual investigation, these data were analysed in a context of already existing 
information of the database. 
The MapView tool was also used for the navigation through the alignment since *.soap file 
was converted to a compressed MVF binary file (Bao et al., 2009). MapView allows the 
alignment visualisation of only uniquely mapped reads and their sequences could add further 
information to Genome Browser visualisation.   
For each linkage region, exon coverage was analyzed and a table with the following 
annotations was created (Table 5.7). Read-depth categories were arbitrarily established in 
order to unequivocally evaluate variant calls. In a family with a suspected recessive trait, a 
homozygous or two compound heterozygous mutations were expected. A read-depth of 10X 
was evaluated sufficient to detect them or to pinpoint a false positive call. On the other hand, 
in a dominant disease a heterozygous mutation was expected and a higher read depth was 
required (20X). 
 
with probe GENE of 
LINKAGE 
REGION 
Exon UTR/ coding 
no probe 
(only for 
coding 
Exons) no reads  low coverage (<10 reads) 
high coverage  
(≥10 reads) 
 
 
Table 5.7: Tables headers used in coverage analyses for a recessive and dominant disease respectively. 
 
Through these tables, technical problems due to probes design, capture or sequencing steps 
were highlighted, in order to better understand technical limits and to cover low-coverage 
target regions by direct sequencing. 
 
 
Analysis of the WES variants 
Single nucleotide variants (SNVs) and indels were analysed first for linkage regions and 
genes listed in OMIM database (OMIM and “review” genes). A detailed analysis was 
performed starting from *.snp.filter and *.indels files. When required, a deeper investigation 
of *.snp files was carried out. In order to rule out all other variants in the whole-exome, final 
*.xls files containing all rare and novel variants were also investigated.  
The nearly 100,000 total variants in *.snp.filter and *.indel.gff files were reduced to 
manageable pools by filtering out all variants which clearly represented technical errors based 
on the presence of homopolymeric nucleotide sequences flanking the variant, multiple-
mapping reads, the occurrence in other non-correlated in-house exomes, the evaluation of the 
number of reads representing each allele in a variant call. Limits of variant detection was 
overcome by considering calls in at least one individual and evaluating whether the read depth 
in the not-sharing patient could be sufficient to exclude its presence. 
The prevalence and the late-onset of the disease can lead to the annotation of causative 
mutations in variant databases, thus a threshold of minor allele frequency (MAF) of  1% or 
2% was used to filter out polymorphisms from dbSNP137, dbSNP138, NHLBI Exome 
with probe GENE of 
LINKAGE 
REGION 
Exon UTR/ coding 
no probe 
(only for 
coding 
Exons) no reads 
Very low coverage  
≤10 reads 
low coverage 
(10<reads<20) 
high coverage 
(≥20 reads) 
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Variant Server and 1000 Genome Browser. In addition, the HapMap and Human Genome 
Diversity Project allele tracks in NCBI Genome Bowser were visualised. The false positive 
rate which could characterize a single database was thus minimized by the integration of 
allele frequency data annotated in different databases. Moreover, information on the 
validation status and number of submissions in dbSNP database was indicative of a rare or 
false positive variant. 
Variants were analyzed also by functional predictors, in order to prioritize them on the basis 
of a putative pathogenic effect. The type of amino acid substitution, the localization in known 
or predicted functional domains, the high sequence conservation were evaluated. The 
potential pathogenic effect was predicted using PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2) MutationTaster (http://www.mutationtaster.org) and 
SIFT (http://sift.jcvi.org) programs and likelihood ratio test LRT (Chun and Fay 2009). The 
evolutionary conservation of sequence was calculated by by phyloP (Pollard et al., 2010), 
GERP (Davydov et al., 2010), phastCons (Siepel et al., 2005) and SiPhy tools (Garber et al., 
2009). Further information about the functional role of the encoded protein was searched in 
databases such as Gene Card and STRING servers in order to find a link with the pathogenic 
pathways already known for the disorder (following chapters). Finally, the correct segregation 
analysed by means of haplotype reconstructions led to filter out other variants. 
 
 
5.3 Bioinformatic tools 
UCSC Genome browser 
UCSC Human Genome Browser (http://genome. ucsc. edu/) is an online bioinformatics tool 
created by the University of California, Santa Cruz (UCSC). Interesting annotated tracks 
include reference genomic sequence (RefSeq), OMIM genes and updated DNA variations. 
Useful information for understanding technical yield of high throughput sequencing 
alignment are displayed by “Hi Seq Depth” and “Mapability” tracks. Genomic regions 
affected by problems of alignment can be detected by these tracks, which indicate 
troublesome regions due to repetitive elements and sequence similarities throughout the 
genome. “GC Percent” track can indicate critical regions for the library enrichment step. 
Putatively pathogenic variants are annotated by LOVD, HGMD, UniProt, ClinVar mutation 
databases or published in literature (“publications” track), while frequent polymorphisms 
were annotated in dbSNP, 1000 genome Project, HapMap, HGDP allele tracks. 
Moreover the user can upload and visualize his own files or retrieve the data of already 
existing tracks by “Table Browser” application. 
 
Variant databases 
dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/) is a free public archive 
developed by the National Center for Biotechnology Information (NCBI) and the National 
Human Genome Research Institute (NHGRI). This database includes different classes of 
polymorphisms, such as SNPs, indels and short tandem repeats. Information on allele 
frequency and validation status allows to understand whether a submitted variant represents a 
real polymorphism rather than a rare or false positive variant. Exome sequencing output data 
(*snp.filter.gff) refer to the build 130 of dbSNP, created in 2009. By more recent releases 
(dbSNP132, 135, 137 and 138) more details have been added, and SNPs are divided into 
“Common” (in at least 1% of the population), “Multiple” (mapped in more than one genomic 
position) and “Flagged” (probably clinically associated). 
The false positive rate of dbSNP was minimized by the integration of allele frequency data 
annotated in other databases, such as Exome Variant Server (NHLBI GO Exome 
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Sequencing Project (ESP), Seattle, WA; http://evs.gs.washington.edu/EVS/). EVS has been 
developed by National Heart, Lung, and Blood Institute (NHLBI) and currently collects 
exome variant calls of 6503 samples (13,006 chromosomes) from different projects. Samples 
have been selected in order to represent controls from African-American and European-
American population.  
1000 genome browser (http://browser.1000genomes.org/) represents a deep catalog of human 
genetic variation from 1092 individuals belonging to different populations (phase 1 of the 
1000 genome project). 
GEnomes Management Application (GEM.app, https://genomics.med.miami.edu/) is a 
software tool to annotate and visualise datasets of variants from exome sequencing. GEM.app 
currently contains 1,600 whole exomes belonging to patients affected by 50 different 
phenotypes. 
 
In silico study of proteins 
For not functionally characterized proteins, conserved protein domains were assessed by 
InterProScan, which allows to scan protein sequence for matches against the InterPro 
collection of protein signature databases (http://www.ebi.ac.uk/Tools/pfa/iprscan). The search 
for known and predicted direct and indirect interactions between proteins was performed by 
STRING database. It currently covers 5214234 proteins from 1133 organisms (Franceschini 
et al., 2013). 
Jpred3 (Cole et al., 2008), Psipred (Jones 1999) and SOPMA (Geourjon and Deleage 1995) 
prediction tools were used to investigate the effect of a mutation in the secondary structure of 
the protein. Alterations in the most common post-translational modifications, such as 
phosphorylation and acetylation were predicted by Phosida, NetPhos and NetAcet servers 
(Blom et al., 1999;Gnad et al., 2011;Kiemer et al., 2005). 
Three-dimensional structure of the full-length protein or a single domain (target) was 
predicted by homology modelling starting from the amino acid sequence alignment with a 
crystallized protein (template with a pdb code available). PDB database contains information 
about experimentally-determined structures of proteins, nucleic acids, and complex 
assemblies obtained by means of NMR spectroscopy or X-ray crystallography. The amino 
acid sequence alignments were obtained by NCBI-BLAST (Altschul et al., 1997) or ClustalW 
tool (Larkin et al., 2007) whether target and template were already known. For oligomeric 
proteins the modelling of a single domain is considered more reliable. SWISS-MODEL gave 
the output file of the best target-template alignment, and HOMER server performed the 
homology modeling which was visualised by PyMol program (Kiefer et al., 2009) 
(URL:http://protein.bio.unipd.it/homer/) (URL:http://www.pymol.org). The surface 
conservation of the structure was evaluated by Consurf server (Ashkenazy et al., 2010). The 
evolutionary conservation starting from linear sequence was assessed by ConSeq server 
(Berezin et al., 2004). 
A potential regulation of splicing site was predicted by ASSEDA server (Mucaki et al., 2013), 
ESEfinder (Smith et al., 2006), Human Splicing Finder (Desmet et al., 2009), MaxEntScan 
(Yeo and Burge 2004), Computational approach for Silencer motifs (Sironi et al., 2004) and 
FAS-ESS server (Wang et al., 2004). 
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5.4 Molecular studies 
 
Salting-out genomic DNA extraction 
The genomic DNA extraction was performed by using a modified protocol based on the 
salting-out method described by Miller et al., which relies on the physical-chemical rationale 
that macromolecules are less soluble at high salt concentrations (Miller et al., 1988). 
10 ml of peripheral blood were collected in tubes containing disodium-EDTA and stored at -
20°C. After thawing, 40 ml of isotonic N-N solution (NaCl 0.9%, Nonidet 0.1%) were added 
and leukocytes were pelleted by centrifugation (30 min at 4000 rpm, 4°C). Pellet was rinsed 
twice in 30 ml of N-N solution and resuspended in 4 ml of hypotonic TEN buffer (Tris-HCl 
10mM pH 8, EDTA 2mM, NaCl 400 mM). After the addition of 300 µl of 20% SDS solution, 
samples were incubated at 80°C for 3 hours under vigorous mixing, in order to lyse nuclei and 
solubilise proteins. The supernatant was collected after adding 1 ml of saturated NaCl (higher 
than 6 M) and centrifugation (10 min at 4000 rpm), followed by the addition of an equal 
volume of chloroform and another centrifugation (10 min at 4000 rpm). The supernatant 
containing DNA was thus separated from proteins. An equal volume of isopropanol was 
added and after centrifugation (10 min at 4000 rpm) the DNA was precipitated. 2 washes of 
pellet were performed with 1-2 ml of ethanol 70%. The pellet with DNA was dried from all 
ethanol and resuspended in 300-500 µl TE buffer (10 mM Tris-HCl pH 8, 1 mM EDTA). 
 
 
DNA quantification 
DNA concentration was quantified by measuring the optical density (OD) at 260 nm with 
NanoDrop ND-1000 UV-Vis spectrophotometer (CELBIO). Starting from 1.5 µl of DNA 
sample, the 260nm/280nm absorbance ratio assesses eventual contaminations by proteins 
(Absorbance of proteins at 280 nm). Values between 1.8 and 2 are indicative of a sufficiently 
pure DNA sample. In addition, the 260nm/230nm absorbance ratio assesses eventual 
contaminations by carbohydrates and phenols, which absorb near 230 nm. Values higher 2 are 
indicative of a sufficiently pure sample. 
 
 
Genome amplification with GenomiPhi DNA amplification kit 
Whether the genomic DNA was not sufficient or partially degraded for the following 
analyses, it was amplified with GenomiPhi DNA amplification kit (GE Healthcare). Few 
nanograms of genomic template were added to the sample buffer (50 mM Tris-HCL pH 8.2, 
0.5 M EDTA), containing random hexamer primers. After denaturation of 3 min at 95°C, 
reaction buffer (dNTPs and buffer) and enzyme mix (Phi29 DNA polymerase and other 
hexamers) were added. The polymerization reaction was carried out at 30° C for 90 min. The 
final step of enzyme inactivation was performed at 65°C for 10 min.  
Amplified DNA was then purified through ethanol precipitation. 
 
DNA amplification by Polymerase Chain Reaction (PCR) and Sanger sequencing 
All exons and adjacent intron regions of candidate disease genes, not well covered target 
regions and regions where interesting variants map were amplified by PCR reaction. Primers 
were designed by Primer3 software (http://primer3. wi. mit. edu/) based on the sequence data 
in UCSC Human Genome Browser and taking into account unspecific annealings predicted 
by Oligo Analyzer v 1.0.3. tool. Large exons were covered by multiple amplicons. 
PCR reactions were carried out in a 15 µl volume, which contains 50 ng of DNA template and 
the remaining volume of master mix. The master mix includes primer (4 pmoles each), dNTPs 
(200 µM), PCR buffer (1X), MgCl2 (1.5 mM) and of DNA polymerase (0.8 U). DNA 
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polymerase was either Taq Gold® DNA Polymerase (Applied Biosystems) or AccuprimeTM 
GC-Rich DNA Polymerase (Life Technologies) or Fast Start® Taq DNA Polymerase (Roche) 
or GoTaq® Polymerase (Promega) or AmpliTaq® 360 DNA Polymerase (Life Technologies) 
depending on the different amplicon. PCR reaction was performed in a Peltier PTC-200 
thermal cycler (MJ Research) using standard or touch-down protocols. Whether a high GC 
content was present in the template sequence, DMSO or a specific GC buffer was added 
according to the manufacturer’s protocol.  
The PCR yield was checked by gel-electrophoresis in 2% w/v agarose gel stained by GelRed 
(Biotium). DNA bands were visualized under ultraviolet trans-illumination and compared 
with a known molecular-weight marker. Amplified exons were purified in order to remove 
unincorporated dNTPs and primers, which might interfere with the following sequencing 
process. A 5 µl of PCR product was purified by Antarctic Phosphatase (1 U) and Exonuclease 
I (5 U). Samples were incubated at 37°C for 15 min and 80°C for 15 min for the inactivation 
of the enzymes. The purified PCR products with 3.2 pmoles of primer were sent to BMR-
Genomics (Padua, Italy) for the Sanger sequencing. Sequencing was carried out by 
ABI3730XL DNA Sequencer using Big Dye dideoxy-terminator biochemistry (Applied 
Biosystem). Electropherograms obtained in *.abi format were analyzed by SeqManII software 
(DNASTAR).  
Candidate variants identified with the exome sequencing were validated by Sanger 
sequencing. Unsufficiently covered coding exons which map in the linkage regions were 
sequenced as well. The most promising disease genes (SACS and SIGMAR1) were also 
investigated by direct sequencing in other unrelated patients. Amplicon sizes, primer 
sequences and condition of amplification are reported in Appendix A, B, C and D. 
 
Test of variants by restriction assay and ARMS PCR 
The amplification products can be also digested by restriction endonucleases which 
specifically recognize reference or alternative allele, thus producing restriction fragments of 
different lengths. The genotyping of a specific genomic position was alternatively inspected 
by tri-primer ARMS (Allele Refractory Mutation System) PCR reaction. In a standard PCR 
master mix, outer and inner primers specific for the amplicon with the variant were favoured 
by a higher concentration (3 pmoles of each primer) while the outer primer competitor of the 
inner one was added at a lower concentration (0.3 pmoles). 
The presence of the best candidate variants mapping in SACS, FBXO41, LPP and SIGMAR1 
genes was examined in a pool of unrelated healthy subjects in order to study variant frequency 
in the same population and to exclude a polymorphism. Other candidate variants identified 
with the exome sequencing were validated by enzyme restriction. All tested variants with 
primer sequences and conditions are reported in Appendix C. 
 
RNA isolation and Reverse Transcription 
Total RNA was extracted by fibroblasts pellet using RNeasy Mini Kit (Qiagen), according to 
the manufacturer’s protocol. The content of RNA of each sample was quantified using 
Nanodrop 2000 spectrophotometer (Thermo Scientific). RNA was reverse-transcribed in a 20 
µL reaction volume consisting of MgCl2 (5 mM), PCR BufferII (1X), RNase inhibitor 
(1U/µL), Moloney Murine Leukemia Virus Reverse Transcriptase (50 U, Promega), random 
primers (2.5 µM) and dNTPs (1 mM each). Reaction was performed in the thermal cycler at 
37°C for 1 hour and 85°C for 5 sec. 20 µL of RNase-free water was added to each tube at the 
end of the reaction. 
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Quantitative real-time PCR (qPCR) 
Quantitative real-time polymerase chain reaction was performed in a 10 µl reaction containing 
5 µl of KAPA SYBR® FAST qPCR Master Mix 2X (KAPABiosystems) with fluorescent dye 
SYBR® Green I, 2 µl of the reverse transcription reaction and 600 nM primers, by using 
Mx3000P™ real-time PCR system (Stratagene). The amplification program consisted of 
denaturation at 95°C for 3 min, 40 cycles of denaturation at 95°C for 3 sec, annealing 60°C 
for 30 sec and extension at 72°C for 1 sec. Finally 1 min at 72 °C. Real-time PCR assays were 
performed in triplicate for each condition. The cycle threshold (Ct) value was measured for 
SACS gene and the Ct value of GAPDH gene was used as internal reference for normalization. 
Primers specific for SACS cDNA that were used are: 
Forward (exon9): TTTAAAGGAAGCTGCCCAAA 
Reverse (exon10): CCAAACCATCTTAAGCCATGA 
Specific primers for GAPDH cDNA that were used are: 
Forward (exon2): GAAGGTGAAGGTCGGAGTC 
Reverse (exon4): GAAGATGGTGATGGGATTTC 
 
 
5.5 Functional studies on fibroblasts 
 
Fibroblasts culture 
Skin fibroblasts were obtained from the skin biopsy of X patient of the family 1.  
Patient and control fibroblasts were maintained into flasks (CORNING) and culture medium 
containing DMEM Glutamax (GIBCO) supplemented with Fetal Bovine Serum 10% (v/v) 
(Life Technologies), 100U/mL of penicillin and 100µg/mL of streptomycin (Life 
Technologies). Cell growth were in controlled temperature (37°C) and atmosphere (5% CO2 
v/v). When cells reached confluence were detached with trypsin and seeded at a density of 
5,000 cells/cm2
 
for propagation. 
 
Protein extraction and Western blotting 
Cell monolayer was detached by trypsine, pelleted and resuspended in lysis buffer with 1x 
complete protease inhibitor cocktail (Roche). Supernatant was collected after centrifugation 
and proteins were quantified using a Bradford colorimetric assay with bovine serum albumin 
(Sigma). 40µg of proteins were denatured at 95°C for 5 min and loaded in each well of a 4-
12% gradient NuPAGE Bis-Tris gel (Life Technologies). Electrophoresis was performed for 5 
hours at 200 V with  morpholinepropanesulfonic acid (MOPS)-sodium dodecyl sulfate (SDS) 
running buffer (Life Technologies). Proteins were blotted overnight at 4°C onto a 
nitrocellulose membrane (Whatman). Membrane was incubated with rabbit anti-sacsin 
(1:500) and mouse β-actin (1:10,000, Santa Cruz) primary antibodies diluted in BSA 5% 
Tween20-PBS. Fluorescent immunodetection was carried out using secondary antibodies 
conjugated to fluorescent dyes (1:10,000, Dako). 
 
Immunostaining of the mitochondria and Imaging  
Cells were grown at 70% confluence on glass coverslips and fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS) for 15 min. Permeabilisation was performed in 0,2% Triton 
X-100 in PBS for 5 min. Cells were washed and incubated in blocking solution (10%goat 
serum, 1% BSA, 0,02% Triton X-100 in PBS) for 45 min. Rabbit polyclonal anti-Tom20 
antibody (1:500, Santa Cruz) was used in blocking solution for 2 hours, and AlexaFuor (568 
nm) goat anti-rabbit antibody  (1:1,000, Life Technologies) in blocking solution for 1 hour. 
Three washes with PBS were followed by the nuclear staining with 1 µg/ml DAPI (4,6′-
diamidino-2-phenylindole) for 2 min.  
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Cover slips were mounted and images were acquired with a Zeiss LSM510 inverted 
microscope equipped with a 63Χ oil-immersion objective (1.4 NA) and zoom 1.5. For each Z-
stack about 16 cross-sectional images were taken in increments along the Z-axis to encompass 
the entire fibroblast volume. 
 
Image processing and 3D reconstruction 
Image processing, 3D reconstructions and surface rendering were performed with Surpass 
mode of Imaris software (Bitplane AG, St. Paul, MN). Each mitochondria were considered 
one object for the analysis and three-dimensional morphometry measures (area, ellipticity, 
sphericity and volume) were conducted. To reduce background noise, background 
fluorescence was subtracted by manual threshold adjustment and invalid objects were 
manually deleted. Experiment was repeated three times, with a total of 100 patient fibroblasts 
and 100 control fibroblasts collected. 
 
Statistical analysis of data 
Statistical analyses were performed using GraphPad Prism software (GraphPad Prism version 
5.0 for Windows, San Diego, CA). In normally distributed data, parametric Student’s t-test 
was used. In not normally distributed data (confirmed by D’Agostino test), non parametric 
Mann Whitney test was used. Differences were considered significant for p-values < 0.05. 
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APPENDIX A 
 
Mutational screening of unrelated index cases 
 
Amplicon Forward and Reverse Primer sequences 5’-3’ Amplicon lenght (bp) PCR conditions DNA Polymerase 
EX10_1 F:   CCTTCCAGTACTGTGTTATTTGTGA R:   TTCTGCAATGGCATCTTCTC 562 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_2 F:   CAAAAACTTGGAGGGTTTGTC R:   AAACTGAGGGTGGGAAATAGG 700 
TD 70-60°C 
30"30"45" x10+25 Taq Gold 
EX10_3 F:   TCCAAATGTGCTTGAGTGGT R: GCAAAATATGCTGGAATTGATAGTAG 677 
TD 70-60°C 
30"30"45" x10+25 Taq Gold 
EX10_4 F:   AAACCTGGAAAAAGCATTAGG R:   GGCATGGAACTTTTAGCCATT 695 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_5 F:   AAGCCCCAACACACCAGTT R:   CCCAGGATTGGATTTGTCTT 570 
TD 70-60°C 
30"30"45" x10+25 Taq Gold 
EX10_6 F:   AAAAAGGGGAGAAGTTGACAAAG R:   TGATCTGAAGAATGCAAGATGAC 653 
TD 70-60°C 
30"30"45" x10+25 Taq Gold 
EX10_7 F:   ACCAACCCCAGTTTAGCACA R:   CCAGGTCCCGTAAGACACTC 687 
TD 72-62°C 
30"30"45" x10+25 Taq Gold 
EX10_8 F:   TATCAATGGGTGCTTTGCTG R:   TCCCGAGAACTCATCAACTTTT 616 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_9 F:   TGTTGAACTTCCTTCTTCGGTAA R:   AACTGTTGCCTTTCCAGTCC 623 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_10 F:   GCTAGAACGTGCAGTGTCAGTAG R:   CCCACGGTTTCAAAAAGTTC 681 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_11 F:   GAAGCCTTGATGCAAAATGA R:   GGATGCTCTTAATTCTGCTGGT 634 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_12 F:   GACATACCCAGGGAAGTAGCA R:   CTGATGCTGGAACAGACGAA 700 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_13 F:   TTTGGATGCAGATTTTAGGACA R:   CATTATCATCACGCCACAGG 698 
TD 70-60°C 
30"30"45" x10+25 Taq Gold 
EX10_14 F:   TCAGCTCACAAGAACCAAGA R:   TGAAACCAATTTCTAAAAGGAGATG 691 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_15 F:   TGATGGCTCTGACTTGCACT R:   AAGTCTTTGCGGGATGGA 558 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_16 F:   GAAGCTGCCTTGTCGTCTG R:   AAGATGCTTGTGGGGCTCT 741 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_17 F:   TTCCAAATGCCCAGAGTGA R:   GAAATGCTTTGCTTGCTTTAGT 686 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_18 F:   GAAACACCTCTTACCAAAAATTGA R:   TACCTCTTGATATTGAGGATGAAA 586 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_19 F:   TGAGGGCTAATACAGAAAACTGG R:   TGAAATGTGCCAAGTTCTAAAGG 682 
TD 71-61°C 
30"30"45" x10+25 Taq Gold 
EX10_20 F:   CGAGGGGTTGCTTTTGTG R:   GAACACAACGCTCCAAACTG 617 
TD 70-60°C 
30"30"45" x10+25 Taq Gold 
EX10_21 F:   AAATGTTAGTTGATCTCAGCCAGT R:   TCATTGGGTCCATAAGCAGA 699 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_22 F:   AGGATGCAATGATATTTACAGGA R:   GGTTCTCTGGATTTTTGTCAGG 662 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_23 F:   CAAACATCAGTCCCCCAAAA R:   TTCCCCTCACAGCATAGTCA 614 
STD 60°C 
30"30"45" x35 Taq Gold 
EX10_24 F:   GGCTAAGACAAGCCAGAGCA R:   TCATCCCAATCATTCAAATCC 639 
TD 67-57°C 
30"30"45" x10+25 Taq Gold 
 
Table 1: Primers and amplification conditions for the SACS gene. For the proband of Family 1, full-lenght cDNA 
from fibroblasts were screened. The mutational screening of unrelated cases displaying a similar clinical 
phenotype was performed for the most extended and frequently mutated exon10. 
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Amplicon Forward and Reverse Primer sequences 5’-3’ Amplicon lenght (bp) PCR conditions DNA Polymerase 
EX1 F:   GAGGAAATGGTTCAACCGAAG R:   GTCCTAGGTCCGGGGATG 422 
STD 58°C 
30"30"30" x35 
360 Taq 
GC buffer 
EX2 F:   CGGCAGTACGCTGGTGAG R:   ATGGCCCAGCCAAACATC 423 
TD 68-58°C 
30"30"30" x10+25 
360 Taq 
GC buffer 
EX3 F:   CATGCCCTCCTTTCTGATGT R:   CCCAACACACTCCTTTTCCA 267 
STD 58°C 
30"30"30" x35 FastStart Taq 
EX4 F:   TCCCCACCCCTAGTTAGTCC R:  GCTCCAGCAAGTGGATATGTG 394 
STD 58°C 
30"30"30" x35 FastStart Taq 
 
Table 2: Primers and amplification conditions for the SIGMAR1 (NM_005866) gene. The mutational screening 
of 12 unrelated cases displaying a similar clinical phenotype to the Family 2 was performed. 
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APPENDIX B 
 
Validation of candidate variants identified by the exome sequencing 
 
Family 2 
 
Chr  Candidate Variant (gene, position, effect) 
Forward and Reverse Primer sequences  
5’-3’ 
Amplicon 
lenght 
(bp) 
PCR conditions DNA Polymerase 
Chr8 
SGK223  
c.1529T>C 
missense 
F: TGTCAGCCACCATCACAGTC 
R: CTCTCCTTGGGCTTGCTCTC 214 
STD 59°C 
30”30”40” x35 FastStart Taq 
Chr8 
MTMR7 
c.1749T>G 
missense 
F: ATGATTTTTCCCCTGAAATTGTT 
R: CAGAATCTTCATCGCCTTGTG 220 
STD 60°C 
30”30”30” x35 FastStart Taq 
Chr11 
ABTB2_intron5 
g.34189543A>G (hg19) 
splice site 
F: GTGCCCGATCTGTGGTTT 
R: AGCTCTGTGGGGCTTCCT 206 
STD 60°C 
30”30”30” x35 FastStart Taq 
Chr16 
PLEKHG4 
c.1986G>T 
missense 
F: TTCCGAAAGATGTGGGCTCT 
R: GGGAGTCAGGACCCAAGACA 442 
STD 60°C 
30”30”30” x35 FastStart Taq 
Chr16 
PLEKHG4 
c.1658C>G 
missense 
F: GTCTCTGCAGGAGCAGGTCA 
R: GGCAGCATGACCAAGAAAAG 290 
STD 58°C 
30”30”30” x35 FastStart Taq 
ChrX 
ABCD1 
 c.1823G>A 
missense 
F: TGTTGGGGCTTGaACTCCACCGTA 
R: CACGGCGtTGGTGCATTCATCCAG 489 
STD 67°C 
30”30”40” x35 
FastStart Taq 
+digestion 
with HpnI 
 
Table 3: Primers and amplification conditions for validation of candidate variants by Sanger sequencing or 
enzymatic digestion (when indicated) in Family 2. 
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Table 4: Primers and amplification conditions for validation of candidate variants by Sanger sequencing or 
enzymatic digestion (when indicated) in Family 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chr Candidate Variant (gene, position, effect) 
Forward and Reverse Primer sequences 
5’-3’ 
Amplicon 
lenght 
(bp) 
PCR conditions DNA Polymerase 
Chr2 FBXO41 c. 950G>A 
missense 
F: TGAGGCTCTGGGGTAAGAGA 
R: GTAGAGGAGGGAAGGCAGGT 291 
TD 68–58°C  
30”30”30”x10+26 
Taq Gold 
+digestion 
with BstUI 
Chr3 
LPP (NM_001167671.1) 
c.1142C>T 
missense 
F: TGCAATCGCTGCTTGTTTAG 
R: TTCCAATTACTAAGGAAGGAAATCA 279 
TD 65–55°C, 
30”30”30”x10+26 
FastStart 
Taq 
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Family 4 
 
Chr  Candidate Variant (gene, position, effect) 
Forward and Reverse Primer sequences  
5’-3’ 
Amplicon 
lenght 
(bp) 
PCR 
conditions 
DNA 
Polymerase 
Chr1 MAPKAPK2 c.643A>C 
missense 
F: GAGTAGAGGAAGGGAGGAACC 
R: CCCCAGATAGCCAAGAGGAG 296 
STD 57°C 
30"30"30" x35 
FastStart 
Taq 
Chr2 FARP2 c.2530A>T 
missense 
F: GCCCTACACAAGGAAGAGCA 
R: CAATGGGGACCAAGGAAAA 255 
STD 60°C 
30"30"30" x35 
FastStart 
Taq 
Chr4 PALLD c.1394G>A 
missense 
F: TGTATCTGTTTTGTCTGAGGTTTGG 
R: GGGCACTTCTCCTTACTTTTCTG 264 
STD 60°C 
30"30"30" x35 
FastStart 
Taq 
Chr5 
CLINT1_intron10 
g.157151286T>C (hg19) 
Splice site activating 
F: CAGCCAGCGGTAGAACTTG 
R: GGGGAGAGTATGAGGTAAATGAA 367 
STD 59°C 
30"30"30" x35 
FastStart 
Taq 
Chr5 RANBP17 c.2548G>A  
missense 
F: AGTGTGTCCCATAACTACTTTGAAT 
R: CTAACTCCCTGGGCTTCATTA 374 
STD 57°C 
30"30"30" x35 
FastStart 
Taq 
Chr6 SYNE1 c.24422G>C 
missense 
F: GGGATGAAATGTTTACTTAATGGACT 
R: CTTTTCTACTGGTGTATGGGTCAG 248 
STD 59°C 
30"30"30" x35 
FastStart 
Taq 
Chr7 hnRNPA2B1 c.1048A>G 
missense 
F: TGGATGGATATAAAATAGAATCAACTG 
R: CGATAACCTGAAGCTGTTCTG 396 
STD 59°C 
40”40”40”x35 
and Digestion 
BseRI 
FastStart 
Taq 
Chr8 SLC26A7 c.808T>C Stop codon abolishing 
F: TCTAAGGGCAAGGCTGCT 
R: CTGGAGTGGAGAGGGACTG 328 
STD 59°C 
30"30"30" x35 
FastStart 
Taq 
Chr9 SMC2 c.1583C>T 
missense 
F: TTTTGCTGATTCTACTTTCATTTCA 
R: GAGTCGTTCTCCAGCCACTAA 236 
STD 57°C 
30"30"30" x35 
FastStart 
Taq 
Chr9 SVEP1 c.4781C>A 
missense 
F:  TGAAAGAAGGAAATTCTCACCA 
R: CTCCACCCCCATCTCTAAAA 260 
STD 59°C 
30"30"30" x35 Taq Gold 
Chr9 MEGF9 c.380C>T 
missense 
F: GACTGCTGGACCCTCTTCCA 
R: GGTACGGTGGTCGCTACAGG 174 
STD 59°C 
30"30"30" x35 
Taq Gold 
+ digestion  
with MnlI 
Chr9 HSDL2 c.130G>C 
missense 
F: GGTCGTATTTGTTCTGTTGTAGGA 
R: AAACTCTCCAGCAAATTCTCTATGT 260 
STD 59°C 
30"30"30" x35 Taq Gold 
Chr9 
CTNNAL1_intron18 
g. 111705122G>T 
(hg19)  
Splice site activating 
F: GCTCTCTTAGTCCAACTTCTTTCA 
R: TTAAAAATGTCAGCTTCATCACA 295 
STD 58°C 
30"30"30" x35 
FastStart 
Taq 
Chr9 RNF20 c.2854A>C 
missense 
F: TGGGTTTTCTTCTTGGTTGTG 
R: GCTCCTCTTCTTCTCTTGACTTAGA 292 
STD 58°C 
30"30"30" x35 
FastStart 
Taq 
Chr9 FNBP1 c.1646A>C 
missense 
F: GCCGCTCTAACTCTAACCCA  
R: GACCACCAAAAGCAACCATC  390 
STD 60°C 
30"30"30" x35 
FastStart 
Taq 
Chr11 SHANK2 c.1664C>T 
missense 
F: CCCTCAGTCCCCTTCGTT 
R: CCACATTCTCTCCACCTTCG 248 
STD 60°C 
30"30"30" x35 
FastStart 
Taq 
Chr12 KCNMB4 c.604G>A 
missense 
F: GCCCTTTCTTTCTTATTCTCCA 
R: GTCTTCCAGTTGTGCCTGTTT 365 
STD 60°C 
30"30"30" x35 
FastStart 
Taq 
Chr21 
TMEM50B_ex3  
g.34839414A>C 
missense 
F: TGAAGAAAGCCAATGTGGAA 
R: TGATCTGTAGGACAAAAGGAATG 199 
STD 59°C 
30"30"30" x35 Taq Gold 
Chr21 c21orf67 c.579C>A 
nonsense 
F: CTCACTCGCTTCCTCCTGT 
R: AGCCATTTACCCCGTTTG 328 
STD 58°C 
30"30"30" x35 
FastStart 
Taq 
 
Table 5: Primers and amplification conditions for validation of candidate variants by Sanger sequencing or 
enzymatic digestion (when indicated) in Family 4. 
 117 
APPENDIX C 
 
Frequency study of candidate variants in the healthy population 
 
Gene and variant Primers for PCR or ARMS PCR Reaction 
SACS c.11104A>G 
missense 
F outer: TTCTGCATCATATATTCCAAGAACGAAT 
R outer: GTTATTGATTACCTTATCAAGAGGAGGATC 
R inner(mut): CAATGTGATGTACTCCAGCTGTTATTGG 
Tri-primer ARMS 
TD 76-66ºC 30”30”30”x10+25 
FBXO41 c. 950G>A 
missense 
F: TGAGGCTCTGGGGTAAGAGA 
R: GTAGAGGAGGGAAGGCAGGT 
TD 68–58°C 30”30”30”x10+27 
 and Digestion with BstUI (New 
England Biolabs) 
LPP 
(NM_001167671.1) 
c.1142C>T 
missense 
F outer: CTTTTTCCTCTCCAGTGCAATCGCTGCT 
R outer: CGAAGTCAGCTCTAGGCCCCACTCACCA 
R inner(mut): GGAATGAAGGGGCAACTGCCA 
Tri-primer ARMS 
TD 70–60°C 30”30”30”x10+24 
SIGMAR1 
(NM_005866) 
c.412G>C 
missense 
F: ATTGTCACTCAGGGCGCTAC 
R: CCCAACACACTCCTTTTCCA 
STD 61°C 30"30"30"x35 
 and digestion with MnlI (New England 
Biolabs) 
SIGMAR1 
(NM_005866) 
c.448G>A 
missense 
F:   TCCCCACCCCTAGTTAGTCC 
R:  GCTCCAGCAAGTGGATATGTG 
STD 58°C30"30"30"x35 
 and digestion with Alw26I (Promega) 
 
Table 6: SACS, FBXO41 and LPP variants were investigated in 200 healthy Italian subjects by these assays. 
SIGMAR1 variants were investigated in 100 healthy subjects belonging to the same Southern region of Family 2. 
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APPENDIX D 
 
Direct sequencing of poor-covered coding exons 
 
Family 2 
 
Chromosome Amplicon Forward and Reverse Primer 
sequences  
5’-3’ 
Amplicon lenght 
(bp) 
PCR 
conditions 
DNA 
Polymerase 
Chr8 NDRG1_ex16 F: GAGAGGGCACCCACGTAATAG R: AGCGTCACTTCTCTGGATGG 365 
STD 61°C 
30”30”40” x 35 FastStart Taq 
Chr8 SGK223_ex2 F: GGCATTACCTGTGCATACCTG R: CCCAAGAAACTGTCCCTCAC 372 
STD 60°C 
30”30”40” x 35 FastStart Taq 
Chr8 SGK223_ex5 F: CCTTCTCCGCAAACTTCATC R: GATCGTGTCTGCTTCCCAGT 383 
STD 60°C 
30”30”40” x 35 FastStart Taq 
Chr8 RP1L1_ex4 F: TCCTGATTGGGGACCAGTGT R: TTCAGGGGCATCAAGGAGAA 406 
STD 62°C 
30”30”40” x 35 FastStart Taq 
Chr8 ERI1_ex1 F: GCCTCCCTCTTGTTCGTCCT R: GCGGGACACCTGAGAAGAAA 457 
STD 61°C 
30”30”40” x 34 FastStart Taq 
Chr8 TNKS_ex1 F: GTTCCCTTGGCTGTTCTCTG R: GAGGACGACGGTGAATTGTT 565 
STD 59°C 
30”30”40” x 34 FastStart Taq 
 
Table 7: Primers and amplification conditions to sequence poorly-covered coding exons in Family 2. 
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Family 3 
 
Chromosome Amplicon Forward and Reverse Primer sequences  5’-3’ 
Amplicon 
lenght (bp) 
PCR 
conditions 
DNA 
Polymerase 
Chr2 C2orf65_ex10 F: CCAGTCATTTGCCAGGTTTT R: TTCAACCCCAACTGTCTTCA 180 
STD 57°C 
30”-30”45” x 
34  
Taq Gold 
Chr2 AUP1_ex1 F: AGCAGGCGGACAGTAGGAC R: AGCAGCACGAGCAGTAGGA 485 
STD 61°C 
30”30”45” x 34  FastStart Taq 
Chr2 WDR54_ex1 F: CATCCCCAGCTGAACTGAA R: CGAGCCAAATAAGTGTGATGA 385 
STD 57°C 
30”30”45” x 34  Taq Gold 
Chr2 PRADC1_ex1 F: GACCCGGAGAGTATGCTG R: ACCACCACCCACTTATTCC 533 
STD 61°C 
30”30”45” x 35  Taq Gold 
Chr2 BOLA3_ex1 F: GGGACCCTATCCATGAAACAG R: GGGAGCCAGTCCTCAAGC 449 
TD 67-57°C 
45”45”45” 
x10+26  
360 Taq 
GC buffer 
Chr2 FBXO41_ex1A F: CCCTGAGCCTTCCTGACC R: CTCGGCCAACTCCTCACA 516 
STD 61°C 
30”30”45” x 34  FastStart Taq 
Chr2 FBXO41_ex1B F: CTGCTGCACCACCACCAT R: GATCTTCTGCTCCACCTCCTC 378 
STD 60°C 
30”30”45” x 35  Taq Gold 
Chr2 FBXO41_ex1C F: TGATGTGGCCTACGAAGAGG R: CACAGTGACCCGCACAGG 377 
STD 61°C 
30”30”45” x 35  Taq Gold 
Chr2 EGR4_ex1A F: AGGTGGGAAGCGCATCTA R: TTCGGAAAACTCGCTAAGGT 578 
TD 68-58°C 
30”30”45” 10 + 
30 
360 Taq 
GC buffer 
Chr2 EGR4_ex1B F: TGTCCATGTTTGGGCATTT R: TCCTGGTTCTCAGGTATGGTG 569 
TD 66-56°C 
30”30”45” 
x10+30  
Accuprime GC-
rich 
Chr2 EGR4_ex2A F: TTGTAGGTAGGGGCTGTGGA R: CAGAACGCCTCTGGGAAA 411 
STD 58°C 
30”30”45” x 34  Taq Gold 
Chr2 EGR4_ex2B F: AACCTCATGTCGGGCATCTT R: CCCACTAGGAGGGGTCAGG 570 
STD 61°C 
30”30”45” x 36  Taq Gold 
Chr2 EGR4_ex2C F: GGGGCCTATGACGCTTTC R: GCTGTGCCGTTTCTTCTCAT 582 
STD 59°C 
30”30”45” x 35  Taq Gold 
Chr2 EGR4_ex2D F: CTGCCTCCGCAACTTCAG R: GCCTGTCTCTGGGGGTTATAG 556 
TD 67-57°C 
30”30”45”  
x10+26 
Taq Gold 
Chr2 DCTN1_ex8 F: CCTTCCCTTGCCATATTCTC R: CCTCACCCTTTCTGATCCAA 408 
STD 61°C 
30”30”45” x35  Taq Gold 
Chr2 ALMS1_ex1A F: CAACGTCGCCTGTAGCAAA R: CGACAGCGGAGGCAAAAT 482 
TD 68-58°C 
30”30”30” 
x10+25 
Taq Gold 
Chr2 ALMS1_ex1B F: GGACTCCGACTCTCACTACGG R: GAGTCTGGGCCGCCTACTA 302 
STD 60°C 
30”30”45” x 34 
cicli 
FastStart Taq 
Chr3 LEPREL1_ex1A F: CGAGGGAAGGTGGGAGAG R: CCAACAAGGAGCGGAAAA 430 
STD 56°C 
30”30”45” x 35 
Accuprime GC-
rich 
Chr3 LEPREL1_ex1B F: CGCCTACTACAGCGGAGACTA R: TCTGGATTCACAAACTGAGACAC 463 
TD 67-57°C 
45”45”45”  
x10+26 
360 Taq 
GC buffer 
Chr3 CLDN16_ex1 F: ACCACCACTAGCCCACAGTT R: CACCATCCAACAGTCAGTCC 422 
STD 57°C 
30”30”45” x 34  Taq Gold 
Chr21 USP25_ex1 F: CCTCTCTCCCTTCCCCAAA R: CGGCAGAAGGAAGTGGATT 653 
STD 55°C 
30”30”45” x 35  FastStart Taq 
Chr21 SAMSN1_ex1 F:ACATCCCCATCTGTTCCTGA R: TGGAATCCCTTTAAATCCAAAC 300 
STD 56°C 
30”30”30” x 34 Taq Gold 
 120 
Chr21 BTG3_ex1 F: GGTAGGGCGAGGGTGTGT R: CTCCCCCGATACCCACAG 454 
STD 59°C 
30”30”45” x 35 FastStart Taq 
Chr21 NRIP1_ex1 F: GCTGGTCGGAGGGAAGAG R: GGCAGCAGAGGCAGGATT 273 
TD 64-54°C 
30”30”45” 
x10+28 
FastStart Taq 
Chr21 NRIP1_ex2 F:CAACAACTATGTCCAAAGAAAGCA R: ACAAATGGCAAGGTAGTTTATCC 397 
STD 61°C 
30”30”30” x 34 Taq Gold 
Chr21 NRIP1_ex3 F: AATGAACCAGCATTCATAAACAA R:AAGGAAGGATTGTAGCTCTTTCA 467 
STD 60°C 
30”30”30” x 34 Taq Gold 
 
Table 8: Primers and amplification conditions to sequence poorly-covered coding exons in Family 3. 
 
 
 
Family 4 
 
Chromosome Amplicon Forward and Reverse Primer 
sequences  
5’-3’ 
Amplicon 
lenght (bp) PCR conditions 
DNA 
Polymerase 
Chr9 ALG2_ex1 F: GCAGAAGACCCCCATCAG R: GAACCGCAGACAGGGAAG  495 
STD 59°C 
40”40”40”x35 FastStart Taq 
Chr9 ABCA1_ex2 F: GCAGTCCTCATTGGTGTATGG R: ATCCCCAACTCAAAACCACA 247 
STD 60°C 
40”40”40”x35 FastStart Taq 
Chr9 COL15A1_ex16 F: CCTTTTCTAGCAAGCGTGTGT R: AGGCAAGGTCAGGTTTAGGG 220 
STD 60°C 
40”40”40”x35 FastStart Taq 
Chr9 NIPSNAP3A_ex1 F: GCTCAGCACAGCAGAGAAAGA R: CATTGCTCGCACGTACCC 343 
STD 60°C 
40”40”40”x35 FastStart Taq 
Chr9 NIPSNAP3B_ex1 F: CCGAAGAGAAAGACGCCAAC R: TCGCACGCTTCAGAAATACC 325 
STD 60°C 
40”40”40”x35 FastStart Taq 
Chr9 SEC61B_ex2 F: CGGGTGTGGGTGTCTAGG R:CAATCTTCACATGCTAGGGTCTC 270 
STD 60°C 
40”40”40”x35 FastStart Taq 
Chr9 GRIN3A_ex1 F: CTCCTGGGACCGCTTCAC R: GTTGTCCACGGCAAATAGGA 532 
TD 65-55°C 
30”30”40”x10+25 FastStart Taq 
Chr9 KLF4_ ex2 F: GGGTTTTGGCTTCGTTTCTT R: CTCGTTCAGTGGCTCTTGGT  343 
STD 60°C 
40”40”40”x35 FastStart Taq 
Chr9 KLF4_ ex3a F: CGCCAGCACGTCAGTATGT R: ACGACGAAGAGGAGGCTGA 350 
STD 63°C 
30”30”30”x35 FastStart Taq 
Chr9 KLF4_ ex3b F: CGGAGAGAGACCGAGGAGT R: CCTTTGCTGACGCTGATG 573 
TD 66-56°C 
30”30”40”x10+25 FastStart Taq 
Chr9 KLF4 _ex3c F: GCAAGTTCGTGCTGAAGG R: GAGCATCATCCCGTGTGT 500 
STD 59°C 
40”40”40”x35 FastStart Taq 
Chr9 SLC44A1_ex1 F: GCCGCCTCTTGAGTACCAG R: TGGGGACAGCGAGAGGTAT 292 
STD 56°C 
40”40”40”x35 
Accuprime GC-
rich 
Chr9 TGFBR1_ex1 F: CCTCCGAGCAGTTACAAAGG R: GCCATGTTTGAGAAAGAGCA  317 
STD 56°C 
40”40”40”x35 
Accuprime GC-
rich 
Chr9 TMEFF1_ex1a F: ACAAAGGGAAGGCGAGGA R: GAGAGAAGGCGAAGAGCAGA 464 
TD 69-59°C 
30”30”40”x10+23 Taq Gold 
Chr9 TMEFF1_ex1b F: TCCAGGGGCACCAGTCAT R: AACGGAGGGGTGGGAAGA 257 
TD 69-59°C 
30”30”40”x10+23 Taq Gold 
 
Table 9: Primers and amplification conditions to sequence poorly-covered coding exons in Family 4. 
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APPENDIX E 
 
Family 2 nucleus 1 
 
Homozygosity mapping for each patient 
 
Patient V-3 
chr from (bp) to (bp)  from SNP to SNP Mb Total RefSeqs 
Comments about relevant 
genes/loci 
1 194072229 201517349 rs533405 rs11577209 7.4 40 - 
1 203281175 211082285 rs17534202 rs1777250 7.8 98 SYT14 for Spinocerebellar ataxia 11 (AR) 
1 220009989 224897974 rs12143315 rs6669720 4.9 39 - 
2 155651200 156917835 rs2591154 rs7578557 1.3 1 - 
8 6754919 12718090 rs2738148 rs6997599 5.96 120 - 
9 5487980 8342540 rs10975134 rs1846695 2.9 14 - 
11 33904286 68855954 rs4756076 rs4930265 35 >100 
- BSCL2 for dHMNV and SPG17 
(AR/AD) 
- IGHMBP2 for dHMNVI (AR) 
- B3GNT1 for Muscular dystrophy-
dystroglycanopathy 
15 27706279 35370551 rs6497269 rs6495749 7.7 70 - 
18 55201461 61901187 rs754789 rs4328542 6.7 44 - 
21 42694667 48061211 rs2838011 rs2256070 5.4 >100 - 
Patient VI-6 
chr from (bp) to (bp)  from SNP to SNP Mb Total RefSeqs 
Comments about relevant 
genes/loci 
1 168986374 170383224 rs2146201 rs10919392 1.4 18 - 
3 143505568 144824171 rs1868179 rs7432650 1.3 2 - 
6 118543515 119841070 rs9398485 rs10485006 1.3 1 - 
6 128829399 130019354 rs6938035 rs17057640 1.2 3 LAMA2 for muscular distrophy 
7 135650363 152608306 rs10261276 rs6954929 17 >100 
- DHMN1 locus 
- CLCN1 for Myotonia congenita/levior 
(AR/AD) 
- myotonia-c locus 
8 6754919 22111871 rs2738148 rs4872456 15.4 >100 
- RP1L1 for occult macular dystrophy 
(AD)                                             - 
Vps37A (SPG53 -AR)                                                                                       
- ASAH1 for SMA with progressive 
myoclonic epilepsy                                                                  
- distal Myopathy 3 locus 
8 139484985 146292734 rs16909195 chrom end 6.8 >100 SLC52A2 for Brown-Vialetto-Van Laere 
syndrome 2 (AR) 
11 15829043 17007220 rs11023727 rs2353369 1.2 3 - 
11 27266037 28629115 rs10835148 rs11030385 1.4 11 - 
12 41301332 42140826 rs11178982 rs1497166 0.8 2 
- CNTN1 for congenital Myopathy 
- CMT2G locus 
- SPG26 locus (AR) 
12 122471031 131490145 rs7137708 rs12313737 9 81 - 
 
Table 10: Candidate homozygous regions selected after haplotype evaluations for each patient. Regions spanning 
more than 1 Mb were reported here (even variants were checked also for smaller regions). For each region 
chromosomal positions (hg19 release), flanking SNP markers, total validated Refseqs and relevant genes 
mapping to the region were annotated. In gray the regions totally or partially shared by the second patient. AR= 
autosomal recessive; AD= autosomal dominant. 
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Variants identified in the candidate regions (Table 10) 
 
Chr Candidate Variant 
Variant call 
V-3 
Variant call 
VI-6 
Predicted 
Effect 
Allele 
frequency Haplotype Functional Role 
Confirmation 
by Sanger 
sequencing 
8 MTMR7 
c.1749T>G 
A(ref)87/C82 
(Q=99) 
A(ref)0/182C 
(Q=89) 
Missense 
tolerated 
rs145244130, 
MAF= 0.3% 
EVS: 1 
homozygous 
subject 
Excluded 
from 
unaffected 
subjects 
Lipidic pathway, 
myotubularin-
related  
MTMR2 cause of 
CMT4B1 (AR) 
Homozygous 
only in VI-6 
11 
ABTB2_intron5 
g.34189543A>G 
(hg19) 
A(ref)0/19G 
(Q=52) 
A(ref)19/G13 
(Q=99) 
Splice Site 
damaging 
rs370573932, 
unknown 
frequency 
Excluded 
from 
unaffected 
subjects 
Cytoskeleton 
regulation, ion 
transporter 
Homozygous 
only in V-3 
  
Table 11: Filtered SNVs found in homozygosity regions for single patients. Variant calls are expressed with 
number of reads for each allele (ref=reference allele) and Q=Phred-like quality score of variant call. In gray the 
variant calls which could explain the mode of transmission for the disease trait are highlighted. 
 
 
 
Family 3 
 
Homozygosity mapping for at least 2 out of 3 patients 
 
chr from (bp) to (bp) from SNP to SNP Mb 
Total 
RefSeqs Shared by 
Comments about 
relevant genes/loci 
2 50754813 53356999 rs759507 rs1424972 2.6 1 IV-6; IV-7 - 
2 72251751 75681462 rs1878503 rs10496198 3.4 56 All patients 
- ALMS1 for Alstrom syndrome 
(AR) 
- DCTN1 for HMNVIIB (AD) 
3 188161706 188500658 rs2162259 rs3846183 0.34 1 All patients - 
3 188952524 192088525 rs1562761 rs9859577 3.14 16 All patients - 
6 22248576 23401282 rs9356810 rs6932335 1.2 2 IV-6; IV-7 - 
21 14658830 19044397 rs2258300 rs2824435 4.4 21 All patients - 
 
Table 12: Candidate homozygosity regions selected after haplotype evaluations. For each region chromosomal 
positions (hg19 release), flanking SNP markers, total validated Refseqs and relevant genes mapping to the region 
were annotated. AR= autosomal recessive, AD= autosomal dominant. 
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Variants identified in the poorly-covered exons in the patient IV-2 (WES in 2011) 
 
Gene and Exon Gene function Expression (Gene Cards) Variants Comments 
CLDN16_exon1 Claudin in tight junctions Mainly in kidney 
Indel rs56086318 
Missense rs76555381 cause of Renal hypomagnesemia 3 
ALMS1_exon1A Protein for ciliogenesis in collecting duct cells Also in brain 
c.63delGAGGAGGAG, 
No rs 
cause of Alström syndrome (cone-rod 
retinal dystrophy, cardiomyopathy and 
type 2 diabetes mellitus) 
 
Table 13: Poorly-covered exons selected for Sanger sequencing with relative informations, where variants were 
detected. 
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APPENDIX F 
 
Statistics of exome-sequencing data 
 
Family 2 
 
Patients V-3 VI-6 
Target region (bp)(1) 49874469 50031585 
Raw reads 79933210 96182744 
Raw data yield (Mb) 7194 8656 
Reads mapped to genome 70830461 82046555 
Reads mapped to target region(2) 50591639 60247551 
Data mapped to target region (Mb) 3826.33 4545.89 
Mean depth of target region(X) 76.72 90.86 
Coverage of target region (%)(3) 97.35 97.53 
Average read length (bp) 89.85 89.86 
Rate of nucleotide mismatch (%) 0.33 0.33 
Fraction of target covered >=4X (%) 93.05 93.65 
Fraction of target covered >=10X (%) 87.14 88.45 
Fraction of target covered >=20X (%) 78.78 81.19 
Capture specificity (%) 72.35 74.72 
Reads mapped to flanking region(4) 6824962 8573186 
Mean depth of flanking region(X) 18.34 22.44 
Coverage of flanking region (%) 91.38 92.43 
Fraction of flanking covered >=4X (%) 71.44 75.82 
Fraction of flanking covered >=10X (%) 47.65 53.60 
Fraction of flanking covered >=20X (%) 28.79 34.27 
Fraction of unique mapped bases on or near target (%) 81.50 84.67 
Duplication rate (%)(5) 6.26 10.06 
Mean depth of chrX(X) 96.07 58.51 
Mean depth of chrY(X) - 144.85 
GC rate (%) 43.82 43.81 
Gender test result F M 
 
Table 14: Statistical analysis of output data of patients V-3 and VI-6. Data were provided by BGI. (1) regions 
actually covered by the designed probes, (2) reads within or overlapping with target region, (3) the percentage of 
uniquely mapped reads aligning to target region, (4) regions +/-200 bp on both sides of each target region, (5) 
PCR duplicates would have the same start and end for both mates, which rarely occur by chance. Duplication 
rate is the fraction of duplicated reads in raw data. 
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Family 3 
 
Patients IV-2 (2011) 
IV-7 
(2013) 
Target region (bp)(1) 50031585 51339787 
Raw reads 118816412 151049882 
Raw data yield (Mb) 10693 13594 
Reads mapped to genome 95752656 124889294 
Reads mapped to target region(2) 67005013 97603841 
Data mapped to target region (Mb) 5042.99 7663.11 
Mean depth of target region(X) 100.80 149.26 
Coverage of target region (%)(3) 97.84 99.79 
Average read length (bp) 89.80 89.90 
Rate of nucleotide mismatch (%) 0.29 0.20 
Fraction of target covered >=4X (%) 94.03 99.53 
Fraction of target covered >=10X (%) 88.91 99.04 
Fraction of target covered >=20X (%) 81.87 97.96 
Capture specificity (%) 71.02 78.70 
Reads mapped to flanking region(4) 9947003 11046587 
Mean depth of flanking region(X) 25.55 29.62 
Coverage of flanking region (%) 93.48 98.26 
Fraction of flanking covered >=4X (%) 77.93 88.98 
Fraction of flanking covered >=10X (%) 56.55 68.94 
Fraction of flanking covered >=20X (%) 37.34 48.49 
Fraction of unique mapped bases on or near target (%) 80.87 87.24 
Duplication rate (%)(5) 15.82 14.81 
Mean depth of chrX(X) 65.28 165.50 
Mean depth of chrY(X) 151.49 - 
GC rate (%) 43.48 48.69 
Gender test result M F 
 
Table 15: Statistical analysis of output data of patient IV-2 and IV-7. Data were provided by BGI. (1) regions 
actually covered by the designed probes, (2) reads within or overlapping with target region,  (3) the percentage 
of uniquely mapped reads aligning to target region, (4) regions +/-200 bp on both sides of each target region, (5) 
PCR duplicates would have the same start and end for both mates, which rarely occur by chance. Duplication 
rate is the fraction of duplicated reads in raw data. 
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Family 4 
 
Patients III-2 III-4 III-6 
Target region (bp)(1) 50238347 50080510 50080510 
Raw reads 74388348 76554006 71048998 
Raw data yield (Mb) 6695 6890 6394 
Reads mapped to genome 64020072 65485534 61714360 
Reads mapped to target region(2) 44510426 44978621 43793351 
Data mapped to target region (Mb) 3299.62 3339.55 3268.15 
Mean depth of target region(X) 65.68 66.68 65.26 
Coverage of target region (%)(3) 96.92% 97.36% 96.95% 
Average read length (bp) 89.8 89.8 89.8 
Rate of nucleotide mismatch (%) 0.38 0.39 0.4 
Fraction of target covered >=4X (%) 92.07 92.88 92.18 
Fraction of target covered >=10X (%) 85.43 86.7 85.66 
Fraction of target covered >=20X (%) 75.85 77.62 76.25 
Capture specificity (%) 70.58 69.71 71.94 
Reads mapped to flanking region(4) 8568356 9045966 7258570 
Mean depth of flanking region(X) 20.06 20.62 18.14 
Coverage of flanking region (%) 92.26 93.3 91.16 
Fraction of flanking covered >=4X (%) 75.63 78.2 71.83 
Fraction of flanking covered >=10X (%) 53.25 55.77 48.79 
Fraction of flanking covered >=20X (%) 32.89 34.18 29.47 
Fraction of unique mapped bases on or near target (%) 83.35 82.75 83.19 
Duplication rate (%)(5) 8.14 8.56 6.98 
Mean depth of chrX(X) 43.06 82.11 80.84 
Mean depth of chrY(X) 94.56 - - 
GC rate (%) 43.44 43.8 43.89 
Gender test result M F F 
 
Table 16: Statistical analysis of output data of patient III-2, III-4 and III-6. Data were provided by BGI. (1) 
regions actually covered by the designed probes, (2) reads within or overlapping with target region, (3) the 
percentage of uniquely mapped reads aligning to target region, (4) regions +/-200 bp on both sides of each target 
region, (5) PCR duplicates would have the same start and end for both mates, which rarely occur by chance. 
Duplication rate is the fraction of duplicated reads in raw data. 
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APPENDIX G 
 
Copy Number Variants (CNVs) analysis 
 
Family 2 
 
Sample ID Chromosome Start Stop State bp 
V-3 chr1 192129479 192321379 duplication 191900 
V-3 chr6 31949857 31952238 duplication 2381 
V-3 chr6 31991645 31994158 duplication 2513 
V-3 chr6 31999315 32002118 duplication 2803 
VI-6 chr6 138566629 138582839 duplication 16210 
V-3 chr7 5939904 5944932 duplication 5028 
VI-6 chr10 37451926 37478499 duplication 26573 
VI-6 chr10 46961921 47161432 duplication 199511 
VI-6 chr10 48247655 48264451 duplication 16796 
V-3 chr11 60971540 60978753 duplication 7213 
V-3 chr11 60989841 60999048 duplication 9207 
 
Table 17: CNVs obtained from exome-sequencing data of patients V-3 and VI-6, obtained by Copy Number 
Inference From Exome Reads (CoNIFER) program. Data were provided by BGI. 
 
 
Family 3 
 
Sample ID Chromosome Start Stop State bp 
IV-2 chr1 12921055 13001464 deletion 80409 
IV-2 chr1 1640152 1644787 duplication 4635 
IV-2 chr1 1650711 1663987 duplication 13276 
IV-7 chr2 73215372 73249722 duplication 34350 
IV-7 chr2 96943497 96945302 duplication 1805 
IV-7 chr2 219288977 219292801 duplication 3824 
IV-2 chr2 233244190 233245765 deletion 1575 
IV-2 chr3 48606963 48609515 deletion 2552 
IV-7 chr4 3230424 3237187 duplication 6763 
IV-7 chr4 5800296 5811351 duplication 11055 
IV-2 chr5 140710198 140726105 deletion 15907 
IV-7 chr5 149441046 149449650 duplication 8604 
IV-2 chr5 176310998 176316593 deletion 5595 
IV-7 chr6 33631436 33633029 duplication 1593 
IV-7 chr6 34496387 34497650 duplication 1263 
IV-2 chr7 141764133 141786132 deletion 21999 
IV-2 chr7 143880564 144070392 duplication 189828 
IV-2 chr8 7753944 7808529 duplication 54585 
IV-2 chr8 11965649 11969283 duplication 3634 
IV-2 chr9 117072756 117092301 duplication 19545 
IV-2 chr10 37486558 37505335 duplication 18777 
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IV-2 chr10 47911019 47920112 duplication 9093 
IV-2 chr12 129569025 129822390 deletion 253365 
IV-2 chr15 75575199 75581841 deletion 6642 
IV-2 chr16 15035613 15043997 duplication 8384 
IV-2 chr17 78972133 79059549 deletion 87416 
IV-2 chr19 7030585 7049467 duplication 18882 
IV-2 chr19 52130647 52217377 deletion 86730 
IV-2 chr20 21314159 21319763 duplication 5604 
 
Table 18: CNVs obtained from exome-sequencing data of patients IV-2 and IV-7, obtained by Copy Number 
Inference From Exome Reads (CoNIFER) program. Data were provided by BGI. 
 
 
Family 4 
 
Sample ID Chromosome Start Stop State bp 
III-2 chr3 180320621 180322450 duplication 1829 
III-2 chr3 180334050 180337798 duplication 3748 
III-4 chr4 69340364 69426440 duplication 86076 
III-2 chr6 32317502 32410748 duplication 93246 
III-4 chr14 19553373 19571443 duplication 18070 
III-4 chr14 20014465 20249432 duplication 234967 
III-6 chr16 70180024 70190819 duplication 10795 
III-6 chr17 18387175 18395342 duplication 8167 
III-2 chr19 14142675 14157177 duplication 14502 
 
Table 19: CNVs obtained from exome-sequencing data of patients III-2, III-4 and III-6, obtained by Copy 
Number Inference From Exome Reads (CoNIFER) program. Data were provided by BGI. 
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